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ABSTRACT 
 
DAVID TAYLOR SZABO: Toxicokinetics and Effects of 1,2,5,6,9,10-   
Hexabromocyclododecane Stereoisomers In Mice 
(Under the direction of Linda S. Birnbaum) 
 
Despite its small contribution to global production and usage of 
hexabromocyclododecane, α-HBCD is the major flame -retardant diastereomer found in 
environmental samples and human tissue. Limited toxicology studies suggest that the 
commercially available HBCD mixture (CM-HBCD) is a developmental reproductive and 
neurotoxicant, as well as an endocrine disrupter.  This dissertation investigates the link 
between exposure and dose of the two major HBCD stereosiomers, α and γ.  The thrust and 
novelty of this research rest on the examination of the different stereoisomers of HBCD. We 
hypothesized that these isomers differed in pharmacokinetic and toxicological properties and 
moreover could interconvert, thus conclusions based on testing the commercially-available 
mixture might not adequately predict the outcome of real-life exposures. To test this 
hypothesis and provide information essential to the human health risk assessment of HBCD, 
the basic toxicokinetic parameters of α-HBCD and γ-HBCD were characterized in adult 
mice, which included: the impact of repeated dosing on the disposition and elimination of α-
HBCD and γ-HBCD and the disposition and elimination of α-HBCD and γ-HBCD in 
infantile mice were also investigated.  Pathway analysis was performed which may shed  
iii 
 light on the mechanisms involved in effects leading to cognitive (learning and memory) 
deficits. 
 
We found that in adult female mice, α-HBCD and γ-HBCD are both well absorbed, 
90 and 85% respectively.  Distribution is dictated by lipophilicity for α- but not for γ-HBCD. 
This is due to the rapid elimination of γ-HBCD by metabolism and stereoisomerization in 
contrast to the much slower elimination of α-HBCD, with a terminal whole -body half life of 
4 days for γ-HBCD and 17 days for α-HBCD.  Repeated exposure results in higher body 
burdens than a single exposure alone, demonstrating the potential for bioaccumulation of α-
HBCD.  This was not observed for γ-HBCD.  α-HBCD has toxicokinetic properties similar to 
other POPs. Tissue distribution in developing animals is similar to adults; however, actual 
concentrations are higher in younger animals for both α-HBCD and γ-HBCD because of a 
less developed metabolism and excretion capability. A systems biology approach involving 
transcriptomics, proteomics, and metabolomics was used to characterize the mechanisms 
involved in the infantile mouse response to α-HBCD, γ-HBCD and CM-HBCD in liver and 
brain.  Alteration in synaptic long term potentiation is a potential mechanism observed from 
these studies which may account for the reported developmental neurotoxicity previously 
observed in vivo.   Overall, we have identified differences in both, the toxicokinetics and 
molecular effects associated with the two HBCD stereoisomers. 
 
 
 
iv 
ACKNOWLEDGEMENTS 
 
I am sincerely grateful to my advisor, Linda S. Birnbaum, for her guidance, support, 
encouragement, mentorship and friendship throughout my graduate school experience. I have 
benefited greatly from her experience including that provided by Janet Diliberto; whose open 
door was invaluable. I would also like to thank the members of my dissertation committee for 
their direction on my dissertation project. 
 
I would also like to express my gratitude to the following people who were not only 
collaborators but shared their thoughts and insight along the way: Heldur Hakk and Janice 
Huwe. I appreciate the educational experience extended by the University of North Carolina, 
Curriculum in Toxicology as well as the Integrated Systems Toxicology Division, Office of 
Research and Development, U.S. Environmental Protection Agency. 
 
I am grateful to Vicki Richardson, Chris McPherson and Rachael Turner for their 
encouragement and friendship during graduate school.  Finally, I am infinitely thankful to my 
family, father Steven Szabo Sr., mother Kasija Szabo and aunt Olga Milkovich, who has 
been role-models while unconditionally supporting me throughout the years. A special 
acknowledgement is extended to my twin brother Steven Szabo Jr. who, along with my 
parents, has been exceptionally inspirational in my life.     
 
v 
TABLE OF CONTENTS 
 
LIST OF TABLES.................................................................................................................xiv 
LIST OF FIGURES………………………………………………………………….…........xv  
LIST OF ABBREVIATIONS………………...………………………...………...….…....xviii 
Chapter 
 I.   GENERAL INTRODUCTION…..….................................................................................1 
                What are flame retardants..........................................................................................2 
                How do brominated flame retardants inhibit fires?...................................................2 
                What are hexabromocyclododecanes?.......................................................................3  
                HBCD stereoisomers are detected in the environment and in humans………..……5  
                Diastereomer shift………………………………..…………………….…….....….7 
                Toxicokinetics (absorption, distribution, metabolism and excretion……..… ….….9 
                Overview of HBCD toxicity………………………………………………..……..10 
                What are potential mechanisms for HBCD toxicity?  ............................................12                                   
                           Hepatic weight and thyroid hormone…………………………….……...…12 
                           Developmental neurotoxicity…………………………………..……..........13 
                Need for research…………………………………………….…………..…….….13 
                        Rationale and hypothesis……..……………………………………………..…….15 
                       References………..……………………………………………………….………18     
 
vi 
II.   TOXICOKINETICS OF THE FLAME RETARDANT    
 HEXABROMOCYCLODODECANE GAMMA: EFFECT OF DOSE,  
 TIMING, ROUTE, REPEATED EXPOSURE METABOLISM.....................................22 
               
Abstract…........................................................................................................................25 
                 
 Introduction......................................................................................................................26 
Materials and Methods…………..……………………………………………….……..29 
                             Chemicals……………………………………………………….….…29 
                             Dosing Solutions………………………………………………….…..30 
                             Animals……………………………………………...………….….....31 
                             Route of Exposure……………………………………………….…....31 
                       Treatment……….…………………………………..……………..….31 
                             Sample Analysis…………………………………………………..…..32 
                             Tissue Extraction and Analysis…………………………………...…..32 
                             Data Analysis………………………………………………..…..…...34 
Results…………….….………………………………………………………………….34                                 
Dose Response…………………………………………………………..……..34 
                             Repeated Exposure………………………………………………..…..37 
          Time-Course…….……………………………………..……………...37 
                             IV vs. Oral: Tissue Disposition……………………………………….40 
                             Elimination…………………………………………………………....42 
                             IV vs. Oral: Elimination…………………………………….………...43 
           Thin Layer Chromatography (TLC)……………………………….….45 
 
 
vii 
   Gel Permeation Chromatography (GPC)………...…………..…...…..48 
 
                             Liquid Chromatography- Mass Spectroscopy (LC-MS)....……...……48 
               Discussion………….………………………………………………….…..…..52 
Acknowledgement and Disclaimer………………………………………..…..57 
                References……………………………………………………………………..58 
 
III. TOXICOKINETICS OF THE FLAME RETARDANT    
       HEXABROMOCYCLODODECANE ALPHA: EFFECT OF DOSE,  
       TIMING, ROUTE, REPEATED EXPOSURE AND   METABOLISM………....……...62 
 
Abstract…..........................................................................................................................65 
 
Introduction.......................................................................................................................66 
 
Materials and Methods………………….………………………………………………..70 
                                       
                                    Chemicals………..….………………………………………………...70 
                            
Dosing Solutions..……..………………………………….…………..72 
                                       
Animals…………..…………….……………………………………..73 
 
Route of Exposure…………………………………………………….74 
 
Treatment……………………………………………………………...74 
 
Sample Analysis………………………………………….…………...74 
 
Tissue Extraction and Analysis………….……………………………75 
 
Data Analysis………………….……………………………………...77 
Results……………………………….…………………………………………………..78                               
Tissue Disposition 
                                      Dose Dependency…………………..………..………………...78                                                                       
                                       Repeated Exposure……………………………………….…….81 
 
viii                                       
Time-Course….………………………………………………...81 
                             IV vs. Oral: Absorption………..………………………………84 
                             Elimination 
                                       Dose/Response and Repeated Exposure……………………….84 
                                       IV vs. Oral: Absorption……….…………..……………………86 
                                       Thin Layer Chromatography (TLC)…………………………...88 
                                       Gel Permeation Chromatography (GPC)………………………90 
                                       Liquid Chromatography- Mass Spectroscopy (LC-MS)………90 
         Mass Balance…..……………………..…………………….….94                    
 Discussion..………………………………………….…………………………..……...94 
         Acknowledgement and Disclaimer………………………..……….…………………...98 
         References…….…………………………………….…………………………………..99 
IV. DIFFERENCES IN TISSUE DISTRIBUTION OF HBCD ALPHA AND  
      GAMMA BETWEEN ADULT AND DEVELOPING MICE …………………......…...103 
 
Abstract……....................................................................................................................105 
 
Introduction…..................................................................................................................106 
 
Materials and Methods….................................................................................................110 
                                        
                     Chemicals……….……………….…………………………..110 
                                        
                     Dosing Solutions………………………..………………..….110 
                                                                                                                                                                                                          
                     Animal and treatment………….………..…………………...111 
                                                                                                                                                                                                        
                     Exposure…….……….…………………………………...….112 
                               
                     Sample Analysis………..……………………………..……..112 
                     Data Analysis………………………...……………...……....112 
 ix 
Results..............................................................................................................................113 
                     Tissue Distribution of α-HBCD and γ-HBCD………………..113 
                     Body Burden of α-HBCD vs. γ-HBCD……………………….115 
                     Adults vs. developing animals- tissue levels……………….…116 
                     Adults vs. developing animals - body burden……………..….117 
Discussion………………………………..……………….………………..………..….119
Acknowledgement and Disclaimer……….….…………….……………………..…….126 
References..…………………………………………………….……………………....128 
 V. EFFECTS OF HBCD IN DEVELOPING MICE: SYSTEMS BIOLOGY  
      APPROACH TO DEVELOPMENTAL NEUROTOXICITY…..…………………..….133                 
            
Introduction......................................................................................................................133                                                                        
 
Materials and Methods.....................................................................................................137 
 
                       Chemicals……….………………………………….………...137 
          
                       Dosing Solutions………………………………….……….…138 
                       Animals and Treatment.….…….…………………………….138 
Sample Analysis………….…………………..…………...….138                                                    
                     Transcriptomics……………..………………………………..139 
                                  RNA Extraction……………………….……….……..139 
                                  Microarray Hybridization……………………….……139 
                                  Microarray Data Normalization and Quality Control..140                                        
Identification of differentially expressed probes….….140 
                                    Ingenuity Pathway Analysis (IPA)…………………..141                                                           
                        Proteomics…………………………………………………...141 
x 
                                     
Anitbody Array Slide…………..……………………141 
                                    Tissue Preparation…………………………………...142 
                                    Buffer Exchange/Protein Purificaiton……………….142 
                                      
                                    Protein Quantification and Quality Control…………143 
                                     
                                    Protein Labeling-Biotynylation of Protein Samples...143                                               
                                     
                                    Blocking……………………………………………..143 
                                     
                                    Coupling……………………………………………..143 
                                     
                                    Detection…………………………………………….144                                           
                                     
                                    Scanning of Antibody Slides………………………..144 
                                     
                                    Anitbody Array Data Normalization and QC……….144 
                                     
                                    Identification of differentially expressed probes…….145 
                                     
                                    Comparison of Transcriptomics with Proteomics…...145 
                                                    
Metabolomics………………………….…………………….146 
                                     
                                    Sample Preparation and data acquisition ……………146 
                                     
Data Reduction and Visualization……........................147                         
 
Results……………………………….………………………………………………….148 
                        
Transcriptomics of Hippocampus………………….………...149 
 
Hippocampal Genes……….…………………………150 
 
Principal component analysis….……………….…….150 
                        
Hippocampal Gene Pathway analysis………….……….……154   
                                   Proteomics of Hippocampus……………………...….155 
xi 
Hippocampal Proteins………………………………..160 
                                   Hippocampal Protein Pathway Analysis…………..…161 
                                   Comparison - transcriptomics and proteomics……….162 
Transcriptomics of Liver…….…..…………………….….…163                  
                                   Liver Gene Expression…………………………….…163 
                                   Principle component analysis……………………..….164 
                                   Liver Gene Pathway analysis……………………..….167  
                                   Proteomics of Liver…………………………….…….170 
                                   Liver Proteins………………………………………...170 
                                   Liver Protein Pathway Analysis………….…………..171 
                                   Metabolomics of Serum………………………….…..171  
      Discussion.………………………………………………………………….…….……..178 
References………………………………………………………………..……………..188 
VI.  SUMMARY AND IMPACT………………………………...……………………...….190                                                                                
Summary of this dissertation...........................................................................................191 
 Toxicokinetics of γ-HBCD in Female Mice..............................193 
Toxicokinetics of α-HBCD in Female Mice…….….…………193 
Repeated Dosing on the Disposition of α and γ………….........194 
                                       Disposition and Elimination of α-HBCD and γ-HBCD  
                                       in a Developmental Mouse Model……………………………195 
 
                                      Molecular Mechanisms of Developmental Neurotoxicity…….196 
Overall Conclusions…………………………………………...198 
 
xii 
                                        
                                       
Impact of this dissertation………………….…………………………………………199  
Future directions………………..…………………………………………..…………203 
Toxicokinetics and Behavior……….……….………….……...203   
Development of a PBPK model for HBCD…..……………….203                    
Validation of Transcriptomics and Proteomics………………..204 
Dose/Response…….…………………………………..………………………..…….205 
                                       Long Term Potentiation………………….…………….……..205 
                                       Metabolomics - biomarkers and systems biology…………….206 
Concluding remarks………….….…………………………………………….………210 
References.....................................................................................................................213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
LIST OF TABLES 
 
Table 
 
1.1. Water solubility for HBCD technical mixture and the three main stereoisomers….….......7 
 
2.1. Disposition of γ-HBCD in Mice……………………………………………………….....36 
 
2.2. Estimated Tissue Half-lives of γ-HBCD in Mice…………………………………….......40 
 
2.3. Summary of Metabolite Profiles in Female Mouse Tissue and Excreta at 14 days after  
       Oral Exposure to γ-HBCD……………………………………………………………….51  
 
3.1. Disposition of α-HBCD in Mice……...………………………….……………………....79 
  
3.2. Estimated Tissue Half-Lives of α-HBCD derived radioactivity in mice….…..…….…...83 
 
3.3. Summary of Metabolite Profiles in Female Mouse Tissue and Excreta after  
       Oral Exposure to 3mg/kg α-[14C]HBCD…..…………..……………………..……...…..93  
 
4.1a. Disposition of γ – [14C] HBCD derived radioactivity at multiple time points  
          following a single 3 mg/kg oral dose at PND 10. All data are mean ± standard  
          deviation; percent dose………….………………………….………………………...113   
 
4.1b. Disposition of α-[14C] HBCD derived radioactivity at multiple time points  
         following a single 3 mg/kg oral dose at PND 10. All data are mean ± standard  
         deviation; percent dose………………………….…………………………………….114 
 
5.1. Results of ANOVA on gene lists using three criteria…………………………………..149 
 
5.2. IPA pathway analysis of genes expression data from mouse hippocampus after  
     exposure to α-HBCD……………………………………………………………..……158  
 
5.3. IPA pathway analysis of genes expression data from mouse hippocampus after  
       exposure to γ-HBCD……………………………………………………………..........159 
 
5.4. IPA pathway analysis of genes expression data from mouse hippocampus after  
      exposure to CM-HBCD……………………………………………………………….160 
 
5.5. Comparison between transcriptomic and proteomics in the hippocampus  
       of infantile mice orally exposed to 30mg/kg of either α-HBCD or γ-HBCD………....162 
 
 5.6. Serum metabolites that best differentiate the high dose and vehicle control study  
        groups for each chemical………………………………………………………….…..175 
 
 
xiv 
LIST OF FIGURES 
 
 
1.1. Structures of α– (left), β– (center), and γ– (right) HBCD isomers…..………......….……4 
2.1. Chemical structures of 1,2,5,6,9,10-Hexabromocyclododecane    
        alpha, (α-HBCD), beta (β-HBCD) and gamma (γ-HBCD).……………………..….…27 
    
2.2. Tissue Specific Two Component Exponential Decay Curve after Oral Exposure to  
       γ-HBCD…………………………………………………………………………..........38 
 
2.3. Cumulative Fecal and Urinary Elimination…………………..……….………………....42 
 
2.4. Cumulative Fecal and Urinary Elimination between IV and Oral Routes...……….……44 
   
2.5. Thin Layer Chromatography of Tissues and Excreta after Oral Administration  
       of γ-HBCD…..……………………………………………..……………………………46 
 
2.6. LC-MS chromatograms of Tissues and Excreta after Oral Administration  
      of γ-HBCD……..……..…………………………………………………………………49 
 
3.1. Chemical structures of 1,2,5,6,9,10-Hexabromocyclododecane alpha, (α-HBCD),  
   beta (β-HBCD) and gamma (γ-HBCD)…..……………..………………………………67  
 
3.2. Tissue Distribution after a single increasing dose and repeat exposure..……..….…..….81 
  
3.3. Cumulative Fecal and Urinary Elimination….………………..……………..……..…....85 
 
3.4. Cumulative Fecal and Urinary Elimination between IV and Oral Routes………………87 
 
3.5. Thin Layer Chromatograms of Tissues and Excreta after Oral Administration  
     of α-HBCD…………..……………………………………………..……………………88 
 
3.6. LC-MS chromatograms of Tissues and Excreta after Oral Administration 
    of α-HBCD…….……………………………………………………………..…….……92 
 
4.1. Dosing Paradigm……………….……………………………………………………….111 
 
4.2. Body burden in developing mice…….....……………………………………………....115 
                                                                                                                                                 
4.3. Tissue Levels between PND 10 vs. PND 60 mice after exposure to  
      α-[14C]HBCD and γ-[14C]HBCD….……………………………………………………117 
4.4a. Body burden of γ-HBCD in Developing vs. Adult mice…………….…….………….118 
 
xv 
 4.4b. Body burden of α-HBCD in Developing vs. Adult mice…………………………….119 
 
 5.1a. Heat map and PCA analysis of genes of the mouse hippocampus  
          differentially expressed between the commercial mixture of HBCD (CM-HBCD)  
        and corn oil vehicle (controls) four days post oral exposure at PND 10……………..151 
 
 5.1b. Heat map and PCA analysis of genes of the mouse hippocampus  
          differentially expressed between the commercial mixture of HBCD (α-HBCD)  
and corn oil vehicle (controls) four days post oral exposure at PND 10………….….152 
 
 5.1c. Heat map and PCA analysis of genes of the mouse hippocampus  
          differentially expressed between the commercial mixture of HBCD (γ -HBCD)  
         and corn oil vehicle (controls) four days post oral exposure at PND 10………….….154 
 
5.2. IPA Common Pathways from Gene Expression – Hippocampus…….……………..…156 
 
5.3. IPA Common Proteins in the Hippocampus………………....………………….…..…161 
 
 5.4a. Heat map and PCA analysis of genes of the mouse liver  
          differentially expressed between the commercial mixture of HBCD (α-HBCD)  
         and corn oil vehicle (controls) four days post oral exposure at PND 10………….….165 
 
 5.4b. Heat map and PCA analysis of genes of the mouse liver  
          differentially expressed between the commercial mixture of HBCD (γ-HBCD)  
          and corn oil vehicle (controls) four days post oral exposure at PND 10…………….165 
 
 5.4c. Heat map and PCA analysis of genes of the mouse liver  
           differentially expressed between the commercial mixture of HBCD (α-HBCD)  
          and corn oil vehicle (controls) four days post oral exposure at PND 10……..….….166 
 
5.5. Pathways from gene expression data in the Liver………………………………..……168 
 
 5.6. Common Proteins Changed in the Liver………………………………………………170 
 
 5.7. 950 MHz 
1
H NMR spectrum of metabolites in mouse serum. Signals for the                      
higher concentration metabolites are labeled……………………………………….…172 
 
 5.8. Multivariate analysis (PLS-DA score plot) of bin data obtained for serum  
         from mice exposed to vehicle (green), α- HBCD (blue), γ-HBCD (orange), 
       or CM-HBCD (red)…….………………..…………………………………………….173 
 
 5.9a. Score plot of PLS-DA analysis of metabolite concentration data for the serum  
           samples obtained from mice administered 0, 3, 10, and 30mg/kg doses of  
         α-HBCD, indicating separation between the control (red) and dose groups………...174 
 
xvi 
 5.9b. Score plot of PLS-DA analysis of metabolite concentration data for the serum  
         samples obtained from mice administered vehicle or 30mg/kg α-HBCD shows  
         a clear separation of study groups (Red, Control; Green, high dose α-HBCD)……...175 
 
 
5.9c. Score plot of PLS-DA analysis using the subset of metabolites that best                               
         define the HBCD-Alpha high dose group from the control group. An  
         improvement of the separation of the dose group from the control group  
         (Red, Control; Green, high dose α-HBCD) was achieved using the subset of  
         metabolites……………………………………………………………………………176 
 
5.10. PLS-DA plot of metabolite concentration data derived for serum samples obtained from    
        mice administered vehicle control (green), or a high dose (30mg/kg) of CM-HBCD  
        (red), α-HBCD (blue), or γ-HBCD (orange)………………………………………..…177    
 
5.11. Proposed Molecular Mechanisms for HBCD-Mediated Inhibition of Long  
         Term Potentiation (LTP) on Glutamatergic Neurons in Developing Mouse  
         Hippocampus……………………………………………………………………..…..182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvii 
LIST OF ABBREVIATIONS 
 
 
ADME              absorption, distribution, metabolism and excretion 
BDE #               brominated diphenyl ether IUPAC # 
BFR                  brominated flame retardant 
BSEF                Bromine Science and Environmental Forum  
DNT                  developmental neurotoxicity 
HBCD               hexabromocyclododecane 
LOEL                lowest observable effect level 
MDR                 multi-drug resistant proteins 
NOAEL            no observable adverse effect level 
NOEC               no observable effect concentration 
OAT                  organic anion transporter 
PBDE                polybrominated diphenyl ether 
PBT                   persistent, bioaccumulative, toxic 
PentaBDE         pentabrominated diphenyl ether 
Pgp                    P-glycoprotein 
PHDD               polyhalogenated dibenzodioxins 
PHDF                polyhalogenated dibenzofurans 
POP                   persistent organic pollutant 
PND                  postnatal day 
T
4
                       thyroxine 
TBBPA             tetrabromobisphenol A 
xviii 
CHAPTER I 
 
 
GENERAL INTRODUCTION 
What are Flame Retardants? 
 
 Every year, fires kill over 3000 people, injures more than 20,000, and results in 
property damages exceeding an estimated $11 billion in the United States alone (Karter, 
2002). Fire incidence has dropped over the past twenty-five years, which are suspected to be 
due to  decreases in the incidence of smokers, increases in fire alarms and smoke detectors, 
and fire prevention policies requiring the presence of flame retardant chemicals in many 
industrial products, There are over 175 different types of flame retardants, most of which are 
generally divided into classes that include the halogenated organics (usually brominated or 
chlorinated), phosphorus-containing, nitrogen-containing, and inorganic flame retardants. 
The brominated compounds are currently the largest market group because of their low cost 
and high performance efficiency.  
 
How do brominated flame retardants inhibit fires? 
 
A flame retardant is added to a variety of products to slow down the burning process 
or to delay the ignition or combustion of the product. In order for a flame retardant to work, it 
must interfere with one of the three elements required for combustion; heat, fuel, or oxygen. 
There are four stages during a fire: ignition; propagation; steady combustion; and 
termination. A flame retardant can interfere at any of these stages (Kesner et al., 2001). 
When BFRs absorb the required amount of energy (heat), the carbon-bromine bond breaks 
leading to the formation of bromine radicals. The bromine radical reacts with the hydrogen 
atoms in the polymer or captures free hydrogen atoms to form HBr (Kesner et al., 2001).  
2 
RH + Br• →HBr + R•, where RH is the polymer 
HBr slows down the chain reaction that takes place during the burning process. One example 
of this is deactivation of hydroxyl radicals, thereby reducing the amount of free oxygen to 
fuel the fire and forming water (Kesner et al., 2001).  
                                                          ·OH + HBr →H2O + ·Br   
The overall effect is that the bromine atom withdraws energy from the combustion-
propagation stage of the fire, slowing the burning process (Kesner et al., 2001). A good flame 
retardant should be inexpensive, stable to heat, colorless, easily blended in with the polymer, 
should decompose  before the polymer, must not change physical and mechanical properties 
once it is in the final product, must be stable at temperatures at which the product is formed, 
and does not release toxic substances into the environment (Kesner et al., 2001).  
 
What are Hexabromocyclododecanes?  
 
1,2,5,6,9,10-hexabromocyclododecane (HBCD, C12H18Br6) is the most widely used 
aliphatic BFR and historically,  the third BFR in global production volume following 
tetrabromobisphenol A and polybrominated diphenyl ethers (PBDEs), before the phase out of 
PBDEs in this past decade.  In 2001, global demands for HBCD (~16.7 kilotons) was almost 
double that of the pentabromodiphenyl ether mixture (~7.5 kilotons) (Heeb et al 2005; de Wit 
et al., 2002). There are currently no restrictions on the use of HBCD in the US.  There are 
two types of flame retardants, reactive and additive. Reactive flame retardants are covalently 
bonded to the polymer and additive flame retardants are added as a component of the                    
 
3 
dissolved material.  HBCD is an additive flame retardant. Being additive, there is the risk that 
HBCD can leach into the environment during use or after disposal of the product; other 
sources of release occur during production and manufacturing of the final product. HBCD is 
the principal flame retardant in extruded (XEPS) and expanded (EPS) polystyrene foams 
used as thermal insulation in the building industry. The amount of HBCD in plastics ranges 
from 0.5 to 7%, depending on the type of plastic (Remberger et al., 2004). Extruded 
polystyrene contains ~1-2% HBCD (Lassen et al., 1999; Zitco et al., 1993). Secondary uses 
of HBCD include residential and commercial upholstery textiles and electronics. 
HBCD is synthesized by high temperature gas phase bromination of 1Z, 5E, 9E-
cyclododecatriene (Peled et al., 1995). The resulting technical HBCD mixture (CM-HBCD) 
consists primarily of 3 HBCD diasteromers: α, β and γ (Figure 1.1). (The assignment of 
Greek letters is based on their elution order from a reverse phase HPLC column.)  
Figure 1.1.  Structures of α– (left), β– (center), and γ– (right) HBCD isomers.  
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Other isomers exist in lower quantities and attention has focused on the three 
main HBCD stereoisomers, which themselves are racemic mixtures of enantiomers.  The 
proportions of the isomers in the technical mixture are dependent on the final synthetic 
process. Industrially, there are four different CM-HBCDs: low melt, medium range, high 
melt and thermal stabilized (Peled et al., 1995). Although there is a range, the overall 
average approximate proportions of each isomer in each technical mixture are 6, 8, and 80% 
for HBCD -α, -β and -γ, respectively. What makes each technical mixture different is the 
percent of γ-HBCD present, which ranges from ~70-90%. The selection of CM-HBCD grade 
used depends on the on the usage of the end-product.   CM-HBCD is a solid, white powder at 
room temperature (National Academy Press, 2000). Physicochemical properties of CM-
HBCD are as follows: molecular weight of 641.7 g/mol; melting point ranges from 185-
195
o
C and depends on the isomer ratio and impurity composition; vapor pressure of 4.7 x 10
-
7
mm Hg (at 25
o
C) and the log octanol water partition coefficient (log Kow) of  approximately 
5.6 (National Academy Press, 2000). The fact that HBCD has similar physiochemical 
properties to other persistent organic pollutants such as polychlorinated biphenyls (PCBs) 
and PBDEs, suggests that CM-HBCD may be persistent, bioaccumulative, and toxic 
(Remberger et al., 2004). 
 
HBCD Stereoisomers are detected in the Environment and in Humans  
 
Possible emission sources of HBCD stereoisomers into the environment 
include; manufacturing, use and disposal (Remberger et al., 2004). Emissions during  
5 
manufacturing can be by air, but due to HBCD stereoisomers‟ low volatility, emissions are 
more likely to occur with the release of plastic in dust (Remberger et al., 2004). The presence 
of HBCD stereoisomers in household dust has suggested that dust serves as a major source of 
exposure (Abdallah et al., 2008). Because it is an additive flame retardant, HBCD 
stereoisomers can leach from the material it has been impregnated into during the lifetime of 
the product. This can occur over a long period of time, as some products have long lifetimes. 
After disposal of a product in a landfill or during recycling it is possible for HBCD 
stereoisomers to leach into the air (particle bound) and water (surface and ground) 
(Remberger et al., 2004; Morris et al., 2004). HBCD (either as a total of each stereoisomer or 
each stereoisomer individually) has been quantified in sewage treatment plant sludge, which 
suggests that HBCD is associated with suspended particulate material and can be removed 
during the wastewater treatment process (Morris et al., 2004). E-waste is a source of HBCD 
to the local population and the local environment (Law et al., 2008). Recent trends in Asia 
show a leveling in concentrations of PBDEs but increases in concentration of HBCD 
stereoisomers (Law et al., 2008). 
HBCDs has been shown to be bioavailable by measuring levels of HBCDs in 
pike captured near textile factories along the River Viskan in Sweden (Sellstrom et al., 1998). 
This suggests that food intake may be another major source of human exposure (Darnerud et 
al., 1998) coming mostly from fish with the estimated intake being approximately three times 
greater than certain PBDE congeners . HBCDs have been detected in the few human 
exposure studies conducted to date. Thomsen et al. (2007) reported that all serum samples 
tested in workers from an industrial plant occupationally exposed to CM-HBCD tested  
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positive for the presence of HBCD stereoisomers (ranged 6-856 ng/g lw). Ryan et al. (2006) 
reported that the mean concentrations in human breast milk of the HBCD stereoisomers 
collected in Ontario, Canada (2002-2003) and Texas, USA (2002) were 3.8 and 0.5 ng/g lipid 
weight (lw), respectively. Kakimoto et al. (2008) analyzed breast milk from Japanese women 
(age 25–29) over the period 1973–2006; total mean HBCD stereoisomer concentration over 
the period 2000 – 2006 ranged from 1 to 4 ng/kg lw. Higher values were reported in breast 
milk of women living in Spain between 2006-2007 (Eljarrat et al. 2009) where the mean 
concentration was 27 ng·kg-1 lw (range 3 to 188 ng/kg lw). Abdallah et al., (2011) detected 
HBCD in all breast milk samples in a UK population (average ΣHBCDs=5.95 ng/g lw).  
 
Diastereomer shift 
 
Until recently, all HBCD physicochemical property measurements were 
performed on the technical mixture as individual isomers were not readily available. Table 
1.1 displays measured differences in water solubility were for α-, β-, and γ-HBCD 
stereoisomers (MacGregor and Nixon   
         
        Table 1.1. Water solubility for HBCD mixture and the three main stereoisomers.  
 Technical 
Mixture 
α–HBCD β –HBCD γ –HBCD 
Water Solubility(ug/L) 3.4 48.8 14.7 2.08 
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(2004). Log Kow for α-, β-, and γ-HBCDs have also been shown to have measurable 
differences from one another (5.65, 6.05 and 6.34, respectively) (Kuramochi et al., 2010). 
The 3-dimensional views of the isomers (Figure 1.1) show that the α– and γ–isomers both 
have a C2
 
axis of symmetry while β–HBCD does not.  High concentrations of HBCD 
stereoisomers have been detected in some top predators (marine mammals, birds of prey, 
humans) indicating persistence and biomagnification of HBCDs. At the diastereomer level, 
environmental samples, such as sediment and dust are shown to be predominately γ-HBCD 
(Covaci et al., 2006).  Interestingly, recent studies have shown that there is a predominance 
of α-HBCD in wildlife and humans (Law et al., 2008). Abdallah et al., (2011) report in a 
breast milk biomonitoring study that α-HBCD dominated; comprising of 62-95% of 
ΣHBCDs while β- and γ-HBCD constituted 2-18% and 3-33% respectively. Law et al., 
(2006a) observed a sharp increase in α-HBCD levels within the blubber of harbor porpoises 
beginning in 2001 (within a period of 1994-2003). Another study by Law et al., (2006b) 
identified that α-HBCD had higher levels than other HBCD stereoisomers measured in Lake 
Winnepeg food chain. However, it is currently unknown whether this process is due to in 
vivo biotransformation (γ to α) or simply bioaccumulation, where the low levels of α-HBCD 
released into the environment accumulate in biota and biomagnify up the food chain. Limited 
evidence in the variation in  solubility and partitioning behavior have been thought to explain 
the predominance of α-HBCD in aquatic and terrestrial organisms however, uptake and in 
vivo distribution and metabolism (stereoisomerization) of individual diastereoisomers 
currently remain untested.  
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Toxicokinetics (absorption, distribution, metabolism and excretion). 
 
Information on the toxicokinetics of CM-HBCD and stereoisomers is limited. 
There is no human data on the toxicokinetics of HBCD for any route of exposure. Also, there 
are no peer-reviewed in vivo kinetic studies on the CM-HBCD or individual stereoisomers in 
any mammalian model. One study conducted by a manufacturer showed that the CM-
[C
14
]HBCD commercial mixture was readily absorbed in rats (unknown sex and strain) that 
received a single oral dose (Yu and Atallah, et al., 1980). The half-life was exceedingly short, 
i.e. approximately 2h.  Within 72h, 16% of the dose was excreted in the urine and 72% in the 
feces.  Four metabolites of unknown structure were found. CM-HBCD derived radioactivity 
had deposited in every sampled tissue in the rat, and the tissues with the highest levels were 
the adipose, liver, kidney, lung, and gonads.  In another study conducted by a manufacturer, 
7-9 mg/kg of the CM-HBCD was given to rats (unknown sex and strain) as a single oral 
dose, and gastrointestinal absorption was facile (Dean et al., 1977). However, the exact 
extent of oral absorption is unknown.  Approximately 86% was eliminated in 72h, the 
majority in the feces (70%) and a lesser amount in the urine (16%).  The half-life was again 
estimated to be less than 2h.  Conflicting data was obtained in another unpublished study in 
which CM-[C
14
]HBCD commercial mixture was administered daily for 5 days at 500 mg/kg 
(Ryuich et al., 1983).  In that study design, there was no detectable urinary excretion over 
96h, and the average daily fecal excretion ranged from 29-37%.  In yet another unpublished 
study (NRC-NAP, 2000), CM-HBCD (500 mg/kg-d for 5 d) was found to accumulate 
exclusively in the adipose tissue with none detected in spleen, pancreas, liver, kidney, or 
heart of male Wistar rats.  No toxicokinetic studies via the dermal or inhalation exposure  
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routes were reported in any experimental animals for individual diasterreomers.  However, 
female New Zealand white rabbits exposed dermally to a high dose (8 g/kg) of CM-HBCD in 
saline experienced diarrhea and slight weight loss (Dean et al., 1977). This finding indicates 
that at least some absorption occurs via the dermal route. A dermal in vitro study on human 
skin has been performed according to OECD Test Guideline 428 in order to assess the rate 
and extent of dermal absorption of CM=HBCD (Roper et al., 2005). A value of 4% is 
assumed to be applicable for uptake of CM-HBCD commercial powder by the dermal route 
(Hughes et al., 2006). With conflicting data regarding the oral route of exposure and limited 
studies with other routes, these are clear data gaps which need to be filled. 
 
Overview of HBCD Toxicity 
 
The literature available for HBCD toxicity is relatively limited; however, 
increasing public attention on HBCDs has spurred more research to be conducted. Public 
health concern has focused primarily on potential hazardous effects resulting from exposure 
of infants and young children. These concerns are founded based on evidence from rodent 
studies showing that the  CM-HBCD is a developmental neurotoxicant (Eriksson et al., 
2006), as well as endocrine disruptor (Chegelis et al., 2001, van der Ven et al., 2006) and that 
exposure estimates suggest nursing infants and young children have the overall highest 
exposure to other flame retardants (Jones-Otazo et al., 2005). CM-HBCD has previously 
demonstrated developmental neurotoxicity (DNT) in mice following a single exposure 
(Eriksson et al., 2006). In this study, mice exposed on postnatal day 10 (PND 10) to one                                  
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single dose of the  CM-HBCD exhibited permanent aberrations in spontaneous behavior and 
habituation capacity behaviors that continued to worsen over time, including changes in 
learning and memory. Other reports have identified toxicity of CM-HBCD in cerebella cells 
and CM-HBCD has been shown to alter levels of the neurotransmitters, glutamate and 
dopamine in vitro (Mariussen and Fonnum, 2003). Because evidence is mounting for toxicity 
in combination with persistent exposure, it is important to understand the toxicokinetics and 
toxicity of HBCD stereoisomer, α and γ in potentially susceptible populations (i.e., young, 
developing animals) especially considering there are no stereoisomer toxicity studies in any 
mammalian system.  
 
A 28 day study was conducted in female and male Wistar rats (van der Ven et 
al., 2006), using a benchmark model design and oral administration of the CM-HBCD. The 
study mainly shows effects on the liver, thyroid, and pituitary. A NOAEL/BMD-L of 22.9 
mg/kg/day for liver weight increase is calculated from this study. It has been suggested that 
the liver weight increase is caused by hepatic enzyme induction, as indicated by 
histopathology (proliferation of SER) and induced hepatic enzyme activities/mRNA/protein. 
Although there is no consistent difference in sensitivity towards hepatic enzyme induction 
between females and males, the concentration of HBCDs was higher in females than in 
males. Enzyme and protein induction is clearly involved, and is likely the most important 
reason for the liver weight increase; however pathways analysis has yet to be established. 
With regard to effects on the thyroid system, studies have either shown: no effect, effects in 
vitro effects only in females, or effects in both sexes concluding that the thyroid system 
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appears to be an inconsistent marker of toxicity after exposure to the CM-HBCD. 
Considering other toxicity endpoints, CM-HBCD has also been linked to carcinogenesis by 
inducing intragenic recombination in mammalian cells, similar to PCBs (Helleday et al., 
1999).  
 
What are potential mechanisms for HBCD toxicity?  
 
Hepatic weight and thyroid hormone 
 
So far, studies on the toxic potential of CM-HBCD have mainly focused on 
endocrine disruption. Although an inconsistent measure of toxicity after exposure to the CM-
HBCD, adverse effects on the thyroid hormone system have been studied (Ema et al. 2008; 
Hamers et al. 2006; Palace et al. 2010; van der Ven et al. 2006). Effects on hepatic gene 
expression and hepatic enzymes have been observed (Cantón et al. 2008; Germer et al. 2006; 
Ronisz et al. 2004; Zhang et al. 2008). A hepatic mechanism of thyroid hormone disruption 
has been speculated after exposure to CM-HBCD. This would lead to increased liver weight 
through induction of XMEs. Induction of CAR and PXR mediated XME would metabolize 
thyroid hormones, facilitating its elimination. Ultimately, this results in a reduction of 
circulating T4 levels. In addition, induction of CAR and PXR mediated XMEs is associated 
with the hepatic weight increases.  
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Developmental neurotoxicity 
 
The mechanisms for behavioral and cognitive effects are not currently known for HBCD. It 
is assumed that a reduction in serum thyroid hormone levels during development may causes 
a reduction in the levels of thyroid hormone in the brain (van der Ven et al., 2009) leading to 
neurotoxicity. However, brain levels of thyroxine have not been measured and it is difficult 
to get a reliable measure considering the low levels present. Furthermore, direct effects of 
HBCD on neuronal cells (independent of thyroid hormone mechanism) have also been 
observed, but the overall acute in vivo toxicity studies of HBCD appears limited (Darnerud 
2003). Researchers have suggested that the observed neurotoxic developmental effects in 
mice may be associated with alterations in cholinergic receptors (Eriksson et al. 2001) as 
well as due to oxidative stress and the cellular antioxidant defense systems in fish brain 
(Zhang et al. 2008). In vitro neurotoxicity data on CM-HBCD or stereoisomers is also 
limited. So far, only inhibition of dopamine uptake in rat synaptosomes (IC50: 4 μM) and 
synaptic vesicles (Mariussen and Fonnum 2003) has been observed. 
 
Need for Research 
 
Brominated flame retardants represent major industrial chemicals whose use has 
increased dramatically over the past few decades. They are produced to decrease 
flammability and increase the time to flash over and thus can have a direct and obvious 
benefit. However, concerns are being raised because of their persistence, bioaccumulation, 
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and potential for toxicity, both in animals and humans. Production and use patterns are 
different in various parts of the world. There is clearly a need for more systematic 
environmental and human monitoring to understand how and where these chemicals are 
being released into the environment, and what is happening to them once they enter the 
environment. What fate and transport processes are involved in their environmental 
movement? Are the commercial products stereoisomerizing in the environment or in biota? 
And if they are degrading, what are the resultant products? How are all of these chemicals 
getting into people?  Is dietary intake the major pathway, as true for many other POPs or are 
there other potential sources? Once we understand what the exposure levels are in both 
people and wildlife, what should be our level of concern? Our toxicology database is 
inadequate to truly understand the risk associated with HBCDs. Many of the studies that do 
exist involve the commercial mixtures, which do not represent human exposure. Studies are 
needed that focus on the individual stereoisomers, and potentially their metabolite products, 
present in people and wildlife in order to understand the risk from exposure to HBCDs. 
 
Classical toxicology is traditionally focused on understanding xenobiotic 
metabolism, the dose-response relationships between chemicals and adverse health effects, 
and mode-of-action evaluation for toxicant-induced disease. Novel molecular, biochemical, 
genetic and genomics approaches are increasingly used to understand the mechanisms of 
environmental agent-related organ injury. Toxicogenomics, proteomics and metabolomics is 
a rapidly maturing field which  
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provides the ability to define in greater detail the underlying molecular events preceding or 
accompanying toxicity. The incorporation of this new information requires careful validation, 
and altered gene expression patterns should be corroborated with conventional indices of 
toxicity (ie. developmental neurotoxicity; learning and memory).  The systems biology 
approach intends to bring together -omics databases obtained from exposed and unexposed 
cellular or animal models and to establish relevant associations using newly developed 
computational technologies. The paradigm is to use the system biology based methods for 
describing molecular pathways involved in the human endpoint of interest. Applying this to 
the study of HBCDs, the main focus will be on pathway analysis leading to developmental 
neurotoxicity previously observed in vivo (Erikkson et al., 2006).  
 
Rationale and Hypothesis for Project  
 
                    In predicting human health risks posed by HBCD, it is necessary to accurately 
predict systemic dosimetry and the fate of these compounds. The dose/response relationship 
of a chemical must be well characterized in order to accurately describe the associated risk. A 
major focus for HBCD is to establish a basic knowledge of stereoisomer specific absorption, 
distribution, metabolism, and elimination (ADME). Currently, studies on the toxicokinetics 
of HBCDs are very limited and provide no data on specific stereoisomers in any mammalian 
system. There are no peer reviewed published pharmacokinetic studies performed on any 
mammalian system to date with HBCD.   
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Therefore, It is important to characterize the stereoisomers individually as 
differences in isomer properties (i.e. structure, log Kow, and water solubility) can lead to over 
(or under) estimation of the overall toxicity. The differences in the source of exposure from 
either the mixture or from biota may be important as the composition of the HBCD 
stereoisomers which constitutes such matrices may dictate differential effects. Based on the 
limited toxicity profile and the need for basic distribution and elimination kinetics, the major 
commercial stereoisomer, γ-HBCD as well as the major biotic isomer α-HBCD will be 
investigated in adult female mice. In addition, we will examine the toxicokinetic and effects 
of a single oral dose of γ-HBCD and α-HBCD in infantile animals to assess if there are 
differential kinetic behaviors from adults which could at least in part explain the window of 
sensitivity for DNT. Furthermore, we will also investigate the possible neuronal and hepatic 
effects after exposure to CM-HBCD by using a systems biology approach with high 
throughput „omics technologies (transcriptomics, proteomics and metabolomics) to help 
explain the DNT previously observed. These studies will provide data for the development of 
a PBPK model and aid in extrapolation of animal results to humans in order to assess the 
human health risk of HBCD. 
 
The thrust and novelty of this research rest on the examination of the different 
stereoisomers of HBCD. We hypothesized that these isomers differ in pharmacokinetic and 
toxicological properties and moreover could interconvert, thus conclusions based on testing 
the commercially-available mixture might not adequately predict the outcome of real-life 
exposures. To test this hypothesis and provide information essential to elucidating the  
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diastereomer shift while adding valuable information for the human health risk assessment of  
HBCD, specific aims included: (1) characterize basic toxicokinetics in adult female mice; (2) 
investigate the impact of repeated dosing on the distribution and elimination of α-HBCD and 
γ-HBCD in adult female mice; (3) investigate the distribution and elimination of α-HBCD 
and γ-HBCD in infantile mice, a developmental model; and (4) identify mechanisms leading 
to the reported developmental neurotoxicity after exposure to the CM-HBCD and further 
determine whether that toxicity is driven by α-HBCD and/or γ-HBCD.  
 
We hope to gain a much better understanding of the pharmacokinetic properties 
of individual diasteriomers of HBCD in mice as preliminary research suggests that the 
primary health outcomes involve endocrine and neurotoxic developmental effects.  In 
addition, α-HBCD has been hypothesized to be produced from γ-HBCD in animals, resulting 
in increased lipophilicity and bioaccumulation.  Neurobehavioral alterations and thyroid 
hormone disruption have been shown to occur in animals exposed to CM-HBCD. In order to 
understand the health effects it is essential to understand the pharmacokinetic as well as the 
phamacodynamic properties of this commonly-used flame retardant.  
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 ABSTRACT 
 
 
1,2,5,6,9,10-Hexabromocyclododecane-gamma (γ-HBCD) is the predominate 
diastereoisomer in the commercial HBCD mixture used as a flame retardant in a wide variety 
of consumer products.  Three main diastereoisomers, alpha (α), beta (β) and gamma (γ) 
comprise the mixture.  Despite the γ-diastereoisomer being the major diastereoisomer in the 
mixture and environmental samples, the α-diastereoisomer predominates human tissue and 
wildlife.  This study was conducted to characterize absorption, distribution, metabolism and 
excretion parameters of γ-HBCD with respect to dose and time following a single acute 
exposure and repeated exposure in adult female C57BL/6 mice.  Results suggest that 85% of 
the administered dose (3mg/kg) was absorbed after oral exposure.  Disposition was dose-
independent and didn‟t significantly change after 10 days of exposure.  Liver was the major 
depot (<0.3% of dose) four-days after treatment followed by blood, fat and then brain.  γ-
HBCD was rapidly metabolized and eliminated in the urine and feces.  For the first time, in 
vivo stereoisomerization was observed of the γ-diastereoisomer to the β-diastereoisomer in 
liver and brain tissues, and to the α- and β-diastereoisomer in feces.  Polar metabolites in the 
blood and urine were a major factor in determining the initial whole-body half-life (1 day) 
after a single oral exposure.  Elimination, both whole-body and from individual tissues, was 
biphasic.  Initial half-lives were approximately 1 day, whereas terminal half-lives were up to 
4 days, suggesting limited potential for γ-diastereoisomer bioaccumulation.  The 
toxicokinetic behavior reported here has important implications for the extrapolation of 
toxicological studies of the commercial HBCD mixture to the assessment of risk.                 
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INTRODUCTION 
 
 
Flame retardants are added to a variety of consumer goods in an effort to reduce 
flammability.  With the ban of all polybrominated diphenyl ether (PBDE) commercial 
mixtures in the European Union and North America‟s increased awareness of safer 
alternatives, hexabromocyclododecanes (HBCD) has increased in production and use.  
HBCD is a brominated aliphatic cyclic hydrocarbon and a high production volume chemical 
used as a flame-retardant for plastics and textiles.  In 2001 the total market demand for 
HBCD was estimated to be over 16700 tons per year, of which 2800 tons were from the 
United States, 9500 tons from Europe, 3900 tons from Asia, and 500 tons from the rest of the 
world (Law et al., 2006; Hale et al., 2006).  HBCD is used as an additive flame retardant 
allowing release from products into our environment.  HBCD is now a ubiquitous 
contaminant in environmental media and biota (Law et al., 2008).  Currently, there are no 
restrictions on HBCD production and use.  It has been shown in laboratory animals to be a 
hepatic enzyme inducer
 
(Hamers et al., 2006), developmental neurotoxicant (Eriksson et al., 
2006), and endocrine disruptor (van den Ven et al., 2006). Recent studies have suggested 
HBCD is highly bioaccumulative (Law et al., 2006).  
 
Measurable HBCD concentrations have been reported in few human exposure studies 
conducted to date. HBCD can be considered an emerging contaminant with median blood 
values varying in humans between 0.35 and 1.1ng/g lipid (Covaci et al. 2006).  
Occupationally exposed workers in Norway showed higher concentrations in serum ranging  
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from 6 to 856 ng/g lipid (Thomsen et al., 2007).  Dermal and inhalation routes of HBCD 
exposure may be quantitatively important for human uptake (Thomsen et al., 2007).  
However, diet is considered a more important source for HBCD exposure (Schecter et al.,                 
2009), especially for humans consuming large quantities of fish, which reportedly contains 
relatively high HBCD levels from 9 to 1110ng/g lipid (Janak et al., 2005; Xian et al., 2007).  
Besides diet, house dust is likely another important pathway of human exposure to HBCD 
due to high levels present indoors (Roosens et al., 2009).  Non-dietary ingestion of dust and 
soil may especially represent an important route of exposure for toddlers and young children 
(Lioy et al., 2000; Wilford et al., 2005; Wu et al., 2007). 
 
Commercial HBCD is a mixture of different 1,2,5,6,9,10-hexabromocyclododecane 
diastereoisomers (Figure 1)  with previous research focusing on the three diastereoisomers in 
the commercial mixture, denoted as alpha (α), beta (β), and gamma (γ) with the γ-
diastereoisomer predominating (>70%) (Heeb et al., 2005).  
 
 
       
                      α-HBCD                                  β-HBCD                                  γ-HBCD 
 
Figure 2.1. Chemical structures of 1,2,5,6,9,10-Hexabromocyclododecane alpha, (α-HBCD), 
beta (β-HBCD) and gamma (γ-HBCD).   
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High concentrations of HBCD in some top predators (marine mammals, birds of prey, 
humans) indicate persistence and biomagnification of HBCD.  However most of these early 
studies did not examine individual HBCD diastereoisomers.  Recent studies have shown that  
there is a predominance of alpha in biota (Law et al., 2008).  Furthermore, γ-HBCD is 
susceptible to thermal rearrangement at temperatures above 160
◦
C (Peled et al., 1995), 
resulting in predominant conversion to the α-diastereoisomer (Baratoni et al., 2001).  
Differences in water solubility are found for α-, β- and γ-HBCDs (48.8, 14.7 and 2.1 ug/L, 
respectively) (MacGregor and Nixon 2004).  Variations in the solubility and partitioning 
behavior, as well as uptake and metabolism of individual diastereoisomers, are thought to 
explain the predominance of α-HBCD in aquatic and terrestrial organisms.  These physico-
chemical differences of HBCD diastereoisomers in wildlife and laboratory studies may also 
result in different biological effects. 
 
Aside from thermal rearrangement observed during the manufacturing processes of 
residential and commercial foam insulation, in vivo metabolism may also convert the γ-
diastereoisomer in the technical mixture to a prevalence of the α-diastereoisomer in wildlife 
and humans (Covaci et al., 2006).  This phenomenon can be explained by either a difference 
in pharmacokinetic rates, where the γ-diastereoisomer is metabolized and eliminated at a 
more rapid rate than the α-diastereoisomer, and/or stereoisomerization of the γ-
diastereoisomer to α.  Selective metabolism is supported by in vitro assays with 
phenobarbital induced hepatic rat and non-phenobarbital-induced seal microsomes, where the 
γ- and β- diastereoisomers were significantly metabolized, while the α-diastereoisomer was 
 
28 
not (Zegers et al., 2005).  Results from this study further suggest the occurrence of 
cytochrome P450 (CYP) mediated metabolism.  Thus, in order to address the biological fate, 
biotransformation and effects of HBCD, individual diastereoisomers should be studied. 
 
In predicting human health risks posed by HBCD, it is necessary to accurately predict 
internal dose and the biological fate of these compounds.  Therefore, more detailed  
information about the kinetics, toxicology, pathways of exposure, and bioavailability of 
HBCD is needed.  The objective of this study is to describe absorption, distribution, 
metabolism, and excretion (ADME) of γ-HBCD following an acute exposure in adult female 
mice at several doses, after repeated treatment, and up to 14 days.  
 
 
MATERIALS AND METHODS 
 
 
Chemicals: [
14
C]1,2,5,6,9,10-hexabromocyclododecane (HBCD) (2mCi/mmol) was 
purchased from American Radiochemicals Corporation (ARC) (St Louis, MO) as a mixture 
of ß- and γ-diastereoisomer and [14C]1,2,5,6,9,10-hexabromocyclododecane gamma (γ-
HBCD) was purified at the USDA Agricultural Research Service (ARS) laboratory (Fargo, 
ND) by flash chromatography on a silica gel column eluting with hexane containing 
increasing amounts of methylene chloride (0–50 %).  The elution order from the silica gel 
column was γ followed by ß.  The γ-[14C]HBCD was 98% radiochemically and 
diasteromerically pure as determined by thin-layer chromatography (TLC) using silica gel 
plates (250 mm; Whatman Lab. Div., Clinton, NJ) and a 50:50 methylene chloride:hexane  
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mobile phase with radiochemical detection by a System 2000 Imaging Scanner (Bioscan,  
Washington, DC) and by liquid chromatography-mass spectrometer (LC-MS) on a Symmetry 
C18 column (2.1x100 mm) (Waters, Beverly, MA) (details below).  Unlabeled γ-HBCD was 
generously provided by Wellington Labs (98% purity).   Other chemicals used were of the 
highest grade commercially available. 
 
Dosing Solutions: Doses were selected based on published toxicity studies, 
environmental relevance, and specific activity of γ-[14C]HBCD (van der Ven et al., 2006 and 
Law et al., 2008).  A stock solution of γ-[14C]HBCD was made by dissolving 19.23 mg of      
γ-[14C]HBCD (3.12 μCi/mg) in toluene (400ul). Aliquots were used directly from this 
solution for all dosing regimens.  All dosing solutions were subjected to pre- and post- dosing 
radioactivity examination to ensure proper delivery of dose.  All solutions were designed to 
deliver approximately 0.2μCi to each mouse.  Unlabeled γ-HBCD was added to the γ-
[
14
C]HBCD to achieve desired mass (all doses except low dose of 3 mg/kg), and was added 
directly to the dosing solution vial and dissolved in acetone.  Corn oil by weight was then 
added to the vials followed by the evaporation of toluene and acetone under vacuum (Speed 
Vac, Savant Instruments, Inc. Farmingdale, NY).  For intravenous (iv) treatment, 10 ml of 
stock γ-[14C]HBCD was allowed to evaporate in an amber vial, and the γ-HBCD was 
resuspended in 95% ethanol followed by Emulphor
®
.   De-ionized water was slowly added to 
a final volume of 4.3 ml with an ethanol:Emulphor:water ratio of 1:1:8. 
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Animals. Female C57BL/6 mice (~20 grams) were obtained from Charles River 
Breeding Laboratories (Raleigh, NC).  Mice were chosen for these experiments because 1) of  
the limited amount of radiolabeled chemical and 2) neurotoxicity was observed in mice 
(Eriksson et al., 2006). Mice were maintained on a 12 h light/dark cycle at ambient 
temperature (22
◦
C) with relative humidity (56 ± 5%), and were provided with Purina 5001 
Rodent Chow (Ralston Purina Co., St. Louis, MO) and tap water ad libitum.  Prior to the 
commencement of the study, mice were adapted (3 mice/cage) for 1 week to Nalgene 
metabolism cages (Nalgene, Rochester, NY).  Mice were then assigned randomly to 
treatment groups (n= 4-6) and housed individually for the remainder of the study.  All mice 
were 60 days old at time of treatment. 
 
Route of Exposure: Oral treatment (n=4-8). A single dose (0, 3, 10, 30 and 100 
mg/kg) was administered directly by oral gavage into the stomach of each mouse using a  
teflon animal feeding needle.  Dose volume was 10ml/kg.  Intravenous treatment (n=6-8). A 
single dose (3 mg/kg) was administered intravenously via the tail vein at a dosing volume of 
2 ml/kg. 
 
Treatment: Dose/Response: A single dose (3, 10, 30, or 100 mg/kg at 10ml/kg) was 
administered by oral gavage.  After dosing, mice were held in metabolism cages for 4 days 
and urine and feces were collected daily.  Time course: Mice were treated by gavage at a 
single dose of 3 mg/kg and held for 14 days where urine and feces were collected daily.   
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Repeated: Mice were dosed for 9 days with 3 mg cold γ-HBCD/kg and on day 10 with 3 mg  
γ-[14C]HBCD/kg and held for 4 more days (total of 14 days) in metabolism cages for 
collection of urine and feces.  Animals were euthanized by CO2 asphyxiation followed by 
exsanguination via cardiac puncture.  Tissues were collected and weighed: blood, bile, liver, 
lung, kidneys, skin, adrenal glands, urinary bladder, spleen, thymus, adipose (abdominal), 
muscle (abdominal), and brain.  Bile was removed directly from the gallbladder using the 
BDUltra-fine Insulin syringe.  
 
Sample Analysis: Radioactivity in the tissues was determined by combustion to 
14
CO2 
(Packard 307 Biological Oxidizer, Downers Grove, IL) of triplicate samples when available 
(~100mg/sample) followed by liquid scintillation spectrometry (LSS; Beckman, Beckman 
Instruments, Fullerton, CA).  Tissue data are reported based on wet weight.  Feces were air 
dried, weighed, and analyzed for radioactivity by combustion and LSS.  Daily urine volume 
was recorded, and 100 μl aliquots (triplicate) were analyzed by direct addition into scintillant 
for radioactivity determination by LSS.  
 
Tissue Extraction and Analysis:  Liver samples were weighed and then homogenized 
in 3 volumes of 0.9% sodium chloride solution.  Feces were dried and ground into a very fine 
powder with a mortar and pestle.  Serum, liver, bile, urine and feces samples were extracted  
sequentially with 3 volumes of hexane, ethyl acetate, and methanol.  Samples were vortexed 
for 5 minutes and the top organic layer removed.   Brains were homogenized by hand in 2ml  
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of hexane:acetone (1:3.5) while the adipose tissue.  Two milliliters of hexane: ether (9:1) was 
added, vortexed, and centrifuged to allow layer separation.  The upper layer was decanted 
and transferred to a vial.  Extractions were performed twice and pooled.  Several analytical 
procedures were used to determine the concentrations of γ-[14C]HBCD and its metabolites in 
the experiments.  Liquid scintillation counting was used to analyze for total 
14
C while thin-
layer chromatography (TLC) was used to differentiate parent from metabolites of γ-
[
14
C]HBCD based on polarity.  Gel permeation chromatography (GPC) was used to remove 
large macromolecules which can interfere with further analysis of low level of target 
molecules found in brain samples.  Liquid chromatography/mass spectrometry (LC-MS) was 
also used to analyze selected samples.  Liquid scintillation counting was done using a 1900 
CA Scintillation Counter (Packard, Downers Grove, IL), and TLC analysis was done using a 
System 2000 Imaging Scanner (Bioscan, Washington, DC).  TLC was conducted using silica 
gel plates (250 mm; Whatman Lab. Div., Clinton, NJ) and a (50:50) methylene 
chloride:methanol mobile phase. Brain sample extracts were applied to a GPC column (Bio-
Beads S-X3 Beads, 200-400 mesh; Bio-Rad Laboratories Inc., Hercules, CA; Catalog #152-
2750).  Column (40cm height by 1cm diameter) was packed with Bio-Beads, after swelling 
in methylene chloride, and rinsed several times before applying sample.  Sample was applied 
and the column was eluted with methylene chloride, at a flow rate of 0.5ml/min.  Fractions 
were individually assayed by LSC (Packard 1900CA Liquid Scintillation Counter).  Fractions 
(peaks) were collected and submitted for LC-MS.  Unextractable 
14
C was also determined by 
combustion from the liver and feces.  The liquid chromatograph system of the LC-MS was an 
Alliance 2695 Separation Model (Waters, Beverly, MA) equipped with a Symmetry C18  
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column (2.1 mm x 100 mm) and guard column (2.1 by 10 mm), and a quadrupole-time of 
flight mass spectrometer (Waters Q-TOF Ultima API-US; Waters, Beverly, MA).  Isocratic 
elution conditions were used which consisted of 15% aqueous 10 mM NH4OH and 85% 
methanol:acetonitrile (80:20 v/v), 10 mM NH4OH. The flow rate of the mobile phase was 0.3 
mL min
-1
.  The mass spectrometer analysis was performed in negative ion mode (ES-) using 
a 634 m/z filter. 
 
Data Analysis: Mouse body composition estimates for blood, fat, skin, and muscle 
were 8,8,12 and 35% respectively (ILSI, 1994).  In the route of exposure study, the oral 
tissue disposition data refers to the mean of all data collected from the several dose and time 
phases in which a) animals were exposed orally with a 3mg/kg dose, and b) 4 day time points 
were available.  Intergroup comparisons for dose and tissue levels were performed by a two-
way ANOVA followed by Bonferroni post tests significant when p<0.05.  All data are 
presented as mean ± standard deviation (Prism 5.0 is distributed by GraphPad Software, Inc, 
La Jolla, CA).  Hearn Scientific Software (Melbourne, Australia) was used for half-life 
calculations and to calculate the % dose and statistical analysis. 
 
RESULTS  
 
Dose Response  
Tissue distribution results as a percent of γ-[14C]HBCD derived radioactivity in female 
C57BL/6 mice are presented in Table 1.  The top table (A) represents the dose response  
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(where response is a function of disposition) after administration of a single and repeated oral 
dose of γ-[14C]HBCD  at a concentration of 3, 10, 30 or 100 mg/kg.  Tissue distribution was 
analyzed four days after the administration of γ-HBCD. All tissues examined had low but 
measurable levels four days after dosing.  We found tissue disposition to be independent of  
dose for the 3, 10, 30, 100 mg/kg doses.  The largest percentage of the dose in the mice was 
localized in the liver and ranged between 0.21 to 0.29%.  This was followed by skin (0.14% to 
0.17%) and muscle (0.09% to 0.10%).  Low levels were detected in the blood (0.06% to 
0.09%), brain (0.01%) and then fat (0.003% to 0.005%).  These results also demonstrate the 
absence of tissue-specific sequestration.  
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Table 2.1. Disposition of γ-HBCD in Mice  
               (A) 
Dose Adrenals Skin Liver Lung Muscle Kidney Blood Adipose Brain 
mg/kg 
 
   % dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
      3 
 
0.008 ± 0.001 
(492 ± 62) 
 
0.140 ± 0.020 
(248 ± 35) 
0.240 ± 0.023 
(160 ± 15) 
0.018 ± 0.001 
(79 ± 4.3) 
0.090 ± 0.011 
(68 ± 8.3) 
0.013 ± 0.001 
(60 ± 4.6) 
0.081 ± 0.005 
(24 ± 1.5) 
0.005 ± 0.001 
(27 ± 5.4) 
0.008 ± 0.001 
(24 ± 3.0) 
10 
 
0.008 ± 0.001 
(1745 ± 358) 
0.149  ± 0.031 
(744 ± 89) 
 
0.207 ± 0.039 
(440 ± 86) 
0.018 ± 0.002 
(258 ± 23) 
0.100 ± 0.010 
(203 ± 7.2) 
 
0.012 ± 0.001 
(193 ± 12) 
0.086 ± 0.009 
(90 ± 9.5) 
 
0.003 ± 0.001 
(146 ± 73) 
0.007 ± 0.001 
(73 ± 10) 
30 
 
0.009 ± 0.002 
(5537 ± 893) 
0.165 ± 0.069 
(2480 ± 301) 
 
0.289 ± 0.029 
(2015 ± 213) 
0.014 ± 0.001 
(607 ± 406) 
0.101 ± 0.043 
(678 ± 80) 
 
0.014 ± 0.001 
(664 ± 72) 
0.082 ± 0.008 
(270 ± 26) 
 
0.003 ± 0.001 
(625 ± 262) 
0.009 ± 0.001 
(248 ± 28) 
100 
 
0.007 ± 0.001 
(18354 ± 426) 
0.154 ± 0.037 
(7688 ± 809) 
 
0.241 ± 0.061 
(6811 ± 1233) 
0.017 ± 0.002 
(2502 ± 227) 
0.094 ± 0.021 
(2101 ± 87) 
 
0.013 ± 0.002 
(2124 ± 290) 
0.061 ± 0.008 
(867 ± 93) 
 
0.004 ± 0.001 
(2580 ± 890) 
0.008 ± 0.001 
(808 ± 101) 
3 
Repeated 
0.009 ± 0.002 
(504 ± 38) 
0.190 ± 0.020 
(302 ± 70) 
0.260 ± 0.034 
(178 ± 22) 
0.019 ± 0.005 
(80 ± 21) 
0.110 ± 0.020 
(77 ± 14) 
 
0.015 ± 0.001 
(70 ± 5.0) 
*0.134 ± 0.02 
(40 ± 8.1) 
 
*0.008 ± 0.001 
(39 ± 4.9) 
0.010 ± 0.002 
(27 ± 5.4) 
   
              (B) 
Time Adrenals Skin Liver Lung Muscle Kidney Blood Adipose Brain 
 1 hour 
 
0.008 ± 0.001 
(492 ± 1.7) 
0.042 ± 0.002 
(76 ± 7) 
3.33 ± 0.76 
(2309 ± 220) 
0.018 ± 0.002 
(79 ± 6.0) 
0.249 ± 0.050 
(148 ± 3.1) 
0.013 ± 0.001 
(63 ± 3.8) 
1.23 ± 0.30 
(340 ± 85) 
0.002 ± 0.000 
(15 ± 2.5) 
0.013 ± 0.001 
(35 ± 5.2) 
3 hours 
 
0.024 ± 0.002 
(1627 ± 37) 
0.165 ± 0.010 
(248 ± 12) 
 
2.63 ± 0.24 
(1862 ± 86) 
0.083 ± 0.010 
(377 ± 23) 
0.519 ± 0.051 
(311 ± 9.2) 
 
0.11 ± 0.001 
(560 ± 20) 
0.303 ± 0.011 
(113 ± 19) 
 
0.008 ± 0.001 
(40 ± 8.0) 
0.035 ± 0.001 
(101 ± 2.8) 
8 hours 
 
0.018 ± 0.002 
(1145 ± 54) 
0.280 ± 0.026 
(420 ± 37) 
 
1.82 ± 0.51 
(1335 ± 59) 
0.065 ± 0.008 
(270 ± 11) 
0.436 ± 0.020 
(256 ± 14) 
 
0.11 ± 0.001 
(522 ± 19) 
0.278 ± 0.002 
(105 ± 8.7) 
 
0.022 ± 0.001 
(96 ± 7.2) 
0.018 ± 0.001 
(55 ± 10) 
1 day 
 
0.014 ± 0.001 
(850 ± 40) 
0.173 ± 0.018 
(260 ± 21) 
 
0.886 ± 0.03 
(631 ± 26) 
0.032 ± 0.002 
(172 ± 14) 
0.259 ± 0.022 
(155 ± 13) 
 
0.035 ± 0.002 
(163 ± 11) 
0.153 ± 0.001 
(65 ± 9.3) 
 
0.030 ± 0.001 
(108 ± 11) 
0.010 ± 0.001 
(29 ± 175) 
2 days 
 
0.009 ± 0.002 
(498 ± 5.9) 
0.144 ± 0.011 
(251 ± 19) 
0.382 ± 0.09 
(233 ± 15) 
0.023 ± 0.002 
(98 ± 11) 
0.105 ± 0.021 
(84 ± 9.2) 
 
0.015 ± 0.001 
(74 ± 5.0) 
0.100 ± 0.010 
(32 ± 3.1) 
 
0.006 ± 0.05 
(29 ± 3.0) 
0.008 ± 0.002 
(28 ± 3.7) 
4 days 
 
0.008 ±0.001 
(492 ± 62) 
 
0.140 ± 0.020 
(248 ± 35) 
0.240 ± 0.023 
(160 ± 15) 
0.018 ± 0.001 
(79 ± 4.3) 
0.090 ± 0.011 
(68 ± 8.3) 
0.013 ± 0.001 
(60 ± 4.6) 
0.081 ± 0.005 
(24 ± 1.5) 
 0.005 ± 0.001 
(27 ± 5.4) 
0.008 ± 0.001 
(24 ± 3.0) 
7 days 
 
0.007 ± 0.001 
(450 ± 20) 
0.130 ± 0.012 
(192 ± 15) 
 
0.171 ± 0.09 
(139 ± 9.3) 
0.014 ± 0.001 
(61 ± 12) 
0.085 ± 0.010 
(60 ± 10) 
 
0.010 ± 0.002 
(44 ± 4.1) 
0.069 ± 0.002 
(21 ± 2.4) 
 
0.003 ± 0.001 
(20 ± 1.9) 
0.007 ± 0.001 
(23 ± 1.7) 
14 days 
 
0.006 ± 0.002 
(430 ± 38) 
0.123 ± 0.011 
(184 ± 12) 
0.099 ± 0.05 
(76 ± 2.4) 
0.012 ± 0.001 
(50 ± 2.1) 
0.072 ± 0.002 
(47 ± 3.4) 
 
0.009 ± 0.001 
(38 ± 3.4) 
0.052 ± 0.015 
(16 ± 2.1) 
 
 0.0021 ± 0.001 
(15 ± 2.0) 
0.007 ± 0.002 
(22 ± 3.7) 
          
(C)          
Route Adrenals Skin Liver Lung Muscle Kidney Blood Adipose Brain 
i.v. 
 
0.011 ± 0.002 
(677 ± 123) 
 
0.162 ± 0.025 
(287 ±.44) 
*0.289 ± 0.021 
(193 ± 18) 
0.021 ± 0.002 
*(96 ± 9.1) 
  *0.103 ± 0.020 
(75 ± 7.3) 
 *0.016 ± 0.001 
*(72 ± 5.2) 
*0.095 ± 0.007 
*(29 ± 2.1) 
0.006 ± 0.001 
(32 ± 5.1) 
0.008 ± 0.001 
(24 ± 3.0) 
oral 
 
0.008 ± 0.001 
(492 ± 62) 
 
0.140 ± 0.020 
(248 ± 35) 
0.240 ± 0.023 
(160 ± 15) 
0.018 ± 0.001 
(79 ± 4.3) 
0.090 ± 0.01 
(68 ± 8.3) 
0.013 ± 0.001 
(60 ± 4.6) 
0.081 ± 0.005 
(24 ± 1.5) 
0.005 ± 0.001 
(27 ± 5.4) 
0.008 ± 0.001 
(24 ± 3.0) 
             
Disposition of γ-HBCD derived radioactivity (A) four days following a single (3, 10, 30, 100 
mg/kg) and 10 day repeated (3 mg/kg) oral dose,  (B) four days following a 3 mg/kg dose 
through i.v. or oral and (C) at multiple time points following a single 3 mg/kg oral dose. All  
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 data are mean ± standard deviation; represented as percent dose (top value) or concentration 
of nanogram of administered dose/gram of tissue (ng/g; bottom value in parenthesis). 
*Indicates significance as compared to lowest dose (p<0.05). 
 
 
Repeated Exposure  
 
 
 
Tissue disposition was not altered after a 10 day repeated exposure in all tissues except 
for adipose and blood (Table 1. A). Disposition was significantly increased between a single 
and repeated oral exposure of 3mg/kg γ-[14C]HBCD in the adipose tissue (0.005 ± 0.002% vs. 
0.010 ± 0.001% respectively) and in the blood (0.081 ± 0.005 vs. 0.134 ± 0.02).  
 
Time-Course  
 
From the dose/response study, the lowest dose was chosen (3mg/kg) for the kinetic 
study because its behavior was in the linear range and it is the most environmentally relevant 
dose examined from that study.  By observing tissue disposition over time, low but detectable 
concentrations were present in tissues at all time points investigated (Table 1.B).  This 14 day 
time course study shows a biphasic profile with an initial steep decline on average from 1 
hours to 2 days and a less steep decline between 2 days and 14 days for liver, kidney, blood 
and brain (Figure 2).  
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Tissue Specific Two Component Exponential Decay Curve after Oral Exposure to γ-HBCD. 
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Figure 2.2.  Percentage of total γ-HBCD derived radioactivity in tissues vs. time (in days) 
after a single oral administration of 3mg/kg γ-[14C]HBCD.  Each point represents the average  
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value ± standard deviation obtained from 4-6 animals.  The dashed line represents a  
nonlinear regression fit line for a two component exponential decay curve from the maximum 
concentration in each tissue and through day 14. The y-intercept at time = 0 is back 
extrapolated from peak concentration in each tissue. 
 
Liver tissue and blood had the highest observable levels where maximum 
concentrations were measured at 1 hour.  While most tissues had highest measured levels at 3 
hours, γ-[14C]HBCD derived radioactivity had maximum measured concentration at 1 day in 
fat. The delay in maximum measured concentration in the adipose tissue is a function of a 
slow rate of perfusion and possibly transient partitioning based on this compound‟s 
lipophilicity. Times to maximum observed concentrations were plotted in Figure 2. 
 
After oral exposure to γ-[14C]HBCD, the distribution of radioactivity as a function of 
time was examined in the major tissue depots: liver, blood, fat, skin and muscle.  In all cases, 
the loss of radioactivity from the tissue could be described by an exponential decay curve, 
consisting of two components.  As can be seen in Figure 2, γ-HBCD derived radioactivity is 
rapidly cleared from the blood, so that by 1 hour after oral administration, less than 1.3% of 
the dose remained in the blood.  From this point on, a two component exponential decay 
curve is used to fit the clearance of γ-HBCD derived radioactivity from tissues. The half lives 
and pool sizes of these two components are shown in Table 2. 
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Table 2.2. Estimated Tissue Half-lives of γ-HBCD in Mice 
 
     Half-life                          Pool size    
                                        (days)                               (% dose) 
Tissue      α½      β ½    α phase     β phase 
Liver  0.3 ± 0.0 2.3 ± 0.2 2.47 ± 0.42 0.61 ± 0.04 
Blood 0.6 ± 0.1 3.5 ± 0.3 0.21 ± 0.01 0.08 ± 0.00 
Lung 0.4 ± 0.1 2.3 ± 0.2  0.07 ± 0.01 0.03 ± 0.00 
Kidney 0.2 ± 0.0 2.8 ± 0.2 0.12 ± 0.01 0.02 ± 0.00  
Muscle 1.0 ± 0.1 3.6 ± 0.3 0.57 ± 0.03  0.45 ± 0.02 
Skin 0.4 ± 0.0 5.2 ± 0.3 0.24 ± 0.02  0.15 ± 0.01 
Brain 0.1 ± 0.0  0.8 ± 0.1 0.04 ± 0.0   0.02 ± 0.00 
Fat 0.9 ± 0.1 3.6 ± 0.2         --         -- 
 
Tissue specific, biphasic half-lives were calculated from female mice given a single 
oral dose (3mg/kg) of γ-[14C]HBCD.  Calculations are derived from % of administered dose.  
α and β phase time points are individually based on peak tissue concentrations.  Pool size was 
calculated by determining the y-intercept of each phase.  Back extrapolation from adipose 
tissue peak concentration over predicted the pool size due to increased time to reach maximal 
peak concentration based on perfusion coefficient and therefore not reported here. All data 
presented in days. 
 
IV vs. Oral: Tissue Disposition   
 
Environmental chemicals are rarely encountered by an intravenous route.  However, 
by comparing the tissue disposition between iv and oral routes we are able to determine the 
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percentage absorbed through the gut.  To address gut absorption, a dose identical to the oral 
dose was administered to mice by iv, and tissue disposition was compared.  A comparison of 
the major tissue depots 4 days after treatment with the same oral and iv dose is shown in 
Table 1.C.  The percent dose and concentration (ng/g) was similar between both routes, but 
slight differences were observed.  Although every tissue measured had higher levels after iv 
as compared to the oral route of exposure (same values for brain), not all were statistically 
significant.  There were slight increases in the iv as compared to the oral route of exposure.  
Statistically significant differences are listed here as a percent of the oral to iv levels: liver 
(83%), muscle (82%), kidney (83%) and blood (85%).  The higher levels found in these 
tissues after iv administration implies an oral absorption efficiency of 83 ± 2%.  For this 
compound a four day post-exposure turned out to be not the most ideal time point for this 
calculation as only trace levels are present in the tissues during this terminal phase of tissue 
elimination. This was not known prior to the study.  However, as absorption is not a static but 
kinetic process; this analysis is simply a snapshot in absorption and implies a high level of 
absorption.  
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Elimination 
  
  The elimination of γ-HBCD derived radioactivity was analyzed by daily collection of urine 
and feces from individual animals held from 1-14 days post-treatment.  Total cumulative 
elimination after oral administration in urine and feces is shown in Figure 3 for the four 
treatment levels.   
 
 
Cumulative Fecal and Urinary Elimination 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Cumulative elimination of γ-HBCD derived radioactivity following a single, oral    
dose  (3, 10, 30, 100 mg/kg) in feces and urine.  Data presented as mean percent administered 
dose eliminated ± standard deviation (n=4-6/group).  
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           This data clearly demonstrate that the major route for elimination of this compound is 
via the feces.  Approximately 80% of the administered dose had been eliminated in the urine 
and feces, collectively, by the fourth day.  In all groups, 25% of the dose was eliminated in 
the urine on the first day.  By the end of the collection period, up to 30% was eliminated in 
the urine.  Expressed as percent dose, the data demonstrate a lack of dose dependency in 
urinary excretion.  Essentially no radioactivity was detected (<1.5 times background) in the 
urine past Day 5.  Average recovery of 
14
C, including that recovered from urine and feces 
was 80.1 ± 4.2%.  Elimination of 
14
C derived radioactivity into feces was also rapid.  As with 
urinary elimination, there was no dose dependency in fecal elimination of γ-HBCD.  The  
percent of the dose eliminated in feces was consistent between dose groups on all days.  In 
every dose group, approximately 45% was eliminated on the first day (Figure 3).  
Significantly less was eliminated on the second day, averaging 5% of the dose across all dose 
groups.  By day five, a total of 50% had been eliminated in the feces.  
 
IV vs. Oral: Elimination  
 
Figure 4 compares the percent of dose in the urine and feces over four days.  Excreta 
profiles are consistent between iv and oral routes of administration.  Forty-five percent of the 
dose was eliminated in the feces of the iv administered mice on the first day whereas 52% 
was eliminated in the orally treated animals.  After 4 days, 55% percent of the dose was 
eliminated in the feces following oral exposure and 51% following iv, an approximate 8% 
difference in the two routes. 
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Cumulative Fecal and Urinary Elimination between IV and Oral Routes 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Cumulative elimination of γ-HBCD derived radioactivity following a single dose 
(3mg/kg) via i.v and oral route in urine and feces.  Data presented as mean percent 
administered dose eliminated ± standard deviation (n=4-6/group).  Presence of a * data point 
indicates significance of daily percent eliminated (*p <0.05 as compared to other route at 
same time point). 
 
The amount of 
14
C derived radioactivity in the urine eliminated on the first day is 
relatively constant between the iv and oral routes of administrations.  This implies that γ-
[
14
C]HBCD derived radioactivity was absorbed and eliminated similarly after exposure by 
these two routes.  The iv route of exposure had significantly higher levels of 
14
C derived 
radioactivity in the urine than oral at Day 1, 3 and 4.  This change reflects slightly decreased 
oral absorption.  The large variance at Day 2 may have prevented this time point from also  
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being significantly increased.  Twenty eight percent of the dose was eliminated in the urine 
of the iv administered mice on the first day, whereas 23% was eliminated in the oral dosed 
animals.  Cumulatively 31% of the dose was eliminated in the urine following exposure 
following iv treatment, while 26% was eliminated after the oral route in four days.  Based on 
fecal and urinary elimination patterns, comparison between the iv and oral routes indicate 
that γ-[14C]HBCD may be well absorbed (85 ± 3%) orally.  This agrees with the difference 
found in tissues deposition when comparing the iv and oral routes of exposure (83 ± 2%).  
The remaining amount [(85 and 83% of absorbed material) – 100% total absorption] is a 
small portion (an estimated 15-17%) which is most likely unabsorbed material. Ideally to 
calculate absorption, the concentration of radioactivity in the plasma over time is the gold 
standard.  However, the data points in this study were too limited during this time resulting in 
the inability to analyze the absorption this way.  
 
TLC  
 
The nature of the γ-[14C]HBCD derived radioactivity in the urine and feces was examined by 
thin-layer chromatography (Figure 5).  No parent compound was detectable in the urine at 1 
or 2 days after treatment.  TLC consistently revealed one major peak (Rf = 0.0) which 
contains several polar metabolites. A similar metabolite pattern was seen in the blood and 
bile (data not shown). 
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 Thin Layer Chromatography of Tissues and Excreta after Oral Administration of γ-HBCD. 
 
 
                                                      Time (min) 
 
Figure 2.5. 
14
C derived radioactivity was determined based on retention time using TLC.  
Once resolved, peaks were scraped from the silica plate, eluted with acetone, and 
characterized on LC-MS. Chromatographs of A) α-, β-, and γ-HBCD standards B) liver 
homogenate C) feces and D) urine.  A representative sample and extract were chosen for 
presentation.  Blood, bile and urine all contained similar chromatographic profiles.   
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This is in contrast to fecal elimination where low levels of the parent compound are 
present.  It should be pointed out that only 48% of the γ-[14C]HBCD derived radioactivity 
was extractable from the excreted feces.  This contrasts with essentially complete extraction 
of γ-[14C]HBCD following its addition to control feces.  This suggests that nonextractable 
radioactivity was not parent γ-HBCD, but metabolites.  Our results indicate that greater than 
95% of the radioactivity that was excreted from the body was no longer γ-HBCD, but several 
metabolites of this compound.  To verify this, standards for the three main diastereoisomers, 
α-[14C]HBCD, β- and γ- were spotted on TLC plates and two bands with baseline resolution 
formed. In this system, β-[14C]HBCD band migrated on a TLC with a shorter retention (Rf = 
0.50) value than α- and γ-[14C]HBCD which co-migrated as a second band with a Rf = 0.61.  
There were several bands detected in the fecal extracts with reference values at 0.0 and 0.14.  
Interestingly, two bands in the fecal extract (Rf = 0.44 and 0.54) migrated the same as the 
two standard bands (Rf = 0.50 and 0.55).  The slight differences in Rf values can be 
explained as a function of fecal matrix purity and expected.  Fecal co-extractables slightly 
impede migration on the TLC plate. Liver extracts were analyzed near the time of peak tissue 
concentration, 3 hours. In the liver tissue, several bands were detected with Rf values at 0.0, 
0.46, 0.50, and 0.62.  Similar to the fecal extracts, two bands in the liver extracts (Rf = 0.50 
and 0.62) had similar values to the two standard peaks (Rf = 0.50 and 0.55). 
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GPC 
 
The nature of the γ-[14C]HBCD derived radioactivity in the brain and fat was initially 
examined by gel permeation chromatography (GPC).  GPC separates based on size and was 
used as an initial separation and clean up step.  Unlike TLC, GPC is not useful for the 
identification of individual stereoisomers as all HBCD stereoisomers migration at the same 
rate.  GPC chromatograms revealed one major peak (data not shown) which was further 
analyzed using LC-MS.  
 
LC-MS 
 
Due to the inability of TLC to resolve α- or γ-HBCD and GPC to resolve any HBCD 
stereoisomer, the peaks were further characterized by analyzing them with LC-MS.  This was 
also performed to determine whether 1) the parent γ-HBCD was present, and 2) if it had been 
converted to α- or β-HBCD.  This was performed by comparing the TLC bands or GPC 
fraction to LC-MS standards; α-, β-, and γ-HBCD with retention times of 3.40, 4.06, and 4.89 
minutes, respectively (Figure 6).   
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Title: LC-MS chromatograms of Tissues and Excreta after Oral Administration of γ-HBCD. 
 
 
Time (min) 
 
Figure 2.6. 
14
C derived radioactivity was determined based on retention time and molecular 
weight using LC/MS.  Chromatograms of α-HBCD, β-, and γ- standards, liver, and feces 
peaks from TLC were analyzed.  Standards are a representative sample and retention times  
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varied slightly from day to day.  To conserve low levels of radioactivity, brain tissue were 
pooled and Gel Permeation Chromatography (GPC) was used prior to LC/MS analysis. 
 
The TLC peaks in the liver (Rf = 0.50 and 0.61) and fecal extracts (Rf = 0.44 and 
0.54), were scraped, eluted with acetone and injected into the LC-MS.  Results indicate that 
all peaks had a molecular weight of ~641 suggesting that they are HBCD stereoisomers.  In 
the liver, TLC peaks of Rf = 0.50 and 0.61 had retention times of 4.89 and 4.23 minutes, 
similar to γ-HBCD and β-HBCD, respectively.  In the fecal extracts, TLC peak 0.44 had a 
retention time of 4.06 minutes, which corresponds to HBCD-β.  Rf =0.54 resolved into two 
LC-MS peaks with retention times of 3.40 and 4.89 minutes, which corresponding to α-
HBCD and γ-HBCD, respectively.  All three diastereoisomers, α-, β- and γ-HBCD, were 
detected in the feces 1 day post oral administration of γ-[14C]HBCD (Figure 6).  However, in 
the liver we were only able to detect the presence of γ-HBCD and β-HBCD, 3 hours post oral 
administration of γ-[14C]HBCD.  The GPC fraction of the adipose tissue (fat) on the LC-MS 
had molecular weight of 641 and retention times that matched γ-HBCD, β-HBCD and α-
HBCD.  However, the brain extract had a molecular weight of 641 and a retention time 
which matched that of the β-HBCD standard.  
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Summary of the parent, stereoisomer and metabolite profiles in tissues, biological 
matrices and excreta after exposure to γ-[14C]HBCD can found in Table 3.  Most of what has 
been detected in the liver and feces are metabolites, 79 and 85% respectively.  However, 15 
and 11% of the radioactivity present in the liver and feces were stereoisomerized HBCD 
products.  
 
 
Table 2.3. Summary of Metabolite Profiles in Female Mouse Tissue and Excreta at 14 days 
after Oral Exposure to γ-HBCD  
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Matrix   Time Parent Isomerization Metabolites 
 Liver  3 hours 6% 15% 79% 
  Rf = 0.61;  HBCD-γ Rf = 0.50;   HBCD-β Rf = 0.00;  Unknown (62%) 
    Unextractable (17%) 
 Fat 24  hours 84% 16% 0% 
  HBCD-γ  HBCD- β (11% )   
    HBCD- α (5%)  
 Brain 3 - 48 hours 0% 100% 0% 
    HBCD- β     
 Feces 24 hours 4% 11% 85% 
  Rf = 0.54;  HBCD-γ Rf =0.44;  HBCD- β (4%)   Rf = 0.00;  Unknown (29%) 
   Rf = 0.54;  HBCD- α (7%) Rf = 0.14;  Unknown (4%) 
    Unextractable (52%) 
    Urine 
    Blood 
    Bile 
24 hours 0% 
Rf = 0.00;   Unkno 
 
 0% 
Rf = 0.00;   Unkno 
 
100% 
Rf = 0.00;  Unknown 
 
     
     
Stereoisomerized products were also detected in the fat, 16%, and brain, 100%.  Low 
levels of the parent γ-HBCD were found in the liver and feces, 6 and 4%, respectively.  The 
bile, serum and urine contained 100% metabolites.  This data in conjunction with the kinetic 
data support the rapid metabolism and elimination of γ-HBCD. 
 
DISCUSSION 
 
 
The presence and rapid increase in environmental and human concentrations of 
HBCD diastereomers has heightened interest in toxicological consequences of these  
chemicals. The toxicity of HBCD commercial mixtures has been investigated recently;  
however it raises questions as to whether diastereoisomeric specific effects are seen. The 
diastereoisomers of HBCD differ in their structure, physical orientation and chemistry which 
may result in differences in pharmacokinetics, metabolism and biological response 
(Hunzinker et al., 2004; Covaci et al., 2006). It is therefore essential to understand the factors 
involved in human health risk for individual diastereoisomers of HBCD.  γ-HBCD accounts 
for a large proportion of HBCD global production and usage and is consistently the dominant 
diastereoisomer found in the environment.  However, it is usually at lower levels in human 
and wildlife tissues, where α-HBCD predominates (Covaci et al., 2006).  Furthermore, there 
is a large variation in observed human body burden concentrations of HBCD stereoisomers 
that are not explained by exposure data.  
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The objectives of this investigation were to determine the absorption, distribution, 
metabolism and excretion of γ-HBCD in female mice to better evaluate the toxicity and 
behavior of this compound.  This study suggests that approximately 85% of an oral dose of γ-
HBCD was absorbed from the gut and was dose independent.  This was based on the oral and 
iv routes of administration having similar tissue and excreta concentrations of γ-HBCD 
derived radioactivity.  Although, absorption typically is calculated using plasma 
concentration over time, further time points are needed. This compound shows similar 
behavior as other large halogenated molecules (Kedderis et al., 1994, Staskal et al., 2005).  
Distribution of γ-HBCD was initially to the liver and muscle, followed by some 
redistribution to skin and lungs, with very little to adipose tissue.  This is in contrast to other 
persistent organic pollutants, such as TCDD, which accumulates in the liver and fat (Rose et 
al., 1976), and PBDEs, which accumulates in the fat (Staskal et al., 2005).  The pattern seen 
here was not dependant on dose or route of γ-HBCD exposure.  
 
The primary route of γ-HBCD elimination was through the feces (50% of dose).  
However, almost 30% of the administered dose was eliminated via the urine.  Elimination, as 
tissue disposition, was also not affected by the dose within the range studied or by the two 
routes of administration tested.  The rapid rate of elimination of γ-HBCD derived 
radioactivity was in contrast to that observed for TCDD, where a whole-body half-life in 
mice of 3-5 weeks has been reported (Rose et al., 1976), or with BDE-47, which had a 
whole-body half-life of approximately 3 weeks (Staskal et al., 2005). 
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Of the γ-HBCD derived radioactivity eliminated in the urine, 100% were metabolites.  
The same was true for the radioactivity detected in the bile and blood.  Feces and liver 
consisted of both, i.e., parent γ-HBCD and metabolites.  The radioactivity patterns present in 
the liver and feces were similar with the majority 94-96%, being detected as metabolites, and 
only 4-6% was parent γ-HBCD.  Of the metabolites present, 11-15% constituted 
stereoisomerization products.  β-HBCD and parent γ-HBCD were detected in the liver, while 
the three major diastereoisomers, i.e. α-, β-, and γ-HBCD were present in the feces. These 
preliminary results suggest that intestinal flora may alter the biliary metabolites, since the 
chromatographic results for extracts of bile and feces were quite distinct.  The action of 
intestinal microorganisms on HBCD remains unknown.  In a recent study, bacteria isolated 
from soil were shown to metabolize γ-HBCD; however, the same bacterial strain failed to 
degrade α-HBCD (Yamada et al., 2009).  Since the HBCD derived radioactivity eliminated 
in the urine, bile and blood was in the form of polar metabolite(s) and storage of HBCD 
metabolites in the tissues was negligible, the more rapid clearance of HBCD when compared 
to TCDD or PBDEs can be attributed to rapid metabolism of γ-HBCD in the mouse. 
 
It is unclear in the case for γ-HBCD whether the parent compound or its metabolites  
is the toxic agent. Metabolism often results in detoxification.  Using this assumption, we  
might predict that animals with higher rates of metabolism of γ-HBCD will be more resistant 
to its toxic actions.  Such a correlation, in fact, may exist in the mouse.  Differential 
metabolism capacities of γ-HBCD and α-HBCD have been observed in vitro (Zegers et al., 
2005). α-HBCD was more slowly metabolized than γ-HBCD, and because of this was  
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hypothesized to be several times more toxic.  However, for PBDEs and PCBs it is well 
known that hydroxyl or methylsulfonyl metabolites can have a significant endocrine 
modulating effect. At present we simply know very little about the mode of action of HBCD 
and individual diastereomers.  This emphasizes the need for toxicity studies on individual 
HBCD diastereoisomers.    
 
Metabolites have been detected here for the first time in mice after oral exposure of γ-
HBCD.  These metabolites were found in the liver, blood, bile, urine and feces between 3-24 
hours post-exposure. Although, identification of these metabolites is beyond the scope of this 
report, previous reports have identified metabolites after oral administration of the HBCD 
commercial mixture.  One study identified four metabolites of HBCD of unknown structure 
in rats (Yu et al., 2003).  Another in vitro study showed three HBCD metabolites were 
detected with LC-MS, where two metabolites were identified as monohydroxy-HBCD 
(Zegers et al., 2005).  Identification of a monohydroxy-HBCD was also observed after an in 
vitro study using rainbow trout liver microsomes (Huthala et al. 2006).  
Degradation/metabolite products have been observed in office dust samples, i.e. 
pentabromocyclododecene (PBCDe) and two isomers of tetrabromocyclododecene TBCDe 
(Abdallah et al. 2008).  In chicken eggs and whitefish PBCDe was identified using GC 
(Hiebl and Vetter, 2007). Therefore, the presence of HBCD metabolites has been previously 
noted; however, it remains unclear whether these metabolites are the product of α-, β-, or γ- 
HBCD.  The present in vivo study reported here suggests that γ-HBCD can be rapidly  
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metabolized, and may serve as a source of the metabolites identified in these previous 
studies.  In the case of HBCD, it is unclear whether the more highly brominated parent or 
lower brominated metabolites are more or less toxic. 
 
Our in vivo data indicates two factors may be responsible for the shift observed from 
the predominance of γ-HBCD in the commercial mixture and environment relative to α-
HBCD in biota.  First, γ-HBCD is rapidly metabolized and eliminated.  Second, in vivo 
stereoisomerization of γ-HBCD to α- and β- is occurring.  Furthermore, the 
stereoisomerization seen is rapid. Stereoiosmerization is also supported by work previously 
reported in non-mammalian species such as fish (Law et al., 2006).   In vitro experiments 
with rat and harbor seal microsomes have showed biotransformation of β-HBCD and γ-
HBCD was faster than that of α-HBCD (Zegers et al., 2005).  Although we have detected 
rapid elimination of γ-HBCD in this mammalian mouse model, future in vivo kinetic studies 
using α-HBCD are needed to determine whether in vivo bioaccumulation, not seen here with 
γ-HBCD, may further explain the diastereoisomeric shift. 
 
We conclude the biological persistence of γ-HBCD in mice is low and may explain 
low levels of γ in biota.  This ADME data would support the hypothesis that metabolism and 
stereoisomerization, in addition to differential exposure, plays a role in the observed 
stereoisomer profiles in biota. 
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ABSTRACT 
Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic 
pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is 
used as an additive flame retardant in a wide variety of household consumer products.  Three 
main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10%, 10%, and 
80% of the mixture, respectively.  Despite its small contribution to HBCD global production 
and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including 
breast milk and blood in North America, European Union and Asia.  No mammalian or 
human data are currently available regarding the toxicokinetics of α-HBCD.  This study was 
conducted in an effort to fully characterize the absorption, distribution, metabolism and 
elimination of α-HBCD following a single and repeated exposure with respect to dose, time, 
and route of administration in female C57BL/6 mice.  Results indicate that approximately 
90% of the administered dose (3mg/kg) was absorbed after oral exposure.  Disposition was 
1) dictated by lipophilicity as adipose, liver, muscle and skin were major depots and 2) was 
dose-dependent with non-linear accumulation at higher doses.  Elimination, both whole-body 
and from individual tissues, was biphasic.  α-HBCD derived radioactivity was excreted in the 
feces as parent and metabolites whereas, urine only contained metabolites.  Presence of polar 
metabolites in the blood and urine were a major factor in determining the rapid initial whole-
body half-life after a single oral exposure. Initial half-lives were ~1-3 days and much longer 
terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD 
bioaccumulation.  A 10 day repeated study supports α-HBCD bioaccumulation potential.   
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Stereoisomerization previously observed after exposure to γ–HBCD was not seen after 
exposure of α-HBCD.  The toxicokinetic behavior reported here has important implications 
for the extrapolation of toxicological studies of the commercial HBCD mixture to the 
assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people.  
 
INTRODUCTION 
 
1,2,5,6,9,10-hexabromocyclododecane (HBCD) is a brominated aliphatic cyclic 
hydrocarbon and a high production volume chemical used as a flame-retardant primarily in 
polystyrene foams used for insulation, with secondary uses in upholstered furniture,  
automobile textiles/cushions,  packaging material, and electronic equipment.  Concern for 
HBCDs has risen as it has been detected not only in wildlife (Tomy et al., 2004; Covaci et 
al., 2006)  but also human breast milk and serum (Weiss et al., 2004; Thomsen et al., 2005; 
Meijer et al., 2008). Time trend studies indicate that concentrations of HBCD in the 
environment, humans and wildlife are increasing (Sellström et al., 2003; Kakimoto et al., 
2008; Hermanson et al., 2010).  The discovery of HBCD in Arctic marine ecosystems 
provides compelling evidence of long-range transport of this compound (de Wit et al, 2010). 
Field studies in marine mammals and aquatic wildlife have suggested HBCD is also highly 
bioaccumulative (Law et al., 2006).  
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Diet is likely a major source of HBCD exposure.  Intake of HBCD was estimated at 
16 ng/day, primarily from meat; however fish and vegetables also had significant levels 
(Schecter et al., 2010).  Dust, in addition to the diet, is likely another important pathway of 
human exposure to HBCD due to levels present indoors (Roosens et al., 2009).  Non-dietary 
ingestion of dust may represent an important route of exposure especially for toddlers and 
young children (Lioy et al., 2000; Wilford et al., 2005; Wu et al., 2007).  
 
       
                      α-HBCD                               β-HBCD                                γ-HBCD 
 
Figure 3.1. Chemical structures of 1,2,5,6,9,10-Hexabromocyclododecane alpha, (α-HBCD), 
beta (β-HBCD) and gamma (γ-HBCD).                                                                                                
 
Previous literature has focused on the three main diastereomers present in the 
commercial mixture, denoted as alpha (α), beta (β), and gamma (γ); with the γ-diastereomer 
predominating (>70%) (Heeb et al., 2005).  It is well documented that there is a shift in the 
relative diastereomer contribution with increasing trophic species in aquatic food webs 
(Covaci et al., 2006,  Law et al., 2006).  In general lower level organisms contain mostly γ-
HBCD (closely mimicking the commercial mixture and certain environmental levels) while  
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α-HBCD dominates the diastereomer pattern in apex predators. In fish and aquatic mammals, 
HBCD has been observed to accumulate in lipid rich organs including liver, gonads, muscle, 
and adipose tissue (Janák et al.; 2005, Peck et al., 2008; Xian et al., 2008) and, where 
investigated, α-HBCD predominated.  Presence of high concentrations of α-HBCD in marine 
mammals and birds of prey suggests persistence and biomagnifications up the food chain.  
Despite α-HBCD‟s small contribution to HBCD global production and usage (±10% of 
commercial mixtures), α-HBCD is the major congener found in biota.  
 
HBCD has been detected in the few human exposure studies conducted to date and, 
where investigated, α-HBCD predominates.  Thomsen et al. (2007) reported that all serum 
samples tested in workers from an industrial plant occupationally exposed to commercial 
HBCD had 60% α-HBCD and 39% gamma (ranged 6-856 ng/g lw).  Ryan et al. (2006) 
reported that the mean concentrations of α-HBCD in human breast milk collected in Ontario, 
Canada (2002-2003) and Texas, USA (2002) were 3.8 and 0.5 ng/g  lipid weight (lw), 
respectively. Kakimoto et al. (2008) analyzed breast milk from Japanese women (age 25–29) 
over the period 1973–2006; total mean HBCD concentrations over the period 2000 – 2006 
ranged from 1 to 4 ng·kg
-1
 lw where α-HBCD predominated in nearly 90% of samples tested. 
Higher total HBCD (α, β, and γ) values were reported in breast milk of women living in 
Spain between 2006-2007 (Eljarrat et al. 2009) where the mean concentration was 27 ng·kg
-1
 
lw (range 3 to 188 ng·kg
-1
 lw).  α-HBCD dominated a smaller subset of the samples tested 
with γ-HBCD predominating in others.  Thomsen et al., (2007) suggested that the elevated 
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levels of γ-HBCD in some samples are an indication of recent exposure to the commercial 
mixture, and with enough time; γ-HBCD will either be cleared from the system and/or 
converted to α-HBCD. 
 
The field observations described in the current human and wildlife studies are 
unfortunately unable to fully characterize the exposure pathway, dose, and duration of 
exposure. The current hypothesis which may explain of the elevated levels of the α-HBCD 
found in biota is thought to be due to either diastereomer-selective uptake, diastereomer-
specific metabolic rates (Law et al., 2006; Zegers et al., 2005), and/or in vivo 
stereoisomerization (Szabo et al., 2010).  Stereoisomerization of purified γ-HBCD to α 
and/or β was reported in mice after a single oral exposure by Szabo et al.(2010) who 
demonstrated that in vivo stereoisomerization of γ-HBCD is rapid, 3-48 hours post-oral 
exposure, and is tissue specific in the liver, fat and brain.  However, more detailed 
information about the kinetics, toxicology, pathways of exposure, and bioavailability of the 
HBCD diastereomers are needed to help explain observations seen in the environment, 
wildlife and humans.   
 
In predicting human health risks posed by HBCD, it is necessary to accurately predict 
internal dose and the fate of these compounds.  There are currently no toxicokinetic or 
toxicity data on α-HBCD in any mammalian species.  This study is a companion paper to our 
previous work with γ-HBCD (Szabo et al., 2011) where the same methodology was used 
allowing a direct comparison of the kinetics between the two diastereomers. The dose  
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concentrations selected for this toxicokinetic study were based on previous effect studies 
after exposure to the commercial mixture of HBCD.  Developmental neurotoxicity was 
observed in mice after a single (acute) exposure with a LOAEL = 0.9 mg/kg bw/day 
(Erikkson et al., 2006).  A 28 day repeated dose study in rats observed increased thyroid, 
liver, pituitary weight at 3.4, 29.9, and 50.6 mg/kg-bw per day (BMDL of 1.6, 22.9, and 29.9 
mg/kg-bw per day), respectively (Van der ven et al., 2006). In a one-generation rat study, 
decreased concentration of apolar retinoids in the liver, increased immune response, and 
mineral bone density in F1 females were reported at 0.18, 1.45, and 5.1 mg-kg-bw per day, 
respectively (Lilienthal et al., 2009).  Increased liver weight was observed in a 90 day rat 
study with a LOAEL of 100 mg/kg-bw per day (Chegelis et al., 2001). The choices of dose in 
the current study were also driven by limited availability of the α-[14C]HBCD and the 
appropriate comparison to studies of γ-HBCD in mice.  
 
The objective of this study is to characterize the fate of α-HBCD up to 14 days 
following an acute exposure across a range of doses and after repeated administration of a 
low dose to adult female mice.  
 
MATERIALS AND METHODS 
 
Chemicals: [
14
C]1,2,5,6,9,10-hexabromocyclododecane ([
14
C]HBCD) (2mCi/mmol) 
was purchased from American Radiochemicals Corporation (ARC) (St Louis, MO) as a 
mixture of ß-[
14C]HBCD and γ-[14C]HBCD diastereomers as determined by liquid  
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chromatography-mass spectrometer (LC-MS) retention time comparisons with authentic 
standards (α-, ß-, δ-, γ-, and ε-HBCD, Wellington Laboratories, Guelph, ON).  The two 
diastereomers were separated by flash chromatography on a silica gel column eluting with 
hexane containing increasing amounts of methylene chloride (0–50 %) (Szabo et al., 2010).  
A fraction containing predominantly (>90%) γ-[14C]HBCD but some ß-[14C]HBCD  was 
thermally converted  to α-[14C]HBCD by heating at 170°C for up to 3 hr (Heeb et al., 2008).  
α-[14C]HBCD was purified by flash chromatography on a silica gel column as above, 
followed by preparative reverse phase HPLC on two Delta-Pak C18 cartridges (25 x 100 mm) 
(Waters Corp., Milford, MA) in series and isocratic elution with acetonitrile:water (80:20) at 
20 mL/min.  The radiochemical and diasteromeric purities (98% each) were respectively 
determined by thin-layer chromatography (TLC) using silica gel plates (250 mm; Whatman 
Lab. Div., Clinton, NJ) and a 50:50 hexane:methylene chloride mobile phase and by LC-MS 
retention time comparison to authentic standards of α-, ß-, δ-, γ-, and ε-HBCD (Wellington 
Laboratories, Guelph, ON).  The impurities present in the α-[14C]HBCD were detected to be 
<1% each of the other two main stereoisomer β- and γ-HBCD.  Radiochemical detection was 
performed on a System 2000 Imaging Scanner (Bioscan, Washington, DC).  Retention times 
comparisons by LC-MS were made on a Symmetry C18 column (2.1x100 mm) (Waters, 
Beverly, MA) using an isocratic program which separated all five HBCD diastereomers 
(details below).  Additionally, 
1
H-NMR of the α-[14C]HBCD performed on a Bruker AM 400 
spectrometer (Bruker, Billerica, MA) matched the previously published spectrum of this  
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diastereomer (Arsenault et al., 2007).  Unlabeled α-HBCD was generously provided by 
Wellington Labs (98% purity).  Other chemicals used were of the highest grade 
commercially available. 
 
Dosing Solutions: Doses were selected based on published toxicity studies on the HBCD 
commercial mixture due to lack of any available α-HBCD whole animal studies.  
Furthermore, the low specific activity of the radiolabeled compound was a contributing 
factor in choosing 3mg/kg as the low dose ensuring proper detection. A stock solution of α-
[
14C]HBCD was made by dissolving 19.23 mg of α-[14C]HBCD (3.12 μCi/mg) in toluene 
(400ul) . Aliquots were used directly from this solution for the dosing regimens.  Dosing 
solutions were subjected to pre- and post- dosing radioactivity examinations to ensure proper 
delivery of dose.  All solutions were designed to deliver approximately 0.2μCi to each 
mouse.  Unlabeled α-HBCD was added to the α-[14C]HBCD to achieve desired mass (except 
the 3mg/kg low dose), and was added directly to the dosing solution vial and dissolved in 
acetone. Corn oil by weight was then added to the vials followed by the evaporation of 
toluene and acetone under vacuum (Speed Vac, Savant Instruments, Inc. Farmingdale, NY).  
For intravenous (iv) treatment, the α-[14C]HBCD solvent from the stock solution, toluene, 
was allowed to evaporate in an amber vial under the flow of nitrogen, and the α-HBCD was 
resuspended in 95% ethanol followed by Emulphor
®
.  De-ionized water was slowly added to 
a final volume to achieve a ratio of (ethanol:Emulphor
®
:water ratio was 1:1:8).  Where 
applicable, glass was used in the handling, containment, transfer, and storage of the  
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compound; no loss of radioactivity occurred with glass.  Concentration of the dosing solution 
was verified by liquid scintillation chromatography (LSC). 
 
Animals. Young adult female mice were used in this study as limited supply of purified α-
[
14
C]HBCD was available and to compare results to recent toxicokinetic mice studies on 
other related environmental chemicals (Szabo et al., 2010; Staskal et al., 2006; Diliberto et 
al., 1999) including toxicity studies where mice were exposed to the commercial mixture of 
HBCD (Erikkson et al., 2006; Kurokawa et al., 1984).   Future mechanistic studies on 
disposition can be more easily tested in mice as transgenics are also readily available (Hakk 
et al., 2009).  
 
Female C57BL/6 mice (~20 grams) were obtained from Charles River Breeding Laboratories 
(Raleigh, NC). Females were chosen as they appear to elicit a more sensitive response after 
exposure to the commercial mixture of HBCD in several toxicity studies (Lilienthan et al., 
200; Van den ven 2006).  Animals were maintained on a 12 h light/dark cycle at ambient 
temperature (22
◦
C) with relative humidity (56 ± 5%), and were provided Purina 5001 Rodent 
Chow (Ralston Purina Co., St. Louis, MO) and tap water ad libitum. Prior to the 
commencement of the study, mice were adapted (3 mice/cage) for 1 week to Nalgene 
metabolism cages (Nalgene, Rochester, NY). Mice were then assigned randomly to treatment 
groups (n= 4-8) and housed individually for the remainder of the study.  All mice were 60 
days old at time of treatment.   
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Route of Exposure: Oral treatment (n=4-8). A single dose (0, 3, 10, 30 and 100 mg/kg) was 
administered directly by oral gavage into the stomach of each mouse using a PTFE animal 
feeding needle.  Dose volume was 10ml/kg.  Intravenous treatment (n=6-8). A single dose (3 
mg/kg) was administered intravenously via the tail vein at a dosing volume of 2 mL/kg. 
 
Treatment: Dose/Response: A single dose was administered by gavage of either 3, 10, 30, or 
100 mg/kg at a volume of 10ml/kg. The mice were held in metabolism cages for 4 days 
where urine and feces were collected daily. Time course: Mice were treated by gavage at a 
single dose of 3 mg/kg and held for 14 days while urine and feces were collected daily.  
Repeated: Mice were dosed for 9 days with 3 mg unlabeled α-HBCD/kg; and only on day 10 
the mice were exposed to a single gavage of 3 mg α-[14C]HBCD/kg,  and then held for 4 
more days (total of 14 days).  This repeated protocol allows comparison of “naïve” 
radioactive exposures to mice pretreated with unlabeled compound.  
 
Animals were euthanized by CO2 asphyxiation followed by exsanguination via 
cardiac puncture at which point blood was collected.  Liver, lung, kidneys, skin (ears), 
adrenal glands, urinary bladder, spleen, thymus, adipose (abdominal), muscle (abdominal), 
and brain were collected and weighed. Bile was removed directly from the gallbladder using 
a 0.2 millimeter bore needle and syringe. 
 
Sample Analysis: Radioactivity in the tissues were determined by combustion  with a tissue 
oxidizer (Packard 307 Biological Oxidizer, Downers Grove, IL) of triplicate samples when  
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available (~100mg/sample) followed by LSS  (Beckman, Beckman 6000IC, Fullerton, CA) 
with limits of detection (LODs) of 50 dpm (3 x background) or 6.7 ng HBCD for the 3mg/kg 
dose. Tissue data are reported based on wet weight and as percent of administered dose.  
Feces were air dried, weighed, and analyzed for radioactivity by combustion and LSS.  Daily 
urine volume was recorded, and 100 μL aliquots (triplicate) were analyzed for [14C] by direct 
addition into scintillation cocktail.  
 
Tissue Extraction and Analysis:  Livers were weighed, pulverized and then homogenized in 3 
volumes of 0.9% sodium chloride.  Liver samples were extracted sequentially with 3 
volumes of hexane, ethyl acetate, and methanol.   The organic layers were pooled for each 
solvent and assayed by LSC. The liver sample extracts were applied to an acid silica gel 
column (0.5 x 7.0 mm, 40% concentrated sulfuric acid by weight) and eluted with hexane, 
followed by 50:50 hexane:methylene chloride.  The collected fractions were analyzed by 
LC/MS (see below). 
 
Feces were dried and ground into a fine powder with a mortar and pestle, and then 
extracted for 24 h stirring sequentially with 15 mL of hexane, ethyl acetate, and methanol.  
Fecal residues from the extractions were combusted to yield the non-extractable fraction.  
The extractable fractions were reduced in volume to ~1 mL with nitrogen.  Each extract was 
applied to a silica gel column (silica gel 60, EM Reagents, Cincinnati, OH; particle size 
<0.063μm), preconditioned with hexane and eluted with a gradient from 100% hexane to 
80:20 hexane/toluene.  The gradient was increased in 2% increments, and fractions were  
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assayed by LSC.  Peaks of [
14
C] were collected, reduced in volume and analyzed by LC/MS.  
Urine was injected unto RP-HPLC and [
14
C] peaks were collected.  HPLC fractions were 
acidified to pH 2 with 0.01 M HCl, and applied to a C18 SepPak cartridge (Waters) pre-
conditioned with methanol and water.  Each sample was eluted with water followed by 
methanol.  The methanol SepPak fractions were applied to a Sephadex LH-20 (Pharmacia 
Biotech, Uppsala, Sweden) column and eluted with water followed by methanol, and each 
eluted fraction was analyzed by LC/MS (see below).   
 
Serum was extracted with hexane followed by ethyl acetate.  Each extract was applied 
to a silica gel TLC plate, and developed in 50:50hexane:methylene chloride. Bile was 
extracted with methanol and applied to silica gel TLC plate, using a 50:50hexane:methylene 
chloride as a developing solvent.  TLC had limits of detection (LODs) of 200 dpm (S/N =3) 
or 0.03 µg HBCD for the 3 mg/kg dose.  Gel permeation chromatography (GPC) was used to 
remove large macromolecules which can interfere with further analysis of low level of target 
molecules found in brain and adipose samples. Fat samples were pooled (n=4) and 
homogenized in water, and 2 mL of hexane:acetone (1:3.5) was added and sonicated for 15 
minutes. An additional 2 mL of hexane:acetone was added, sonicated and combined with the 
previous organic layer.  Four milliliters of hexane:ether (9:1) was added, vortexed, 
centrifuged, and decanted; this was repeated twice and organic layers were combined with 
the first extracts.  The fat extract was assayed by LSC, evaporated with nitrogen, applied to a 
GPC column (Biobeads SX-3; BioRad), and eluted with methylene chloride.  Fractions were  
 
 
 
76 
collected, reduced in volume, applied to an acid silica column, eluted with hexane followed 
by 50:50 hexane:methylene chloride, and analyzed by LC/MS (see below).   
 
In LC/MS was used to analyze selected samples and consisted of an Alliance 2695 
Separation Model (Waters, Beverly, MA) equipped with a Symmetry C18 column (2.1 mm x 
100 mm) and guard column (2.1 by 10 mm), and a quadrupole-time of flight mass 
spectrometer (Waters Q-TOF Ultima API-US; Waters, Beverly, MA). Isocratic elution 
conditions were used which consisted of 15% aqueous 10 mM NH4OH and 85% 
methanol:acetonitrile (80:20 v/v), 10 mM NH4OH. The flow rate of the mobile phase was 0.3 
ml/min
-1
. The mass spectrometer analysis was performed in negative ion mode (ES-) using a 
634 m/z filter. LC-MS had an estimated LOD of 0.3 ng (S/N =3 calculated for a tissue 
matrix). 
 
Data Analysis: To calculate the percent of dose in each compartment, mouse body 
composition estimates were used for blood, fat, skin, and muscle - 8, 8, 12, and 35%, 
respectively (ILSI, 1994). Estimates were used for tissues for which it was not possible to 
obtain total weights from actual animals.  The oral tissue disposition data refer to the mean of 
all data collected in which a) animals were exposed orally with a 3mg/kg dose and b) 4 day 
time points where available.  Intergroup comparisons were performed by a two-way ANOVA 
followed by Bonferroni post-hoc tests were significant when p < 0.05.  All data are presented 
as mean ± standard deviation. GraphPad Prism 5.0, Hearn Scientific Software (Melbourne, 
Australia) was used to calculate half-life, the percent of dose, and statistical analysis. 
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RESULTS  
 
Tissue Disposition  
 
Dose Dependency  
 
Tissue distribution, as a percent of α-[14C]HBCD administered dose in female 
C57BL/6 mice, are presented in Table 1. The top table (A) shows the disposition after 
administration of single and repeated oral doses of α-[14C]HBCD at concentrations of 3, 10, 
30 or 100 mg/kg or of 10 d repeated exposure to 3 mg/kg.   
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Table 3.1. Disposition of α-HBCD in Mice 
(A) 
           
Dose       Skin Liver Lung Muscle Kidney Blood Adipose Brain 
mg/kg 
 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
% dose 
(ng/g) 
         3 
 
      2.5 ± 0.23 
(9000 ± 828) 
2.70 ± 1.20 
(9720 ± 4320) 
0.4 ± 0.08 
(1440 ± 287) 
1.3 ± 0.21 
(4680 ± 756) 
0.04 ± 0.01 
(144 ± 36) 
1.3 ± 0.29 
(4680 ± 1044) 
3.70 ± 0.42 
(13320 ± 1512) 
0.40 ± 0.23 
(1440 ± 828) 
10 
 
2.5  ± 0.51 
(26700 ± 6114) 
 
3.2 ± 0.31 
(38361 ± 3716) 
0.2 ± 0.01 
(2397 ± 120) 
1.6 ± 0.16 
(19181 ± 1918) 
 
0.06 ± 0.01 
(719 ± 120) 
1.01 ± 0.46 
(12107 ± 5514) 
 
3.93 ± 0.25 
(47112 ± 2997) 
0.52 ± 0.45 
(6234 ± 5394) 
30 
 
2.3 ± 1.41 
(88911 ± 50760) 
 
*4.16 ± 0.50 
(149760 ± 1800) 
0.42 ± 0.02 
(15120 ± 720) 
1.7 ± 0.13 
(61200 ± 4680) 
 
0.06 ± 0.01 
(2161 ± 360 
1.32 ± 0.72 
(47520 ± 25921) 
 
*6.36 ± 0.66 
(22896 ± 23760) 
0.51 ± 0.07 
(18336 ± 2520) 
100 
 
*3.92 ± 1.20 
(373426 ± 143986) 
 
*5.52 ± 1.11 
 (662334 ± 133186) 
0.43 ± 0.02 
(51594 ± 2400) 
*2.1 ± 0.31 
(251748 ± 37196) 
 
0.06 ± 0.02 
(7199 ± 2397) 
1.83 ± 0.39 
(43876 ± 930) 
 
*8.91 ± 1.13 
(106909 ± 40630) 
0.47 ± 0.03 
(56394 ± 3600) 
3 
  Repeated 
2.52 ± 0.51 
(9072 ± 1836) 
*3.75 ± 0.75 
(13500 ± 2700) 
0.61 ± 0.03 
(2196 ± 108) 
*1.9 ± 0.21 
(17100 ± 756) 
 
0.07 ± 0.03 
(252 ± 108) 
*2.4. ± 0.36 
(8640 ± 1296) 
 
*6.50 ± 0.93 
(23400 ± 3348) 
0.48 ± 0.05 
(1728 ± 180) 
 
     (B) 
Time Skin Liver Lung Muscle Kidney Blood Adipose Brain 
1 hour 
 
   0.0001 ± 0.000 
(13 ± 7) 
13.23 ± 4.6 
(47628 ± 16560) 
0.8 ± 0.02 
(2880 ± 72) 
0.80 ± 0.050 
(2880 ± 180) 
7.0 ± 0.001 
(25200 ± 3.4) 
11.31 ± 1.30 
(40716 ± 4680) 
0.002 ± 0.001 
(7.2 ± 3.6) 
3.5 ± 0.1 
(12600 ± 360) 
3 hours 
 
0.0002 ± 0.010 
(30 ± 12) 
 
12.24 ± 2.4 
(44028 ± 8640) 
3.0 ± 0.51 
(10800 ± 1836) 
1.0 ± 0.051 
(3600 ± 184) 
 
5.2 ± 0.31 
(18720 ± 1116) 
7.03 ± 1.01 
(25308 ± 3636) 
 
0.006 ± 0.001 
(22 ± 3.6) 
1.9 ± 0.01 
(6840 ± 36) 
8 hours 
 
0.013 ± 0.26 
(420 ± 37) 
 
9.82 ± 0.51 
(35352 ± 1836) 
2.1 ± 0.08 
(7560 ± 288) 
3.5 ± 0.02 
(13320 ± 72) 
 
 3.6 ± 0.11 
(12960 ± 396) 
4.68 ± 1.21 
(16848 ± 4356) 
 
0.072 ± 0.001 
(259 ± 3.6) 
1.0 ± 0.01 
(3600 ± 36) 
1 day 
 
1.53 ± 1.80 
(2600 ± 2110) 
 
6.23 ± 1.3 
(22428 ± 4680) 
0.62 ± 0.02 
(2232 ± 72) 
3.69 ± 0.22 
(13284 ± 792) 
 
0.8 ± 0.2 
(2880 ± 720) 
2.0 ± 1.24 
(7200 ± 4464) 
 
2.30 ± 0.91 
(8280 ± 3276) 
0.85 ± 0.01 
(3060 ± 36) 
2 days 
 
4.1 ± 1.21 
(14760 ± 4356) 
4.21 ± 0.91 
(13321 ± 3276) 
0.51 ± 0.01 
(1836 ± 36) 
1.8 ± 1.10 
(6480 ± 3960) 
 
0.075 ± 0.01 
(270 ± 36) 
1.60 ± 0.10 
(5760 ± 360) 
 
5.25 ± 0.5 
(18900 ± 1800) 
0.66 ± 0.02 
(2376 ± 72) 
4 days 
 
 
2.5 ± 0.23 
(9000 ± 828) 
2.7 ± 1.2 
(9720 ± 4320) 
0.4 ± 0.08 
(1440 ± 287) 
1.3 ± 1.21 
(4680 ± 4320) 
0.04 ± 0.01 
(144 ± 36) 
1.3 ± 0.29 
(4680 ± 1044) 
3.70 ± 0.42 
(13320 ± 1512) 
0.40 ± 0.23 
(1440 ± 828) 
7 days 
 
2.1 ± 0.21 
(7560 ± 756) 
 
2.1 ± 0.9 
(7560 ± 3240) 
0.2 ± 0.01 
(720 ± 36) 
0.9 ± 0.10 
(3240 ± 360) 
 
0.02 ± 0.02 
(72 ± 72) 
0.71 ± 0.02 
(2556 ± 72) 
 
       3.10 ± 0.01 
(11160 ± 36) 
0.21 ± 0.31 
(756 ± 1116) 
14 days 
 
1.4 ± 0.11 
(5040 ± 396) 
1.2 ± 0.2 
(4680 ± 720) 
0.09 ± 0.001 
(324 ± 3.6) 
0.29 ± 0.02 
(1044 ± 72) 
 
0.004 ± 0.001 
(14 ± 3.4) 
0.33 ± 0.015 
(1152 ± 54) 
 
 2.2. ± 0.001 
(7920 ± 3.6) 
0.04 ± 0.02 
(144 ± 72) 
         
(C)         
Route Skin Liver Lung Muscle Kidney Blood Adipose Brain 
iv 
 
 
2.8 ± 0.24 
(10080 ±.864) 
*3.7 ±  1.12 
(13320 ± 4032) 
0.5 ± 0.09 
*(1800 ± 324) 
 *1.7. ± 0.63 
 (6120 ± 2268) 
 *0.06 ± 0.003 
*(216 ± 11) 
*1.51 ± 0.24 
(5436 ± 864) 
4.1 ± 0.9 
(14760 ± 3240) 
0.45 ± 0.08 
(1620 ± 288) 
po 
 
 
2.5 ± 0.23 
(9000 ± 828) 
2.70 ± 1.20 
(9720 ± 4320) 
0.4 ± 0.08 
(1440 ± 287) 
1.3 ± 0.21 
(4680 ± 756) 
0.04 ± 0.009 
(144 ± 32) 
1.3 ± 0.29 
(4680 ± 1044) 
3.70 ± 0.42 
(13320 ± 1512) 
0.40 ± 0.23 
(1440 ± 828) 
 
 
Note. Disposition of α-HBCD derived radioactivity (A) four days following a single (3, 10, 
30, and 100 mg/kg) and 10-day repeated (3 mg/kg) po dose, (B) at multiple time points  
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following a single 3 mg/kg po dose and (C) four days following a 3 mg/kg dose through iv or 
po. All data are mean ± SD; represented as percent dose (top value) or concentration of 
nanogram of administered dose per gram of tissue (ng/g; bottom value in parenthesis). 
*Indicates significance as compared with lowest dose (p < 0.05). 
 
Tissue distribution was analyzed four days after the administration of α-[14C]HBCD.  
Data is represented in tabular form as it is useful for investigators who wish to model the data.  
All tissues examined had measurable levels four days after dosing.  We found that the relative 
amount of α-[14C]HBCD derived radioactivity was increased in tissues as a function of dose.  
The increases occurred at the 30 and/or 100mg/kg exposures in tissues which contained higher 
lipid content - adipose, muscle and skin, as well as the highly perfused liver tissue. Figure 2 
represents this in a bar-graph format.  
 
Tissue Distribution after a single increasing dose and repeated exposure 
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Figure 3.2. Tissue levels of α-[14C]HBCD four days following a single oral dose (3, 10, 30, 
or 100 mg/kg) or 10 day repeated dose of 3mg/kg. Presence of a * data point indicates 
significance of daily percent of dose measured in the tissue (*p <0.05 as compared with the 
lower dose.) While the presence of a “#” data point indicates significance of daily percent of 
dose measured in the tissue from the 10 day repeated 3mg/kg dose (#p <0.05 as compared 
with a single 3mg/kg dose).   
 
Repeated Exposure 
 
Tissue concentrations were altered after a 10 day repeated exposure.  Levels in the 
adipose, liver, muscle and blood were significantly increased between a single and 9 days of 
repeated oral exposure followed by α-[14C]HBCD at 3mg/kg on the tenth day (Table 1.A and 
Figure 2).  In fact, 4d after a 9 d unlabeled and 10
th
 day α-[14C]HBCD with 3 mg/kg, the % 
dose in the tissues are more similar to the 30mg/kg as opposed to the 3 mg/kg single dose 
(Figure 2).       
 
Time-Course and Half-life 
 
From the dose/response study, the lowest dose was chosen (3 mg/kg) to conduct the 
time course (kinetic) study because it is within the range where effects have been seen 
(Erikkson et al., 2006), the specific activity of the starting radiolabeled material, and to  
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compare the data to previous published kinetic data on γ-HBCD in mice at the same dose 
(Szabo et al., 2010).  Only tissue distribution and elimination over time was performed after 
the 3mg/kg administered dose.  By observing tissue distribution over time, detectable 
concentrations were present at all time points investigated (Table 1B).  This 14 d time course 
study showed a biphasic profile with an initial steep decline from approximately 3 h to 2 d 
and a markedly slower decline between 2 d and 14 d for liver, kidney, blood and brain.  Liver 
tissue had the highest observable level at 1 h.  While most tissues peaked in concentration at 
1 day, α-[14C]HBCD derived radioactivity was found to peak at 2 d in fat.  Basically, the 
highly perfused tissues reached their highest observable peak at earlier time points (1 or 3 
hrs), while the poorly perfused organs such as skin, fat, thymus, and muscle peaked later (at 2 
days).  As can be seen in Figure 2, α-[14C]HBCD derived radioactivity is initially cleared 
rapidly from the blood, so that by 1 hour post-gavage, only 11.3% of the dose remained. By 
1, 2, and 14 days, 2.0, 1.6, and 0.33% of the α-[14C]HBCD derived radioactivity was detected 
in the blood, respectively.  At all time points measured, liver tissue contained higher levels of 
α-[14C]HBCD derived radioactivity than that found in blood.  This was also observed in 
adipose tissue between 2-14 days, where higher levels were measured than those found 
circulating.  A non-linear regression two phase decay curve was used to fit the α-[14C]HBCD 
derived radioactivity elimination from tissues. Half-lives and pool sizes, were analyzed for 
each elimination phase (initial and terminal) separately where appropriate (Table 2).  
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Table 3.2.  Estimated Tissue Half-Lives of α-HBCD derived radioactivity in Mice 
 
    Half-life                            Pool size    
                                       (days)                               (% dose) 
Tissue      α½      β ½    α phase     β phase 
Liver  0.4 ± 0.1 3.0 ± 0.7 13.9 ± 0.91  4.18 ± 0.31 
Blood 0.1 ± 0.0 0.5 ± 0.2 16.6 ± 2.59  3.56 ± 0.41 
Lung 0.3 ± 0.1 15 ± 9.1 3.97 ± 0.22  0.93 ± 0.00 
Kidney 0.2 ± 0.0 2.1 ± 0.4 7.06 ± 0.14  0.15 ± 0.02  
Muscle 0.3 ± 0.1 8.0 ± 4.0 22.4 ± 200  1.59 ± 0.21 
Brain 0.1 ± 0.6  3.0 ± 2.0 5.20 ± 0.21   0.99 ± 0.08 
Fat      --- 17 ± 4.9       ---  17.8  ± 3.00 
     
 
 
Note. Tissue-specific, biphasic half-lives were calculated from female mice given a single po 
dose (3 mg/kg) of α-[14C]HBCD. Calculations are derived from percent of administered dose; 
α and β phase time points are individually based on peak tissue concentrations. Where 
appropriate, the pool size was calculated by determining the y-intercept of each phase. All 
data presented in days. 
 
Although there is uncertainty for those tissues in which the calculated half-life 
exceeds the study‟s data points (ie adipose tissue) we report its value for comparison to other 
tissues and the γ-HBCD stereoisomer (Szabo et al., 2010). Increased variance around the 
estimate is another factor contributing to this uncertainty. 
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IV vs Oral: Absorption   
 
By comparing disposition between iv and oral routes of exposure it is possible to 
estimate the percentage of α-[14C]HBCD that was absorbed into the systemic circulation and 
delivered to the tissues.  A comparison of the major tissue depots 4 d after treatment with the 
same oral and iv dose (3mg/kg) is shown in Table 1C.  The percent dose and concentration of 
the α-[14C]HBCD derived radioactivity in the tissues were similar for both routes. Every 
tissue measured had slightly higher levels after iv as compared with the oral route of 
exposure, but not all were statistically significant.  Statistically significant differences are 
listed here as a percent of the oral to iv levels: liver (93%), muscle (89%), kidney (88%) and 
blood (92%).  By comparing the calculated differences for each tissue between the two routes 
of administration (po vs iv) for the four major tissues, the higher levels found in these tissues 
after iv administration indicate an approximate average oral absorption of 90 ± 3% for α-
[
14
C]HBCD.   
 
Elimination 
 
Dose/Response and Repeated Exposure 
 
Total cumulative elimination of the α-[14C]HBCD derived radioactivity in the urine 
and feces after oral administration is shown in Figure 3 for the four increasing dose groups; 
3, 10, 30 and 100 mg/kg/day.   
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Cumulative Fecal and Urinary Elimination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Cumulative elimination of α-HBCD derived radioactivity following a single, oral 
dose (3, 10, 30, 100 mg/kg) in feces and urine. Data presented as mean percent administered 
dose eliminated ± standard deviation (n=4-6/group). Presence of a „„*‟‟ data point indicates 
significance of daily percent eliminated (*p < 0.05 as compared with previous dose).  
 
This figure shows clear dose dependence on elimination; i.e. as dose increases, the 
amount of elimination decreases via the fecal route but not the urinary. After exposure to 
increasing dose levels, total recovery of α-[14C]HBCD derived radioactivity  is similar 
between all dose groups. At the 3, 10, 30 and 100 mg/kg doses, approximately 84, 82, 80 and  
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81% total radioactivity was recovered, respectively. Average recovery of 
14
C, including that 
recovered from the tissues, urine and feces, was 82 ± 4%.  
 
After 10 daily doses at 3mg/kg, the fecal elimination profile more closely resembles 
that of a single exposure of 30mg/kg; as compared to a single exposure to 3 mg/kg dose 
(Figure 3).  In the urinary elimination profile, a single exposure of 3mg/kg is not different 
than the 10 day repeated exposure.  
 
IV vs Oral: Absorption  
Figure 4 compares the cumulative percent of dose in the urine and feces over four 
days after either iv or oral exposure. Similar elimination profiles are observed between the iv 
and oral routes of administration.   
 
 
Cumulative Fecal and Urinary Elimination between IV and Oral Routes 
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 Figure 3.4. Cumulative elimination of α-HBCD derived radioactivity following a 
single dose (3mg/kg) via i.v and oral route in urine and feces. Data presented as mean 
percent administered dose eliminated ± standard deviation (n=4-6/group). Presence of 
a * data point indicates significance of daily percent eliminated (*p <0.05 as compared 
to other route at same time point). 
 
Comparison of the amount of [
14
C] derived radioactivity eliminated in the urine and 
feces between the oral and iv routes of administration allows another approach to estimate 
absorption.  36% of the dose was eliminated in the feces of the iv administered mice on the 
first day whereas 41% was eliminated in the oral treated animals.  After 4 d, 45% percent of 
the dose was eliminated in the feces following iv exposure and 49% following oral. A 
measurable 4% difference is calculated between the two routes of exposure. This data 
supports the conclusion that α-[14C]HBCD is well absorbed orally. 
 
The iv route of exposure to α-[14C]-HBCD resulted in significantly higher levels of 
[
14
C] derived radioactivity in the feces at days 1, 2 and 3.  However, this difference suggested 
only slightly decreased oral absorption between the two routes.  Urinary elimination was 
similar between iv and oral exposure with 15% of the dose eliminated in the urine following 
oral exposure vs. 17% after the iv route in four days.  Based on fecal and urinary elimination 
patterns, comparison between the iv route and oral route further indicates that α-[14C]HBCD 
is well absorbed orally (89 ± 2%).  This agrees with the estimate derived from the difference 
found in tissue distribution when comparing the iv and oral routes of exposure (90 ± 3%). 
87 
TLC  
The nature of the α-[14C]HBCD derived radioactivity in the urine and feces was 
examined by thin-layer chromatography (Figure 5).   
 
 
Thin Layer Chromatograms of Tissues and Excreta after Oral Administration of α-HBCD. 
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Figure 3.5. TLC radiochromatograms determined for A) α-, β-, and γ-[14C ]HBCD standards, 
B) liver at 3 hours, C) feces at 1 day, D) feces at 2 days, and E) urine . A representative 
sample and extract was chosen for presentation. Blood, bile and urine all contained similar 
chromatographic profiles. Axes; x = time in minutes, y = percent abundance.   
 
No parent compound was detected in the urine at 1 or 2 days after treatment. TLC 
consistently revealed one major peak (Rf = 0.0) which contains polar metabolites. A similar 
metabolite(s) was seen in the blood and bile, with no parent compound detected 
 
This is in contrast to fecal elimination where the parent compound predominates in 
the extractable fraction. Preliminary studies using feces spiked with α-[14C]HBCD 
demonstrated complete extraction.  34% of the α-[14C]HBCD derived radioactivity which 
was extracted from the feces was parent.  Given that approximately 90% of α-[14C]HBCD is 
orally absorbed (see above), at most 10% is unabsorbed α-[14C]HBCD. The remaining 24% 
was absorbed but eliminated unchanged in the feces. 66% of the extracted radioactivity was 
metabolite. The nonextractable radioactivity is assumed to be bound metabolites of α-
[
14
C]HBCD.  Our results indicated that by 1d, greater than 66% of the radioactivity that was 
eliminated from the mice was no longer α-HBCD, but several metabolites.  To examine the 
identity of the extracted α-[14C]HBCD derived radioactivity; the extracts, as well as standards 
of the three main diastereomers (α-, β-and γ-[14C]HBCD) were assayed by TLC (Figure 5).  
In this system, β-[14C]HBCD migrated with a shorter retardation factor (Rf = 0.50) than α-  
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and γ-[14C]HBCD which co-migrated at Rf = 0.61.  One day post-exposure, only one band 
was detected in the fecal extracts with a Rf = 0.54.  Interestingly, by 2 days post-exposure, 
four bands were present in the fecal extract (Rf = 0.00, 0.12 and 0.14 and 0.54), 
demonstrating polar metabolites as well as parent compound.  
 
Liver extracts were analyzed at 3h, shortly after the time of peak tissue concentration, 
1h. In the liver tissue only one clear TLC band was detected with Rf = 0.60, similar to the 
fecal extracts (Rf = 0.54) and the α- and γ-HBCD standard peaks (Rf = 0.61). Migration 
differences between the standard α- and γ-[14C]HBCD peak with the α- and γ-[14C]HBCD 
peak in the feces and liver were attributed to the tissue matrix effects. 
 
The GPC 
 
The nature of the α-[14C]HBCD–derived radioactivity in the brain and fat was 
initially examined by gel permeation chromatography (GPC).  GPC separation is based on 
size but, unlike TLC, GPC is not useful for the identification of individual stereoisomers 
since all HBCD stereoisomers have the same molecular weight.  GPC chromatograms 
revealed one major peak (data not shown) that was further analyzed using LC-MS. 
 
LC-MS 
Due to the inability of TLC to differentiate α- from γ-HBCD, and the inability for 
GPC to resolve any HBCD stereoisomers, the [
14
C]-containing peaks from TLC and GPC 
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were further characterized by LC-MS, which can distinguish individual HBCD 
stereoisomers.   The TLC peaks in the liver (Rf = 0.60) and fecal extracts (Rf = 0.54), were 
scraped from the plates, eluted with acetone, and analyzed by LC-MS for comparison to 
authentic standards, α-, β-, and γ-HBCD, which had retention times of 3.40, 4.06, and 4.89 
minutes, respectively.  The results indicated that all peaks had an M-H of ~640.6 suggesting 
that they were HBCD stereoisomers. Both the liver and the fecal extract peaks had retention 
times of 3.40 minutes, which corresponds to α-HBCD.  Furthermore, only α-HBCD was 
detected in the feces, fat, and brain at 1 d, and at the liver at 3 h post oral administration of α-
[
14
C]HBCD (Figure 6).   
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LC-MS chromatograms of Tissues and Excreta after Oral Administration of α-HBCD. 
 
        
 
   
 
Figure 3.6. LC/MS chromatograms determined for A) α-, β-, and γ-HBCD standards, B) liver 
at 3 h, C) feces at 1 day, D) brain at 1 day, and E) fat at 1 day. . Standards are a 
representative sample and retention times varied slightly from day to day. 
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A summary of the parent, stereoisomer, and metabolite profiles in tissues and excreta 
after exposure to α-[14C]HBCD can be found in Table 3.   
 
Table 3.3. Summary of Metabolite Profiles in Female Mouse Tissue and Excreta after  
Oral Exposure to 3mg/kg α-[14C]HBCD  
 
 
 
 
 
 
Fat and brain contained only parent α-[14C]HBCD.  Liver and feces both contained 
large amounts of parent compounds, 62 and 34% respectively.  No stereoisomerization 
products were detected in excreta and tissues.  Polar metabolites were found at high levels in 
the liver and feces, 38 and 66%, respectively.  The bile, serum and urine contained  
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Matrix   Time Parent Isomerization Metabolites 
     
Liver  3 hours 62% 0% 38% 
    Unextractable (38%) 
     
Feces 24 hours 34% 0% 66% 
    Rf = 0.00;  Unknown (2%) 
    Unextractable (64%) 
     
Fat 24 hours 100% 0% 0% 
     
Brain 24 hours 100% 0% 0% 
     
   Bile 
   Blood 
   Urine 
24 hours 0% 
Rf = 0.00;   Unkno 
 
 0% 
Rf = 0.00;   Unkno 
 
100% 
Rf = 0.00;  Unknown 
 
exclusively polar metabolites.  Metabolites in serum, tissues and excreta are in the process of 
being characterized but beyond the scope of this report. 
 
Mass Balance 
 
Approximately 82% of the α-HBCD derived radioactivity could be accounted for by 
measuring 1) the major mouse tissues and 2) excreta after oral and intravenous routes of 
exposure. This recovery is similar to recent publications on related lipophilic compounds in 
mice: γ-HBCD (Szabo et al., 2010); BDE-154 (Hakk et al., 2009); and BDE-47 (Staskal et 
al., 2005).  Lack of total mass balance after 4 days post exposure in this study could be 
attributed to a number of common factors.  Approximate tissue masses (on a percent basis) 
for blood, skin, fat, and muscle from the literature (ILSI, 1994) were used for the calculation.  
Although, the [
14
C] in most major tissues were measured in this study; the carcasses were not 
and may have contained residual levels not included in the estimates of mass balance.  In 
addition, any exhaled [
14
C] was not trapped. 
 
DISCUSSION 
 
The objectives of this study were to determine the absorption, distribution, 
metabolism and excretion of α-HBCD in female mice to better evaluate its behavior.  This 
study demonstrated that approximately 90% of an oral dose of α-HBCD was absorbed. 
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Distribution of α-HBCD was initially to the highly perfused organs including liver, kidney, 
and lung, followed by redistribution to skin, muscle, and adipose tissues. Of the major 
tissues, adipose contained the highest levels detected across all doses measured.  Tissue 
disposition of α-HBCD was dependant on dose at the higher dose levels (30 and 100 mg/kg) 
in the single (acute) dosing paradigm and also the 10 day repeated exposure paradigm at 3 
mg/kg/d.  
 
Fat was found to be a major tissue depot for α-HBCD derived radioactivity after 
exposure to increasing α-HBCD concentrations. This is in contrast to γ-HBCD which failed 
to concentrate in fat due to its rapid metabolism and excretion (Szabo et al., 2010), but 
similar to another lipophilic BFR, PBDE-47 which accumulated in the fat (Staskal et al., 
2005).  In an industry report, the HBCD commercial mixture was found to  partition to 
adipose tissue in rats (Yu and Atallah, 1980).  HBCD was detected in fish oil supplements 
with a maximum concentration of 5.8 ng/g for total HBCD (UK Food Standards Agency, 
2006). Human adipose tissue obtained by liposuction in the Czech Republic had total HBCD 
concentrations ranging from <0.5 to 7.5 ng kg
-1
 lw (Pulkrabova et al., 2009).    
Elimination of α-HBCD either after oral or iv administration was primarily in the 
feces and to a lesser extent in the urine.  Fecal elimination of α-HBCD derived radioactivity 
decreased as dose increased; this was not observed for urinary elimination. An opposite trend 
in the liver, fat, muscle, and skin occurred, as the tissue concentration increased non-linearly 
with increasing administered doses. Tissue concentrations for α-HBCD are in contrast to  
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what was observed after oral exposure to γ-HBCD where the relative amount of γ-HBCD 
inexcreta or tissues was independent of dose. Van der Ven (2009) reported similar findings in 
the liver of rats exposed daily to the HBCD commercial mixture (up to 175 days) where a 
dose dependent hepatic increase in α-HBCD was observed. This rate of increase for α-HBCD 
was greater than for other HBCD stereoisomers measured.   Similar to the distribution 
observed with α-HBCD; an industry report on the kinetics and distribution of the 
radiolabeled HBCD commercial mixture in rats detected higher levels of HBCD in the liver 
than the blood (Yu and Atallah, 1980).  These finding suggests that there is a HBCD 
stereoisomer specific difference in hepatic function and clearance with increasing 
concentration. Although the mechanism for the non-linear behavior of α-HBCD is not 
known, it is possible that inhibition, and/or saturation of metabolism, including binding to 
hepatic enzymes and transporters, may occur at higher concentrations.   
Of the α-HBCD derived radioactivity detected in the urine, bile and blood; 100% 
consisted of polar metabolites after 24 h.  Feces (24-48 h) and liver (3 h) contained both 
parent α-HBCD and polar metabolites.  Differential metabolic capacities for γ-HBCD and α-
HBCD have been observed in vitro with rat and harbor seal liver microsomes (Zegers et al., 
2005) and are supported by the contrast between this present study of α-HBCD and our 
recently published report on γ-HBCD in mice (Szabo et al.,  2010).  α-HBCD was more 
slowly eliminated in female mice than γ-HBCD and therefore is believed to have a greater 
opportunity to bioaccumulate.  Characterizing the toxicity of each stereoisomer remains to be 
determined. 
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The in vivo mouse data from this as well as the previous study with γ-HBCD (Szabo 
et al., 2010) suggest that two factors may be responsible for the shift observed from the 
predominance of γ-HBCD in the commercial mixture to α-HBCD in biota.  First, γ-HBCD 
was more rapidly metabolized and eliminated with a terminal half-life of  4 days (Szabo et al. 
2010), while α-HBCD was more biologically persistent due to a greater resistance to 
metabolism with a terminal half-life of 17 days.  Bioaccumulation may be even more 
pronounced after chronic exposure, as we observed over 20% of  α-HBCD administered dose 
remained in the mice in the 10 day repeated dose study, but <1% was found in the mice 
exposed to γ-HBCD at the same paradigm (Szabo et al. 2010).  In addition, in vivo 
stereoisomerization (11-15%) of γ-HBCD to α- and β- was observed in female mice treated 
with γ-HBCD (Szabo et al., 2010); however, the stereoisomer shift was not seen for α-
HBCD.   
  
Thus, α-HBCD‟s persistence and bioaccumulation in mice is relatively high and may 
explain the observed predominance of α in biota. These data lend support to a theory that the 
reason α-HBCD is the dominant HBCD stereoisomer in biota is its relatively slower 
metabolism, biological persistence, bioaccumulation potential, and absence of 
stereoisomerization. 
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ABSTRACT 
 
Hexabromocyclododecane (HBCD) is a mixture of three stereoisomers alpha (α), beta 
(β) and gamma (γ).  γ-HBCD dominates the mixture (~70%) and despite α-HBCD‟s minor 
contribution to global HBCD production and usage (~10%), it is the dominant congener 
found in most biotic samples worldwide.  Evidence of toxicity and lack of stereoisomer 
studies drives the importance of
 
understanding HBCD toxicokinetics in potentially 
susceptible
 
populations.  The majority of public health concern has focused on hazardous 
effects resulting from exposure of infants and young children to HBCD due to reports on 
adverse developmental effects in rodent studies, in combination with human exposure 
estimates suggesting nursing infants and young children have the highest exposure to HBCD.  
This study was designed to investigate differences in the disposition of both γ-HBCD and α-
HBCD in infantile mice reported to be susceptible to the HBCD commercial mixture.  The 
tissue distribution of α-[14C]HBCD and γ-[14C]HBCD derived radioactivity was monitored in 
C57BL/6 mice following a single oral dose of either compound  (3 mg/kg) after direct 
gavage at postnatal day 10 (PND 10). Mice were held up to 7 days in shoebox cages after 
which pups were sacrificed, tissue collected, and internal dosimetry was measured. 
Developing mice exposed to α-HBCD had an overall higher body burden than γ-HBCD at 
every time point measured; at 4 days post exposure they retained 22% of the α-HBCD 
administered dose while pups exposed to γ-HBCD retained 10%. Total body burden in 
infantile mice after exposure to γ-HBCD was increased 10 fold as compared to adults.  
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Similarly, after exposure to α-HBCD, infantile mice contained 2.5 fold higher levels than 
adult.  These differences lead to higher concentrations of the HBCD diastereomers at target 
tissues during critical windows of development. The results indicate that the toxicokinetics of 
the two HBCD diastereomers differ between developing and adult mice; whereas distribution 
patterns are similar, concentrations of each HBCD diastereomer‟s derived radioactivity are 
higher in the pup‟s liver, fat, kidney, brain, blood, muscle and lungs than in the adult‟s. This 
study suggests that developmental stage may be a risk factor for the harmful effects of both 
HBCD diastereomers when developing animals may be more sensitive to effects and 
increases in body burden. 
 
INTRODUCTION 
 
Brominated flame retardants (BFRs) are chemicals incorporated into plastics, 
electrical and electronic products, textiles, and other materials to reduce flammability. 
Currently, tetrabromobisphenol A (TBBPA), polybrominated diphenylethers (PBDEs), and 
hexabromocyclododecane (HBCD) account for the largest volume of BFRs.  HBCD is a 
lipophilic additive flame retardant mixture extensively used since the 1970s, primarily added 
to polystyrene insulations and building materials to reduce combustibility (de Wit, 2002).  
Annual demand for HBCD ten years ago was about 17,000 metric tons (Covaci et al., 2006), 
and approximately half of this quantity was consumed in Europe (Hale et al., 2006).  HBCD 
is considered a ubiquitous and global environmental contaminant and undergoes long range  
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transport with detectable levels found in abiotic and biotic samples including human blood 
and breast milk (de Wit, 2002, Law et al., 2005, Law et al., 2008). 
 
Toxicity studies suggest that the HBCD commercial mixture is an enzyme inducer, 
endocrine disruptor, and developmental neurotoxicant.  The commercial mixture has been 
shown to induce both  phase I and II metabolic enzyme systems, specifically CYP2B and 
CYP3A, by interacting with the constitutive androgen receptor (CAR) and/or the pregnane-
X-receptor (PXR) receptor, respectively (Germer et al., 2006).   Van der Ven et al. (2006) 
reports a decrease in circulating total thyroxin (T4) levels, increased pituitary weight, thyroid 
weight, and immunostaining of thyroid stimulating hormone (TSH) in the pituitary and 
thyroid follicular cell activation in adult female rats exposed to the commercial mixture of 
HBCD.  Hypothyroid conditions especially during the period of brain growth can cause 
abnormal brain development with severe physical and/or mental retardation in the offspring 
(Dobbing et al., 1973; Koibushi et al., 2000; Yen et al., 2001), and can cause decreases in IQ 
(Haddow et al., 1999).  Exposure to neonatal mice at postnatal day 10 (PND10) with the 
commercial mixture of HBCD have been shown to cause impairment in learning, memory 
and aberrant spontaneous behavior (Eriksson et al., 2006). HBCD has been shown to directly 
inhibit the uptake of neurotransmitters, dopamine and glutamate into synaptosomes in the 
rodent brain (Mariussen et al., 2003). Therefore, neurodevelopmental effects may be due to 
either a direct or indirect result of HBCD during periods of growth.  
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The commercial mixture is composed of three  diastereoisomers, denoted as alpha 
(α), beta (β) and gamma (γ) with the γ -diastereoisomer predominating (>70%) (Heeb et al., 
2005).  High concentrations of HBCD in some top predators indicate persistence and 
biomagnification.  However, recent studies shown there is a selective predominance of α-
HBCD in biota (Law et al., 2006). Due to the different physical, chemical and biological 
properties of the diastereomers, there is a growing need to characterize the individual 
diastereomers in the commercial mixtures. 
 
To better understand the biological behavior of a chemical requires examinination of 
its toxicokinetic properties. Toxicokinetic information on HBCD is limited. Unfortunately, 
early toxicokinetic and toxicity studies contain study design flaws in which animals were 
administered HBCD suspensions in oil (Yu and Atallah, 1980, Arita et al, 1983, Chengelis et 
al., 2001). Undissolved particles of HBCD in oil, in addition to adsorption to laboratory glass 
equipment, may result in decreased bioavailability and decreased internal absorption. These 
factors create further uncertainties and inconsistencies when comparing dose and effects 
across studies.  
 
To address the growing need for a toxicokinetic evaluation of HBCD at the 
stereoisomer level, our laboratory conducted two studies (Szabo et al. 2010 and Szabo et al., 
2011) to characterize the absorption, distribution, metabolism and excretion of HBCD 
diastereomers, γ-HBCD and α-HBCD, the predominant diastereomers in the commercial 
mixture and in biota, respectively. The results from these studies demonstrate that the  
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stereoisomers have different toxicokinetic behaviors in adult (PND 60) mice. Both are 
readily absorbed from the GI tract (85-90%).  However, γ-HBCD is rapidly metabolized and 
eliminated with a terminal half-life of 4 days (Szabo et al. 2010), while α-HBCD is more 
biologically persistent with a terminal half-life of 17 days (Szabo et al., 2011). 
Bioaccumulation of α-HBCD, but not of γ-HBCD derived radioactivity was observed in 
adipose tissue. Greater than 20% of the α-HBCD administered dose remained in the mouse 
after a 10 day repeated dose study, but <1% was measured in the mice after a similar 
exposure to γ-HBCD.  In vivo stereoisomerization (11-15%) of γ-HBCD to α- and β-HBCD 
was observed in female mice treated with γ-HBCD (Szabo et al., 2010); however, the 
stereoisomer shift was not seen after exposure to α-HBCD.  It was concluded that the 
biological persistence of γ-HBCD in mice was low and may explain low levels of γ-HBCD in 
biota. Overall this data lends support to a hypothesis that the reason α-HBCD is the dominant 
HBCD stereoisomer in biota is its slower metabolism leading to its biological persistence and 
bioaccumulation potential in addition to the absence of α-HBCD stereoisomerization. 
While there is evidence of developmental neurotoxicity in PND 10 mice after exposure to the 
commercial mixture of HBCD (Eriksson et al., 2006), there are currently no toxicokinetic 
studies in developing animals.  Since differences in the two main HBCD stereoisomers have 
been observed in adult mice (Szabo et al., 2010; Szabo et al., 2011), we asked whether a 
difference in the tissue distribution and body burden of alpha and gamma in developing mice 
exists and whether tissue distribution patterns differ between infants and adults. 
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The present study was designed to investigate the tissue distribution and body burden of the 
HBCD stereoisomers α-HBCD and γ-HBCD in 10-day-old mice reported to be susceptible to 
the HBCD commercial mixture.  C57BL/6 mice were exposed to a single oral dose of either 
α-[14C]HBCD or γ-[14C]HBCD (3 mg/kg) on postnatal day 10. Tissue distribution was 
monitored at multiple time points up to 7 days post-dose, and tissue concentrations were 
compared to previously reported adult tissue concentrations using the same exposure 
scenario (Szabo et al., 2010; Szabo et al., 2011).  
 
MATERIALS AND METHODS 
 
Chemicals: [
14
C]1,2,5,6,9,10-hexabromocyclododecane ([
14
C]HBCD) (2mCi/mmol) was 
purchased from American Radiochemicals Corporation (ARC); (St Louis, MO) as a mixture 
of ß-[
14C]HBCD and γ-[14C]HBCD.  Methods for separating the diastereomers and thermal 
conversion of γ-[14C]HBCD to α-[14C]HBCD  were previously published (Szabo et al., 2010, 
2011).  Other chemicals used were of the highest grade commercially available. 
 
Dosing Solutions: Doses were selected based on published toxicity and toxicokinetic studies, 
environmental relevance, and specific activity of α-[14C]HBCD and γ-[14C]HBCD.  A stock 
solution of each was made by dissolving 19.23 mg of α-[14C]HBCD or γ-[14C]HBCD (3.12 
μCi/mg) in toluene (400 uL) . Aliquots were used directly from this solution for all dosing 
regimens.  All dosing solutions were subjected to pre- and post- dosing radioactivity 
examination to ensure proper delivery of dose.  All solutions were designed to deliver  
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approximately 0.2 μCi to each mouse.  Corn oil by weight was then added to the vials 
followed by the evaporation of toluene under vacuum (Speed Vac, Savant Instruments, Inc. 
Farmingdale, NY).   
 
Animals and Treatment: Dams (n=6/diastereomer) and female C57BL/6 mice (PND 9, ~ 7 
grams) were obtained from Charles River Breeding Laboratories (Raleigh, NC).  Dams and 6 
pups per litter were acclimated for 24 hours in shoebox cages.  PND 10 pups were exposed 
by gavaged with a single dose of α-[14C]HBCD and γ-[14C]HBCD at 3 mg/kg.   Animals 
were maintained on a 12 h light/dark cycle at ambient temperature (22
◦
C) with relative 
humidity (56 ± 5%), and were provided with Purina 5001 Rodent Chow (Ralston Purina Co., 
St. Louis, MO) and tap water ad libitum. One pup/litter (total of 6 litters/diastereomer) was 
randomly selected at 3h, 8h, 1, 2, 4 or 7 days following exposure when tissues were 
harvested (Figure 1). 
 
                                    [C14]HBCD 
                                alpha or gamma 
  
                                               Sacrifice and   Sacrifice and          Sacrifice and     Sacrifice and                    Sacrifice and                                                Sacrifice and     
                                                        collect tissues   collect tissues         collect tissues    collect tissues                  collect tissues                                              collect tissues            
 
               DOSING  
  
       DAYS         
                                 0                3hr               8hr                     1                  2                3               4               5               6                 7        
 
 
Figure 4.1.  Dosing paradigm. C57BL/6 female mouse pups were gavaged at PND10 or 
PND60 (Szabo et al., 2010; Szabo et al., 2011) with a single exposure of α-HBCD or γ-
HBCD at 3mg/kg. Pups were sacrificed 3hr, 8hr, 1 day, 2 day, 4 day and 7 day post exposure 
where major tissues were harvested. 
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Exposure: A single dose (3 mg/kg) of each diastereomer was administered directly by gavage 
into the stomach of each mouse using a curved ball-tipped animal feeding needle. Dose 
volume was 10 mL/kg.   
 
Sample Analysis: Radioactivity in the tissues was determined by combustion to 
14
CO2 
(Packard 307 Biological Oxidizer, Downers Grove, IL) of triplicate samples when available 
(~100 mg/sample) followed by liquid scintillation spectrometry (LSS; Beckman, Beckman 
Instruments, Fullerton, CA) with limits of detection (LOD) of 50 dpm (3 x background) or 
6.7 ng HBCD.   Tissue data are reported based on wet weight.  
 
 Data Analysis: Tissue concentrations are presented as nanograms of α-HBCD or γ-HBCD 
derived radioactivity/gram of tissue wet weight and percent administered dose of tissue.  
Intergroup comparisons were performed by a two-way ANOVA followed by Bonferroni post 
tests significant when p < 0.05.  All data are presented as mean ± standard deviation. 
GraphPad Prism 5.0, Hearn Scientific Software (Melbourne, Australia) was used for 
statistical analysis. Excretion was estimated using whole-body analyses of residual 
radioactivity.   
 
 
 
 
 
 
 
 
 
 
 
112 
RESULTS 
 
 
The distribution of the two high profile HBCD diastereomers,  α-[14C]HBCD or γ-
[
14
C]HBCD, were monitored from PND 10 for 7 days following a single oral dose and 
compared to patterns observed in adult animals (Szabo et al., 2010; Szabo et al., 2011). 
Administration of either α-[14C]HBCD or γ-[14C]HBCD in corn oil did not impact pup 
development (as monitored by body weight of pups treated with vehicle only).  No overt 
toxicity was observed in response to oral exposure to either diastereomer. 
 
Tissue Distribution of α-HBCD and γ-HBCD 
 
One pup/litter (total of 6 pups) was randomly selected at 3 hr, 8 hr, 1, 2, 4 or 7 days 
following exposure to either α-[14C]HBCD or γ-[14C]HBCD.  Overall trends resulted in α-
[
14C]HBCD, and to a lesser extent γ-[14C]HBCD, being distributed to lipophilic tissues 
(Tables 1a and 1b).   
 
Time Skin Liver Lung Muscle Kidney Blood Adipose Brain 
3 hours 1.1   1.1 ± 0.1 19 ± 2.2 1.2   1.2 ± 0.1 3.1± 0.8 6.0 ± 0.3 7.3 ± 0.2 1.0 ± 0.1 1.3 ± 0.1 
8 hours    2.7 ±  0.2 1.4 ± 2.4 2.4 ± 0.3 4.8 ± 0.5 2.1± 0.4 3.4 ± 0.2 2.4 ± 0.2 1.0 ± 0.1 
1 day    1.3 ± 0.2 9.0 ± 0.5 0.9 ± 0.2 2.1 ± 0.2 1.1 ± 0.2 2.8 ± 0.1 5.2 ± 0.6 0.9 ± 0.1 
2 days 0.7 ± 0.2 5.0 ± 0.9 0.5 ± 0.0 1.0 ± 0.1 0.4 ± 0.0 1.9 ± 0.0 3.1 ± 0.5 0.5 ± 0.0 
4 days    0.4 ± 0.1 2.8 ± 0.3 0.3 ± 0.0 0.5 ± 0.0 0.2 ± 0.0 1.1 ± 0.2 1.8 ± 0.2 0.3 ± 0.0 
7 days 0.2 ± 0.0 1.3 ± 0.2 0.1 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.5 ± 0.0 0.8 ± 0.2 0.1 ± 0.0 
 
              Table 4.1a. Disposition of γ – [14C] HBCD derived radioactivity at multiple time points  
            following a single 3 mg/kg oral dose at PND 10. All data are mean ± standard deviation;    
            percent dose.   
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Time Skin Liver Lung Muscle Kidney Blood Adipose Brain 
3 hours 2.2 ± 0.1 34 ±  3.2 1.6 ± 0.1 2.1 ± 0.8 9.5 ± 0.3 11 ± 0.3 2.5 ± 0.2 2.5 ± 0.2 
8 hours 3.7 ± 0.2 19 ±  0.9    2.4 ± 0.3 3.8 ±  0.5 3.8 ± 0.4 3.9 ± 0.5 5.3 ± 0.2 1.4 ± 0.2 
1 day 4.9 ± 0.3 13 ±  0.9 1.8 ± 0.2 5.1 ± 0.2 1.9 ± 0.2 2.9 ± 0.1 6.1 ± 0.1 1.1 1.2 ± 0.2 
2 days 2.4 ±  0.3 8.1 ± 0.9 1.3 ± 0.2 4.2 ± 0.1 1.6 ± 0.1 2.0 ± 0.1 7.0 ± 0.5 1.0 ± 0.2 
4 days 3.6 ± 0.3 3.9 ±  0.3 0.9 ± 0.0 3.9 ± 0.3 1.3 ± 0.0 1.6 ± 0.2 5.2 ± 0.4 0.8 ± 0.0 
7 days 2.9 ± 0.2 3.2 ± 0.3 0.8 ± 0.0 3.2 ± 0.0 0.9 ± 0.0 1.1 ± 0.2 4.9 ± 0.4 0.6 ± 0.0 
 
Table 4.1b. Disposition of α-[14C] HBCD derived radioactivity at multiple time points 
following a single 3 mg/kg oral dose at PND 10. All data are mean ± standard deviation; 
percent dose. 
 
Highly perfused tissues, such as liver, kidney and brain had peak concentrations 
within 3 to 8 hrs of administration for both stereoisomers examined. However, peak 
concentrations in slowly perfused tissues, such as muscle and skin, were observed at 24 h 
post dose while lipophilic tissues such as adipose peaked at 2 days after exposure with α-
[
14
C]HBCD. γ-[14C]HBCD had a similar distribution pattern as α-[14C]HBCD, however,  
lower levels of γ-[14C]HBCD were present in each tissue examined, and its peak 
concentrations occurred at earlier time points.  
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Body Burden of α-HBCD vs. γ-HBCD 
 
Total radioactivity in tissues was summed and used here as a measure of total body 
burden.  Since pups were kept with dams in shoebox cages, excreta were not collected. The 
amount of α-[14C]HBCD and γ-[14C]HBCD remaining in the body over time in pup tissues is 
shown in Figure 4.2.  
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Figure 4.2. Body burden is the sum of all the tissues measured in developing mice. Body 
burden was compared as a function of stereoisomer derived radioactivity (γ-[14C]HBCD vs. 
α-[14C]HBCD) over time.  
 
After oral exposure to α-[14C]HBCD,  higher levels of total radioactivity are observed 
at every time point measured  than were observed from exposure to γ-[14C]HBCD.  Over  
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time, the % dose difference in body burden between the two stereoisomers slightly increased.   
At 24 hours, the body burden difference was 1.5- fold higher in α-[14C]HBCD exposed mice 
than γ-[14C]HBCD exposed mice and by 7 days post-dose, the difference had increased to 
2.2-fold.  
 
Adults vs Developing Animals- Tissue Levels 
 
While pup disposition trends paralleled those observed in adults, actual tissue 
concentrations of both α-[14C]HBCD and γ-[14C]HBCD were generally higher in pups than 
levels found in adults previously reported (Szabo et al., 2010; Szabo et al., 2011) (Figure 3). 
The majority of comparisons in this section are based on the concentration of stereoisomer-
derived radioactivity per gram of tissue (ng/g), which normalizes for differences in body 
composition during development and allows for a more direct comparison across age groups. 
When using this dose-metric, concentrations in adipose, blood, brain, kidney, muscle, and 
skin were higher in pups at respective time points after exposure to γ-[14C]HBCD with 
similar trends but higher levels measured after exposure to α-[14C]HBCD at tissues 
measured.   
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Tissue Levels between PND 10 vs PND 60 mice after exposure to 
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Figure 4.3. Tissue disposition of γ-[14C] HBCD and α-[14C]HBCD  derived radioactivity 4 
after oral administration of a single 3 mg/kg dose in  juvenile mice at PND 10 and compared 
to previously published levels in adult mice at PND 60 (Szabo et al., 2010, 2011). Data are 
represented as concentration in the tissue (ng/g wet weight).  
 
Adults vs Developing Animals - Body Burden 
Figures 4a and 4b show the amount of α-[14C]HBCD and γ-[14C]HBCD remaining in 
the body over time, directly comparing total tissue levels measured in pups to those 
previously reported in adult mice (Szabo et al., 2010,2011). Within 24 h after oral exposure 
to α-[14C]HBCD, only 25% of the dose remained in the body of the adult mice versus 33% in 
the pups (Figure 4a).   
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Figure 4.4a. Body burden is the sum of all the tissues measured for γ- 14C HBCD derived 
radioactivity. Body burden was compared as a function of age (PND 10 vs PND 60) over 
time.  
 
By four day post-dose, 17% remained in adults, while 23% of the α-[14C]HBCD 
derived radioactivity remained in the pups. After seven days, 9 and 20% were detected in the 
adults and pups respectively (Figure 4a).  Lower levels of γ-[14C]HBCD derived radioactivity 
were measured in both the adults and pups as compared to  α-[14C]HBCD (Figure 4b).  
Within 24 h, only 2% of the dose remained in the body of the adult mice versus 16% in the 
pups. By the fourth day, less than 1% of γ-[14C]HBCD derived radioactivity was detected in 
the adults while 7% remained in the pups (Figure 4b). 
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Figure 4.4b. Body burden is the sum of all the tissues measured for α-14C HBCD derived 
radioactivity.  Body burden was compared as a function of age (PND 10 vs PND 60) over 
time.  
 
DISCUSSION 
 
 
Neonatal mice have been previously reported to be susceptible to the commercial 
mixture of HBCD (Eriksson et al., 2006). The objectives of this study were to investigate the 
disposition of the α- and γ-HBCD stereoisomers in 10-day-old mice and to compare these 
neonatal levels to adult levels previously reported in Szabo et al., (2010) and Szabo et al., 
(2011).  Overall disposition trends in infant mice were similar to those observed in adults, α-
[
14C]HBCD distributes to  lipophilic tissues to a greater degree than  γ-[14C]HBCD.  Because  
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it has been previously demonstrated that α-HBCD is more water soluble than γ-HBCD, 48.8 
and 2.1 ug/l, respectively (MacGregor and Nixon 2004), it is paradoxical that α-HBCD is 
more biologically persistent and detected to a higher degree than γ-HBCD in adipose tissue. 
Reasons for this may be due to the lack of rapid metabolism of α-HBCD, demonstrated in rat 
and seal microsomal in vitro assays (Zegers et al., 2006) and in a mouse in vivo study (Szabo 
et al., 2011). This in part, would permit α-HBCD to partition into fat stores more readily than 
other HBCD stereoisomers, such as γ-HBCD, which have been shown to be rapidly 
metabolized in vitro (Zegers et al., 2006) and rapid metabolized and eliminated in vivo 
(Szabo et al., 2010).  
 
Tissue concentrations were generally higher in the infant mice exposed to either 
HBCD stereoisomer relative to adults.  The changing physiology of developing animals can 
cause tissue disposition and overall toxicokinetics to differ from those observed in adult 
animals.  Immaturity in the gastrointestinal (GI) tract of neonatal animals can lead to 
increased chemical absorption (Ginsberg et al., 2004). This may be a function of greater 
pinocytic activity of intestinal epithelium (NRC, 1993; Teichberg et al., 1990), higher 
stomach pH, differences in blood flow and absorptive surface area before maturation (NRC, 
1993). Evidence also suggests that milk in the GI tract enhances absorption of certain 
xenobiotics and may contribute to the age differences in bioavailability (Kostial et al., 1978 
and NRC, 1993). Increased GI absorption in developing animals have been observed after 
exposure to lead (USEPA, 1994a; USEPA, 1994b; Bowers and Cohen, 1998; NRC, 1993)  
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polonium nitrate (Haines et al., 1993), mercuric chloride (Walsh, 1982), and for select 
pharmaceuticals (Hoffman, 1982; NRC, 1993).  
 
Age differences in the composition of tissues can also contribute to altered chemical 
disposition. The brain constitutes a higher percentage of body weight in the young, and the 
immaturity of the blood–brain barrier (BBB) may lead to a significant increase in chemical 
partitioning (Renwick et al., 2000), resulting in potential for increased neurotoxic effects 
(Saunders et al., 2000). Tissues such as liver, kidney, and lung undergo rapid growth through 
infancy (NRC, 1993). Liver mass per body weight is greatest in early life (Blanco et al., 2000 
Gibbs et al., 1997), but hepatic elimination of rapidly metabolized chemicals may be limited 
by blood flow (Kedderis, 1997). Renal glomerular filtration rates are reduced in neonates; 
therefore, a reduced rate of excretion and thus greater body burden may in part explain 
increased levels during development seen after HBCD exposure.  In addition, neonates and 
infants have a higher percentage of body water and lower lipid content than adults (Clewell 
et al., 2002, Kearns and Reed, 1989; Morselli, 1989); this can cause an increased volume of 
distribution for water-soluble chemicals, including secondary polar HBCD metabolites which 
could possibly increase half-lives during early stages of life.  
 
Considerable differences in the ontogenic gene expression can contribute to variations 
in xenobiotic metabolism between neonates and adults.  Less efficient drug metabolism and 
transport in neonates may result in increased susceptibility to toxic effects. The cytochrome  
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P450 superfamily is responsible for approximately 75% of xenobiotic metabolism however; 
these levels are generally not mature at birth (Fouts and Adamson, 1959).  Hydroxylated 
metabolites of HBCD have been detected in an in vivo rat study (Brandsma et al., 2009) and 
polar metabolites have been detected after an in vivo exposure to γ-HBCD in mice (Szabo et 
al., 2010). Zegers et al., (2005) determined that individual stereoisomer differences within rat 
and seal microsomes results in rapid biotransformation of gamma and beta, but 
biotransformation of alpha was slower. HBCD has been shown to be an agonist for the CAR 
and PXR nuclear receptors, which regulate the Cyp2b and Cyp3a family of enzymes (Crump 
et al., 2010, Fery et al., 2010, Crump et al., 2008, Germer et al., 2006). The ontogeny of 
Cyp2b and Cyp3a gene transcripts from gestation to adulthood has been investigated in 
C57BL/6 mice (Hart et al., 2009). In female and male mice, Cyp2b10, the ortholog for the 
human CYP2B6, was low at all ages but increased steadily over the first 30 days of life 
followed by a constant plateau to adult levels. Cyp3a11 and Cyp3a41b both code for the 
human CYP3A4 and are either at similar or slightly lower levels at PND 10-15 than PND 60 
in female mice, respectively. This could indicate that endogenous levels of Cyp2b10, and to a 
lesser extent Cyp3a11 or Cyp3a41b, may be driving the differences of HBCD disposition 
between age groups observed in this study.   
 
Active transporters are also expressed at lower levels during development.  In the 
liver, Mdr2 gradually increases over time from birth. Mdr2 expression levels in female 
C57BL/6 at PND 10 are approximately 50% of the adult levels (Cui et al., 2009). The BBB  
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protects the adult brain with the expression of Mdr1a and 1b against xenobiotic insults but 
the expression of both are low in the fetal and neonatal brain. In C57BL/6 mice, the 
expression levels increased after the first 10 days of age and low expression of these 
transporters in the brain correlates with the high vulnerability of the newborn to certain 
xenobiotics. 
 
α-[14C]HBCD and γ-[14C]HBCD disposition trends in pup brains were of particular 
interest in light of previous developmental neurotoxicity studies (Eriksson et al., 2006) which 
demonstrated a single oral dose at PND 10 elicited altered spontaneous behavior, learning 
and memory deficits in adulthood. In our study, the concentrations we measured in the brains 
4 days post-exposure were different as a function of age and stereoisomer. At the 4 day time 
point, γ-HBCD is not measurable in the adult brain (Szabo et al., 2010) but has a 
concentration of nearly 1000 ng/g four days post-exposure in PND 10 mice.  Similarly but to 
a lesser degree,  α-HBCD exposure distributed nearly 25% more to the developing animal 
than in the brains of adults with approximately 2500 ng and 1000ng of derived radioactivity 
per gram of brain tissue, respectfully.  We also observe that higher levels of total 
radioactivity measured in the blood did not lead to significantly increased partitioning into 
the brain after exposure to α-[14C]HBCD or  γ-[14C]HBCD. As previously discussed, it is 
well documented that many active transport proteins along the BBB barrier are responsible 
for controlling xenobiotic access and removal from the tissue and that these transporters may 
not be fully developed in infantile mice (Cui et al., 2009, Schiengold et al., 2001). Since  
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HBCD has been shown to be an agonist for the nuclear receptors CAR and PXR (Fery et al., 
2010) whereby controlling expression of Phase III efflux transporters (pumping out of the 
brain), it is plausible that this may be a mechanism leading to increased levels of α-HBCD 
and γ-HBCD stereoisomer derived radioactivity in developing mice brains as compared to 
adults. Future studies designed to examine HBCD diastereomers as a substrate for membrane 
transporters may in part support the observed toxicokinetics observed here. 
 
In addition to HBCD, other persistent organic pollutants (POPs) such as 
perfluorooctane sulfonate (PFOS), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and PBDEs 
have shown higher body burdens in developing animals than adult animals.  After exposure 
to PFOS, similar tissue distribution patterns were observed between rat dams and fetuses but 
higher levels were measured in the serum and brains at gestational day 21 (Lau et al., 2003).  
The rate of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) distribution to the fetal brains of rats 
was ≥100 times higher than that in adults (Ishida et al., 2010).  In a similarly performed study 
from our laboratory using the PBDE congener BDE-47, disposition patterns in tissues were 
similar across ages, but concentrations of BDE-47 were higher after exposure to PND 10 
pups (Staskal et al., 2006).  Comparing the  body burden differences (between PND 10 and 
PND 60 mice), the three brominated flame retardants (BDE-47, γ-HBCD and α-HBCD) 
resulted in all having higher levels in pups than adults with 3, 8 and 2-fold increases, seven 
days after exposure, respectively. Although γ-HBCD exposed pups contained the highest fold 
change between age groups, body burden levels (on a % dose basis) were lowest after  
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exposure to γ-HBCD  (9% of dose) followed by α-HBCD (20% of dose) and highest for 
BDE-47 (40% of dose).  Along with differences in α-HBCD and γ-HBCD metabolism and 
stereoisomerization in adult mice (Szabo et al., 2010; 2011) the higher overall body burden 
levels seen with BDE-47 may also due to differences in elimination by mouse urinary protein 
(MUP); (Staskal et al., 2005), not observed to occur for either α-HBCD or γ-HBCD (data not 
shown).    
BDE-47, PFOS and TCDD toxicity have been well examined in developing animals, 
however, data on the toxicity of HBCD commercial mixture in developing animals is 
growing, but still remains limited (Saegusa et al., 2009; van der Ven et al., 2009; Eriksson et 
al., 2006; Deng et al., 2009) with no toxicity data in developing animals after exposure to any 
individual HBCD stereoisomer. With larger age-related body burden differences observed for 
γ-HBCD than for BDE-47 and similar differences between α-HBCD and BDE-47, the need 
for HBCD stereoisomer toxicity testing in developing animals should be considered a 
priority.  
There is compelling evidence that the HBCD commercial mixture has the potential to 
disrupt reproductive (Ema et al., 2008), developmental (Saegusa et al., 2009), and 
neurological (Eriksson et al., 2006) processes and may also have epigenetic (Aniagu et al., 
2008), and endocrine-disrupting effects (van der Ven et al., 2009).  Many individuals 
throughout the world have already accrued a measurable body burden, making exposure to 
HBCD a potential health risk (Arnot et al., 2011). α-HBCD appears to be persistent and 
bioaccumulative in adult animals (Szabo et al., 2011) with a greater potential for the 
developing animal. With evidence that γ-HBCD can stereoisomerize to α-HBCD in  
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mammals (Szabo et al., 2010) and higher body burden levels of both stereoisomers are found 
in developing mice as compared to adults, concerns from exposure to both stereoisomers 
should be taken into consideration when assessing the risk of HBCD to the potentially 
susceptible young population. 
 
The results of this study demonstrate that the toxicokinetics of the two HBCD 
stereoisomers, α and γ, are different in developing mice than in adult mice. These differences 
may lead to higher concentrations of HBCD at target tissues during critical windows of 
development. Because HBCD have demonstrated toxicity during development, it is essential 
to understand the kinetic parameters in order to accurately describe the dose available to 
target tissues after exposure, which may more accurately assess risk to human health. This 
age group should remain a target population for defining susceptibility factors in future 
toxicokinetic and toxicodynamic research. 
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Chapter V 
 
EFFECTS OF HBCD IN DEVELOPING MICE: A SYSTEMS BIOLOGY 
APPROACH TO DEVELOPMENTAL NEUROTOXICITY 
 
 Brominated flame retardants (BFRs) are a structurally diverse class of compounds added to 
consumer products for decreased flammability and increased time to burn. Increasing 
concentrations of these compounds in the environment, human food chain, and in human 
tissues raise concern about possible neurotoxic effects, particularly for the developing 
nervous system (Costa and Giordano 2007). This concern has led to voluntary action and 
legislative measures to eliminate the penta‐ and octabrominated diphenyl ethers from the 
market in Europe and North America. After their use was stopped in consumer products, a 
sharp rise in environmental levels of the BFR hexabromocyclododecane (HBCD) was 
observed (Law et al. 2008). This is possibly due to an increased use of HBCD as a 
replacement of the banned polybrominated diphenyl ethers (PBDEs), mainly in polystyrene 
products and textile backings. The technical mixture of HBCD consists of three 
stereoisomers, denoted α‐, β‐, and γ‐HBCD. HBCD has been shown to biomagnify in marine 
food chains (Jenssen et al. 2007). Interestingly, biotic samples are in general dominated by  
 
 
 
the α‐stereoisomer although the technical mixture consists for 70 ‐ 90% γ‐HBCD (Covaci et 
al. 2006). This is probably due to isomer composition changes during heating of the technical 
mixture during industrial application (Heeb et al. 2008), and/or biotransformation of α- to β‐ 
and γ‐HBCD in biota (Szabo et al. 2010).  
 
Fetal and neonatal exposures to neurotoxicants have adverse effects on 
neurodevelopment. Direct effects of xenobiotics on the developing brain could cause these 
effects, during a critical window for neurotoxicity. However, the underlying mechanisms are 
not well understood (Szpir et al., 2006). Of concern is that children, during the infantile 
period, may be more highly exposed than adults to HBCD because of their diet (breast-
feeding/relatively large intake relative to body weight) and behavior (contact with house-
dust) (Jones-Otazu et al. 2005). Disposition studies show that developing mice have higher 
tissue concentrations of HBCD stereoisomers α and γ, compared with adult mice after 
identical dosing regimens (Szabo et al.; 2011b). Behavioral studies have demonstrated 
adverse neurodevelopmental effects on learning and memory after neonatal HBCD exposure 
(Eriksson et al., 2009) _____________________________________  
  
A proteomics approach was used to investigate the effect of a single oral dose of 12 
mg/kg body weight (bw) of BDE-99 on brain protein levels in mice, 24 hr after exposure. 
Levels of striatal proteins associated with neurodegeneration and neuroplasticity and of 
hippocampal proteins associated with metabolism and energy production were found to be 
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changed (Alm et al. 2006). BDE-99 causes similar development neurotoxic behavioral 
effects as observed for HBCD (Eriksson et al., 2001; Eriksson et al., 2006).  It is unclear 
whether such molecular changes occur after exposure to HBCD and whether these effects are 
stereoisomer dependent. 
An adverse effect on learning and behavior in mice (0.9 and 13.6 mg/kg bw) of 
HBCD (Eriksson et al. 2006), as well as on oxidative stress and the cellular antioxidant 
defense systems in fish brain after 28 days exposure to 500 μg/l of HBCD (Zhang et al. 2008) 
have been observed.   In vitro neurotoxicity data on HBCD is limited. So far, only inhibition 
of neurotransmitter uptake in rat synaptosomes (IC50: 4 μM) and synaptic vesicles (IC50: 3 
μM) (Mariussen and Fonnum 2003) and necrotic cell death in cerebellar granule cells after 
24 h exposure (LC50: 3 μM) Reistad et al. 2006) have been reported.  
Alterations in intracellular Ca2+ homeostasis, as observed for PBDEs and 
ortho‐substituted (non-coplanar) PCBs (Mariussen and Fonnum 2006), may play a role in the 
observed cytotoxicity and oxidative stress (Orrenius et al. 2003). In hippocampal neurons, 
the main excitatory neurotransmitters are glutamatergic. Depolarization occurs with 
regulating the influx of Ca
2+
 by voltage gated calcium channels (VGCCs) as well as NMDA 
and glutamatergic receptors, located in the cell membrane which opens, depolarizing the 
neuron. The subsequent rapid influx of Ca
2+
 can trigger various intracellular processes 
including signal transmission and neurotransmitter release (Barclay et al. 2005; Clapham et 
al., 2007).  
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 The main objectives of our study are to 1) to gain insight into the mechanisms 
underlying the observed effects of HBCD on learning and memory (Eriksson et al. 2006). We 
propose that HBCD alters molecular mechanisms responsible for learning and memory as 
seen previously for BDEs and PCBs. This objective investigates the effects of the technical 
HBCD mixture on gene transcription in the hippocampus. The second objective 2) 
investigates the individual HBCD stereoisomers, α-HBCD and/or γ-HBCD, and which is 
responsible for the neurotoxicity observed after exposure to the HBCD commercial mixture.  
Overall, there is little data on stereoisomer specific metabolism in the literature and there is 
currently no in vivo data for effects or gene expression in any mammalian system in any 
organ.  In predicting human health risks posed by HBCD, it is therefore necessary to 
accurately predict diastereomer specific effects.  Based on their toxicokinetic differences in 
adult (Szabo et al., 2010; Szabo et al., 2011a) and developing mice (Szabo et al., 2011b) we 
hypothesize that HBCD-α and -γ will have different transcriptome and proteome profiles in 
the hippocampus of infantile mice, previously shown to be susceptible to HBCD commercial 
mixture effects (Eriksson et al., 2006).  
 
In the present work, we examined the gene expression of the HBCD commercial 
mixture and the gene transcription and protein expression profiles of α-HBCD and γ-HBCD 
in hippocampus from female mice exposure to a single oral dose on PND 10.  Our main 
objective was to elucidate the mechanisms underlying the adverse effect (developmental 
neurotoxicity) previously observed in vivo.  Mice were administered 0, 3, 10, and 30mg/kg  
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dose of α-HBCD, 0, 3 and 30mg/kg of γ-HBCD, and 0 and 30 mg/kg of the CM-HBCD.  
However, this chapter will focus on the effects observed in mice administered the high dose 
for each condition (30mg/kg).  The main target tissue of interest and motivation for choosing 
the  neonatal dosing paradigm  was to report on effects observed in the hippocampal tissue 
and to determine the molecular mechanisms involved after exposure to the commercial 
mixture and whether α-HBCD or γ-HBCD elicit similar or different effects.  
 
Additional data on the metabolomics of the serum, and transcriptomics and 
proteomics of the liver will be presented in this chapter, where applicable, but only to support 
the similarities or difference observed in the hippocampus and briefly discussed. Attention in 
this chapter is focused on the hippocampal effects.   
 
MATERIALS AND METHODS 
 
Chemicals: 1,2,5,6,9,10-hexabromocyclododecane ([HBCD) (2mCi/mmol) was purchased 
from Sigma-Aldrich; (St Louis, MO) as a mixture of α-HBCD, ß-HBCD and γ-HBCD.  
Methods for separating the diastereomers from the commercial mixture (CM-HBCD) and 
thermal conversion of γ-HBCD to α-HBCD were previously described for [14C] labeled 
stereoisomers (Szabo et al., 2010; Szabo et al., 2011a).  Other chemicals used were of the 
highest grade commercially available. 
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Dosing Solutions: Doses were selected based on environmental relevance and published 
toxicity (Eriksson et al., 2006) and toxicokinetic studies (Szabo et al., 2010; Szabo et al., 
2011a, and Szabo et al., 2011b), percent of stereoisomers in the commercial mixture and 
limited supply of purified compounds.  All solutions were designed to deliver approximately 
3, 10, and 30mg/kg doses of α-HBCD, 3 and 30mg/kg of γ-HBCD, and 30 mg/kg of the CM-
HBCD to each mouse.  Corn oil by weight was then added to the vials followed by the 
evaporation of toluene (dissolving agent) under vacuum (Speed Vac, Savant Instruments, Inc. 
Farmingdale, NY).   
 
Animals and Treatment: Mouse dams (n=6) and their infantile female C57BL/6 pups (PND 
9, ~ 7 grams) were obtained from Charles River Breeding Laboratories (Raleigh, NC).  Dams 
and 4 pups per litter were acclimated for 24 hours in shoebox cages.  PND 10 pups were 
gavaged with a single dose of vehicle, α-HBCD, γ-HBCD, or CM at 30 mg/kg at 10 ml/kg.   
Animals were maintained on a 12 h light/dark cycle at ambient temperature (22
◦
C) with 
relative humidity (56 ± 5%). Dams were provided with Purina 5001 Rodent Chow (Ralston 
Purina Co., St. Louis, MO) and tap water ad libitum. Total of 6 pups/treatment group (one 
pup/litter) was sacrificed four days following exposure when tissues were harvested. Mice 
were housed in an AAALAC-accredited facility and the EPA/NHEERL IACUC approved 
the procedures. 
 
Sample Analysis: Tissues harvested from PND 14 mice were the liver, hippocampus, and 
serum. The liver was rapidly diced and separated into two equal tubes: one for transcriptomic  
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and the other for proteomic analysis. The hippocampus from each brain hemisphere was 
harvested, one for each analysis. Tissues were flash frozen in liquid nitrogen and then stored 
in -80 °C until they could be processed for either RNA isolation (transcriptomics) or protein 
isolation (proteomics). Serum samples were frozen at -80C until preparation for the 
metabolomic analysis. 
 
Transcriptomics  
 
RNA Extraction. RNA was extracted using Qiagen RNeasy Mini and Midi Kits (Valencia, 
CA) in accordance with the manufacturer's protocol. Approximately 5 mg of hippocampus 
and 100 mg of liver tissue was used for each RNA extraction (Mini Kit). After extraction, the 
RNAs were resuspended in RNAse-free water and concentrations were measured using a 
spectrophotometer. Integrity of RNA samples from both studies was determined by the size 
distribution of 18 S and 28 S ribosomal RNA using an Agilent Bioanalyzer (Agilent 
Technologies, Palo Alto, CA). In both studies all samples passed quality control and showed 
no signs of degradation. 
 
Microarray Hybridization. 500 ng of total RNA was converted into labeled cRNA with 
nucleotides coupled to fluorescent dye Cy3 using the Low RNA Input Linear Amplification 
Kit (Agilent Technologies, Palo Alto, CA) following the manufacturer's protocol. The 
A260/280 ratio and yield of each of the cRNAs were determined and cRNA integrity was  
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evaluated using an Agilent Bioanalyzer.  nCy3-labeled cRNA (1.65 ng) from each sample 
was hybridized to Agilent Mouse Whole Genome oligonucleotide Microarrays in 4X44K 
format. The hybridized array was then washed and scanned and data were extracted from the 
scanned image using Feature Extraction version 9.5 (Agilent Technologies). All microarrays 
passed QC standards set forth in the Agilent Feature Extraction Software (V9.5) reference 
guide. 
 
Microarray Data Normalization and Quality Control. Raw gene expression intensity values 
were background subtracted and normalized (within array normalization) using the Agilent 
Feature Extractor software. The across array normalization was performed using the Quantile 
normalization method (Bolstad et al., 2003). The normalized data for all samples was used to 
generate Box plots and Density plots as implemented in Bio-conductor 
(www.bioconductor.org). The normalized data was also used for Principal Component 
Analysis (PCA) to investigate the effect of known experimental variables such as treatment 
type (alpha, gamma or mixture) at 30 mg/kg; as well as technical variables such as sample 
hybridizations performed at different times.  
 
Identification of differentially expressed probes. To identify probes that were differentially 
expressed in treated samples compared to controls, we employed Welch‟s t-test which is an 
adaptation of Student‟s t-test for comparing two independent samples in the presence of 
heterogeneity of variance. This test does not utilize pooled variance estimate and computes  
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degrees of freedom associated with variance estimate using the Welch-Satterthwaite equation 
(Welch et al., 1947). The resulting p-values were corrected for multiple testing using 
Benjamini Hochberg‟s method (Benjamini et al., 1995). The fold change values for each 
probe was computed by taking a ratio of expression intensity in treated over control samples.   
 
For each treatment type vs. control comparison, we selected a list of probes that 
satisfy p-values < 0.05 and absolute fold change greater than 1.5 (up-regulation or down-
regulation) as criteria for further analyses.  
 
Ingenuity Pathway Analysis (IPA). We employed IPA to identify over represented biological 
pathways in probe lists selected for each comparison type. For each treatment vs. control 
comparison, probe lists were selected using the aforementioned criteria (p-value < 0.05 and 
Absolute Fold > 1.5) and IPA was used to find enriched canonical pathways that displayed p-
value <0.05 (right-tailed Fisher‟s exact test as implemented in IPA) directly correlated with 
the transcript level changes measured via the Agilent microarray platform.  
 
Proteomics  
 
Antibody Array Slide.  The Phospho Explorer Antibody Array (Full Moon Biosystems; 
Sunnyvale, California), a discovery tool, is a glass microarray slide used to identify protein 
changes after exposure to HBCD. This microarray consists of 1318 well-characterized 
specific antibodies.  It is broad in scope and allows for the detection and analysis of over a  
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thousand proteins simultaneously on a single slide.  The antibodies are printed on standard- 
size coated glass microscope slides and can be scanned on all microarray scanners that are 
compatible with 76 x 25 x 1 mm (3 in. x 1 in. x 1mm) slides. To validate the transcriptomic 
data and support our findings, we performed a pilot study using the antibody array. 
Therefore, mouse hippocampal and liver tissues administered 30mg/kg (high dose) of α-
HBCD and γ-HBCD were processed for proteomic analysis only. Direct comparison between 
the two platforms will be analyzed and discussed for hippocampal effects after administration 
of an oral dose of α-HBCD and γ-HBCD at 30mg/kg. 
      
Tissue Preparation. Tissues were washed with cold 1X PBS (4°C) 3 to 5 times with vortexing 
to remove excess blood.  One tube of lysis beads was added to each 10 – 40 mg of tissues. 
Extraction Buffer was added at 100 ul of Extraction Buffer to 10 – 20 mg of tissue and mixed 
rigorously by vortexing for 30 second. The mixture was then incubated on ice for 10 minutes. 
This procedure was repeated for 10-minute intervals for up to 60 minutes where it was then 
centrifuged at 10,000 x g (14000 rpm) for 15 to 20 minutes at 4°C and the clear supernatant 
was transferred to a clean tube.  
 
Buffer Exchange/Protein Purification.  This step ensures the removal of unwanted buffer 
from the protein extract and replaces it with the Labeling Buffer provided in the Antibody 
Array Assay Kit. 100uL of protein extract was transferred from the tissues to the top of the 
gel of each column. The column was placed in a collection tube and centrifuged at 750 x g 
for 2 minutes, collecting the purified protein. 
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Protein quantification and Quality Control. Protein was measured by UV absorption.  All 
absorbance values were greater than 4 OD to ensure proper protein concentration. Two 
separate peaks were observed at 200-230nm and 240-280nm and were well separated, 
signifying the lysate is clear.  
 
Protein Labeling – Biotinylation of Protein Samples.  100 ul of DMF (N,N-
dimethylformamide) was added to 1 mg of Biotin Reagent to give a concentration of 10 
ug/ul. Labeling Buffer was added to the protein sample to bring the volume to 75 μl.  The 
solution should contain 80 – 150 OD of protein (or 40 – 100 ug with a concentration of 2 – 
10 ug/ul). 3 ul of the Biotin/DMF solution was added to the protein sample, incubated at 
room temperature for 1 – 2 hours with mixing. 35 ul of Stop Reagent was then added to the 
protein samples and incubated for 30 minutes at room temperature.  
 
Blocking. The Antibody Microarray was removed from the refrigerator and allowed to warm 
up to room temperature (30 to 45 minutes). Packages were opened to expose the slides and 
allowed to dry for 10 to 15 minutes. 30 ml of Blocking Solution was added in a 100x15 mm 
Petri dish and each antibody microarray slide was placed in the Blocking Solution and 
incubated on an orbital shaker rotating at 55 rpm for 30 to 45 minutes at room temperature. 
The slides were then rinsed 10 times with Milli-Q grade water.  
 
Coupling.  One tube of biotin labeled proteins (80 – 150 OD or 40 – 100 ug) was vortexed 
and briefly mixed and then the slide was placed in a coupling chamber.  6 ml of Protein  
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Coupling Mix was poured over the slide and then incubated on an orbital shaker rotating at 
35 rpm for 1 – 2 hours at room temperature. The slide was then transferred to a 100x15 mm 
Petri dish containing 30 ml of 1X Wash Solution where it was incubated on an orbital shaker 
rotating at 55 rpm for 10 minutes at room temperature. The wash solution was then 
discarded.  The slides were then rinsed 10 times with Milli-Q grade water.  
 
Detection.  60 ul of Cy3-Streptavidin (0.5 mg/ml) was added to 60 ml of Detection Buffer 
and 30 ml of Cy3-Streptavidn Solution in a 100x15 mm Petri dish. The slide was submerged 
in the Cy3-Streptavidin solution and incubated on an orbital shaker rotating at 55 rpm for 20 
minutes at room temperature in the dark. The antibody slide was transferred to a new 100x15 
mm Petri dish containing 30 ml of 1X Wash Solution and incubated on an orbital shaker set 
at 55 rpm for 10 minutes at room temperature. The wash was repeated twice. The slide was 
then rinsed 10 times with Milli-Q grade water.   It is critical to rinse the slide extensively to 
completely remove solution from the slide surface. The slide is now ready for scanning.  
 
Scanning of Antibody Slides. Scanning of the slides was performed at Full Moon systems 
(Sunnyvale, California) http://www.fullmoonbiosystems.com/Services/ArrayScanning.html.  
 
Antibody Array Data Normalization and Quality Control. Raw protein expression intensity 
values were background subtracted and normalized (within array normalization) using the 
Agilent Feature Extractor software. The across array normalization was performed using the 
Quantile normalization method (bioDBnet: http://biodbnet.abcc.ncifcrf.gov/db/db2db.php).  
 
144 
Identification of differentially expressed probes. To identify probes that were differentially 
expressed in treated samples compared to controls, we employed Welch‟s t-test which is an 
adaptation of Student‟s t-test for comparing two independent samples in the presence of 
heterogeneity of variances. This test does not utilize pooled variance estimate and computes 
degrees of freedom associated with variance estimate using the Welch-Satterthwaite 
equation; for details refer to (Welch et al., 1947). The resulting p-values were corrected for 
multiple testing using Benjamini Hochberg‟s method (Benjamini et al., 1995). The fold 
change values for each probe was computed by taking the ratio of expression intensity in 
treated over control samples.   
 
For each treatment type vs. control comparison, we selected a list of probes that a) p-
value
 *
< 0.05 AND fold > 1.2; b) p-value
 *
< 0.05 AND fold > 1.5, and; c) p-value
 *
< 0.01 
AND fold > 1.5 (up-regulation or down-regulation greater than 1.2 or 1.5 fold) as criteria for 
further analyses.  
 
Comparison of Transcriptomics with Proteomics. To be able to compare the treatment 
specific changes in transcription to changes in the levels of corresponding proteins, we first 
created a mapping between the gene expression probes present on the Agilent mouse chip 
with the antibodies utilized by the Proteomics chip using the db2db utility from (bioDBnet; 
:http://biodbnet.abcc.ncifcrf.gov/db/db2db.php). It mapped the human Uniprot identifier to  
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Agilent mouse identifiers in the following three steps: 
 Human Uniprot identifiers to Mouse analogue ensemble gene identifiers. 
 Ensemble gene identifiers to gene symbols. 
 Gene symbols to Agilent probe identifiers. 
Once the protein probes (antibodies) on the proteomics platform were mapped to their 
corresponding Agilent microarray probes, we employed Spearman‟s correlation test to assess 
whether the changes observed in protein level measurements arising from Proteomics 
platforms correlated to Agilent microarray data. 
 
Metabolomics 
 
Sample Preparation, data acquisition, and processing. Serum samples were prepared for 
NMR analysis by mixing an aliquot (60 μL) of serum with 80 mL of a solution containing 
5mM Formate and 0.2% NaN3 in D2O and by addition of 260 µL of saline.  
 
NMR spectra were acquired on a Bruker Avance III 950 MHz instrument located in 
the NMR facility at David H. Murdock Research Institute, Kannapolis, NC, USA.   
1
H NMR 
spectra were acquired using a CPMG pulse sequence (Nicholson et al., 2003) with water 
suppression (cpmgpr1d) and 256 scans.  All spectra are acquired at 25°C with 32k data 
points, and the quality of each NMR spectrum was assessed for the level of noise and 
alignment of identified markers.  Spectra were accessed for missing data and underwent 
quality checks. Spectra were referenced to a formate signal at 8.44 ppm.  
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NMR data was processed using a traditional binning approach and by a quantitative 
approach (Sumner et al. 2010, Sumner et al. 2009, Pathmasiri et al. 2010).  Binning was 
performed by automated integration (increments of 0.04 ppm) over the spectral window 
(after excluding the region of water suppression), and normalized to the total spectral 
intensity. Metabolites in serum samples were identified and concentrations were determined 
by using the Chenomx NMR Suite 5.1 Professional software. The formate internal standard 
was used as the reference for performing the library matching. This software contains an 
internal library adjustment for increments in chemical shift based on pH variations (Weljie et 
al., 2006). A concentration determination for each metabolite was made by relative 
integration of the analyte to the internal standard, where the library of concentrations was 
developed to account for differences in integral values as related to the relaxation time of the 
signal (Weljie et al., 2006).  This quantitative method has some advantages over binning in 
two major ways. First, small increments in pH can result in portions of metabolite signals 
aligning with different bins when using the binning approach, while deconvolution 
circumvents this problem.  A second advantage is that this quantitative analysis depends on 
the concentration of each metabolite, while the binning approach results in situations where 
each metabolite has multiple signals that fall within separate bins.  For subsequent data 
reduction of the data derived from library matching, the concentration of each metabolite was 
normalized to formate concentration.   
 
Data Reduction and Visualization. Data captured by NMR (metabolite id and concentration; 
or bin region and integral value) were transferred to SIMCA-P+ 12.0 software (Umetrics) for 
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data reduction and visualization.  Several approaches were taken to analyze the NMR data to 
provide the best set of analytes that could distinguish the study groups (e.g., by specific 
chemical or by dose group).  For analysis with binned data, the integral was normalized to 
the total integral for each spectrum.  Principal component analysis and partial least squares 
projection to latent structures discriminant analysis (PLS-DA) was conducted using SIMCA-
P+ 12.0 for the binned and metabolite concentration data. Loadings, variable importance, and 
contribution plots were examined to determine the bins or the metabolites that best define the 
separation of study groups.  
 
RESULTS 
 
Transcriptomics of Hippocampus 
 
To identify altered gene expression after exposure to α-HBCD, γ-HBCD or CM-
HBCD, a Welch-Test (analysis of variance) was performed for the liver and hippocampus 
(Table 1). Three separate analyses were performed and the selection criteria were based on a 
p-value and fold gene expression change.  
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Organ Comparison 
Number of   
Probes with p-
value 
*
< 0.01 
 AND fold > 1.5 
Number of 
Probes with  p-
value 
*
< 0.05 
AND fold > 1.5 
Number of 
Probes with p-
value 
*
< 0.05 
AND fold > 1.2 
Liver Alpha 30 Vs Control 18 186 547 
Liver Gamma 30 Vs Control 115 582 1812 
Liver Alpha 30 Vs Gamma 30 115 371 1585 
Liver Alpha 30 Vs Mixture 35 210 622 
Liver Gamma 30 Vs Mixture 63 288 1264 
Liver Mixture 30 Vs Control 19 177 336 
hippocampus Alpha 30 Vs Control 12 116 385 
hippocampus Gamma 30 Vs Control 17 132 384 
hippocampus Alpha 30 Vs Gamma 30 20 396 396 
hippocampus Alpha 30 Vs Mixture 30 11 211 211 
hippocampus Gamma 30 Vs Mixture 30 15 103 305 
hippocampus Mixture 30 Vs Control 7 89 327 
*p-values are not adjusted for multiple testing 
 
Table 5.1. Results of ANOVA on gene lists using three criteria. Each row in the table lists 
result from a Welch-Test, where α-HBCD, γ-HBCD or CM-HBCD exposed sample at 
30mg/kg are compared to corresponding treatment group for the liver or hippocampus; 
n=6/treatment. The three criteria used with increasing statistical stringency are:  p-value
 *
< 
0.05 AND fold > 1.2, p-value
 *
< 0.05 AND fold > 1.5, and  p-value
 *
< 0.01 AND fold > 1.5. 
 
From increasing statistical stringency (low to high), three analysis consisted of a) p-
value
 *
< 0.05 AND fold > 1.2; b) p-value
 *
< 0.05 AND fold > 1.5, and; c)  p-value
 *
< 0.01 
AND fold > 1.5. Altered gene candidates were observed for each analysis regardless of the 
level of stringency. As the stringency of statistical analysis decreased, the number of genes 
which passed the criteria increased.  Based on the subtle dosing paradigm in this study (a  
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single oral exposure), duration (tissues harvested 4 days later),  small amount of tissue 
harvested,  and future pathway analysis to be performed;  we decided to use the data 
following analysis with the criteria  p-value
 *
< 0.05 AND fold > 1.2, to identify genes that 
were altered after exposure to  α-HBCD, γ-HBCD or CM-HBCD.  Table 1 demonstrates that 
there was an increase in the number of altered genes observed in the liver as compared to the 
hippocampal tissue across all statistical testing parameters.  
 
Hippocampal Genes. There were a number of genes that were significantly up- and down-
regulated in the hippocampus of mice at PND 14 after oral exposure to a single 30mg/kg oral 
dose of α-HBCD, γ-HBCD, or CM-HBCD at PND 10. Analysis of the data demonstrates that 
the number of genes differentially expressed  (using the criteria - fold change > 1.2 up- or 
down-regulated AND p-value of < 0.05) in developing mice exposed to 30 mg/kg of HBCD  
resulted in 385 regulated genes for α-HBCD, 384 for γ-HBCD and 327 for the CM-HBCD, 
respectively (Table 1).  An overlap of 19  genes could be observed between all three 
treatment groups.  
 
Principal component analysis. Principal component analysis (PCA) was applied to the entire 
genomic dataset (30,000 genes) and did not reveal specific clustering of treatment groups (α-
HBCD, γ-HBCD or CM-HBCD) (data not shown). However, very distinctive clustering was 
observed when a subset of genes differentially expressed between groups was identified 
(using a fold change and ANOVA p-value threshold) and then PCA performed. Each  
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treatment condition, α-HBCD, γ-HBCD, or CM-HBCD, was compared to controls using the 
subset of genes which are differentially expressed between the two groups (Figure 1a,b,c). A 
heat map also displays the genes altered for each exposed mouse pup (n=6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1a. Heat map and PCA analysis of genes of the mouse hippocampus differentially 
expressed between the commercial mixture of HBCD (CM-HBCD) and corn oil vehicle 
(controls) four days post oral exposure at PND 10. „Red” signifies an upregulation, “green” a 
downregulation while “black” a no change. (p-value < 0.01 AND fold > 1.5). 
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     controls Mixture 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1b. Heat map and PCA analysis of genes of the mouse hippocampus differentially 
expressed between the commercial mixture of HBCD (α-HBCD) and corn oil vehicle 
(controls) four days post oral exposure at PND 10. „Red” signifies an upregulation, “green” a 
downregulation and “black” a no change. (p-value < 0.01 AND fold > 1.5) 
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           controls  Gamma 30 
Figure 5.1c . Heat map and PCA analysis of genes of the mouse hippocampus differentially 
expressed between the commercial mixture of HBCD (γ -HBCD) and corn oil vehicle 
(controls) four days post oral exposure at PND 10. „Red” signifies an upregulation, “green” a 
downregulation and “black” a no change. (p-value < 0.01 AND fold > 1.5). 
 
The first five columns are gene expression profiles for the 6 control treated mice 
(vehicle; corn oil) and the next 6 columns represent the mice orally administered the HBCD 
solution (α-HBCD, γ-HBCD, or CM-HBCD).   Heat map “boxes” displayed in the color red 
signifies an “upregulation” in gene expression, black signifies “no gene expression change”, 
and green denotes a “downregulation” in gene expression. The degree of gene expression 
change translates to the color intensity, with a high level of gene expression being displayed 
with a more intense “red” during upregulation from controls or “green” if the gene was 
downregulated from controls.  The heat maps and PCA analysis were performed for each of 
the three statistical criteria (p-value and fold change; displayed in Figure 1), however, the 
heat maps displayed in Figures 1a, b, c are results from the highly stringent statistical criteria; 
p-value < 0.01 and fold change > 1.5. This was selected for the ease of visualization as the 
data generated using the p-value < 0.05 and fold > 1.2 resulted in a large amount of genes 
which is unsuitable for display.  However, all of the genes identified on the heat maps in 
Figures 1a, b, and c are also represented (inclusive) using the criteria of p-value < 0.05 and 
fold change < 1.2.  
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Hippocampal Gene Pathway analysis.  The subset of diffentially expressed genes represented 
on the heat maps were used to identify common pathways involved in each gene set. Using 
IPA, there were a number of pathways which the genes mapped to the hippocampus of mice 
at PND 14.  Analysis of the data showed that the number of pathways with alteration in 
developing mice exposed to 30 mg/kg of the HBCD resulted in 32 regulated pathways after 
exposure to α-HBCD, 4 pathways for γ-HBCD, and 15 for the CM-HBCD (Figure 2).  
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                       IPA Common Pathways from Gene Expression - Hippocampus 
4 
Alpha 30 vs control 
38 
Gamma 30 vs control 
11 
Mixture 30  vs  control 
19 
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Figure 5.2. Venn diagram of hippocampal pathway analysis using gene expression changes 
observed in mice for all HBCD treatment groups four days after a single oral dose of 
30mg/kg at PND 10. Genes were selected using an analysis of variance (Welch test) criteria 
of p-value = 0.05 and fold change of 1.2.  IPA pathways selected had p < 0.05. 
 
There were 4 specific pathways identified between the α-HBCD and γ-HBCD treated 
mice, 1 specific between the α-HBCD and CM-HBCD treated mice and 2 between the γ-
HBCD and CM-HBCD treated mice. Interestingly there was 1 similar canonical pathway that 
was altered in all three treatment groups (after single oral dose of 30mg/kg; α-HBCD, γ-
HBCD, or CM-HBCD). 
 
IPA analyzed our experimental data in the context of networks, maps, and identified 
affected pathways. Therefore, taking a conservative approach, only the most significantly 
affected hippocampal pathways at this HBCD dose levels are presented as the outcome of the 
analysis. IPA analysis revealed that there are several pathways affected by HBCD. The top 
pathways based on the gene list are listed beginning with those pathways with the lowest p-
values (increased confidence of relationship). After exposure to α-HBCD we observe 
disruption in pathways related to glutamate receptor signaling (p = 0.002), CREB signaling 
in neurons (p = 0.005), nitric oxide signaling (p= 0.0069), thyroid hormone/RXR (p = 0.01), 
synaptic long term potentiation (p = 0.023), retinoic acid receptor (p = 0.038), arachidonic 
acid metabolism (p = 0.045), and VEGF signaling (p = 0.046). There were considerably less 
neuronal specific pathways identified for γ-HBCD than for α-HBCD, only long term  
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potentiation (p = 0.03). After exposure to CM-HBCD, the genes mapped to toll like receptors 
signaling (p = 0.02) and synaptic long term potentiation (p = 0.04). Pathways affected by 
HBCD of scientific interest regarding learning and memory are shown in Tables 2-4.  The 
genes listed in the glutametergic signaling pathway were all found in the synaptic long term 
potentiation pathway; these were combined and displayed together. 
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Pathways affected by α-HBCD, γ-HBCD, and CM-HBCD 
α-HBCD    
    
Synaptic Long -Term potentiation/ 
Glutamate Signaling   
P= 0.002    
  
Gene Symbol  
   (mouse) 
                  Gene Name      
                    (mouse) 
Gene Expression     
          (fold)                  
       
1  GRM6 Metabotroic glutamate receptor 6          2.61 
2  PRKCE Protein kinase C epsilon           1.62 
3  SLC1A6 Solute carrier family 1 (glutamate transporter)           1.22 
4  CAMK4 Calcium/calmodulin-dependent kinase IV           1.33 
5  ADCY1 Adenylate cyclase type 1         -1.24 
6  GRIN2C N-methyl D-aspartate (NMDA) receptor  2C         -1.27 
7  GLUL  Glutamine synthetase         -1.37 
   
Nitric Oxide Signaling    
P= 0.007   
                   Gene Symbol 
                       (mouse) 
                                    Gene Name  
                                       (mouse) 
         Gene expression                                           
                 (fold)              
1  PIK3R3 Phosphatidylinositol 3-kinase gamma           1.74 
2  FIGF c-fos induced growth factor (VEGF-D)            1.68 
3  PIK3CB Phosphoinositide 3-kinases (PI3Ks)          -1.97 
4  PLN Phospholamban          -3.18 
    
Thyroid Receptor/RXR    
p= 0.01    
  
Gene Symbol 
  (mouse) 
                 Gene Name  
                    (mouse) 
   Gene expression                                    
           (fold)              
1  PIK3R3 Phosphatidylinositol 3-kinase gamma           1.74 
2  APOA5 Apolipoprotein A-V           1.49 
3  CAMK4 Calcium/calmodulin-dependent kinase IV            1.21 
4  COL6A3 Collagen, type VI, alpha 3          -1.42 
5  PIK3CB Phosphoinositide 3-kinases (PI3Ks)          -1.97 
    
Retinoic Acid Receptor    
p= 0.01    
  
Gene Symbol  
  (mouse) 
                 Gene Name 
                    (mouse) 
  Gene expression            
              (fold)                            
1  PIK3R3 Phosphatidylinositol 3-kinase gamma                      1.74 
2  PRKCE Protein kinase C epsilon                       1.62                                 
3  ADCY1 Adenylate cyclase type 1                     -1.24 
4  RBP1 Retinol binding protein 1                     -1.25 
5  ALDH1A1 Aldehyde dehydrogenase 1 family, member A1                     -1.33 
6  PIK3CB Phosphoinositide 3-kinases (PI3Ks)                     -1.97 
    
 
               
     Table 5.2. IPA pathway analysis of genes expression data from mouse hippocampus after  
     exposure to α-HBCD.  
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 γ-HBCD    
    
Synaptic Long -Term Potentiation   
P= 0.03    
  
 Gene Symbol      
   (mouse) 
                    Gene Name 
                      (mouse) 
 Gene expression      
       (fold)                            
1        CAMK4 Calcium/calmodulin-dependent protein kinase IV       1.28                                
2        PRKAR2A Protein kinase type II-alpha  (PKA)      -1.21                               
3        GRIA4 Glutamate Receptor 4      -1.28                              
4        PLCB2 Phospholipase C β2      -1.47 
    
Blood Brain Barrier Integrity   
p=n/a    
  
Gene Symbol     
       (mouse) 
                    Gene Name  
                       (mouse) 
Gene expression     
         (fold)                                 
1        TJP2   Tight Junction Protein 2           -1.21 
2        VEGFC   Vascular endothelial growth factor C           -1.33 
    
Programmed Cell Death   
p= n/a    
  
Gene Symbol       
   (mouse) 
                     Gene Name  
                       (mouse) 
 Gene expression     
      (fold)                         
1         Fas  TNF receptor superfamily member 6            2.34 
    
Solute Carrier Transporter   
p=n/a    
  
Gene Symbol        
    (mouse) 
                     Gene Name  
                       (mouse) 
Gene expression     
      (fold)                         
1      SLCO1B3 Solute carrier organic anion transporter 1B3             -1.27 
    
 
 
 
 
 
          Table 5.3. IPA pathway analysis of genes expression data from mouse hippocampus after exposure  
           to γ-HBCD . 
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CM-HBCD    
    
Synaptic Long-Term Potentiation  
P= 0.04    
  
Gene Symbol        
    (mouse) 
          Gene Name  
             (mouse) 
Gene expression       
       (fold) 
1        ADCY1 Adenylate cyclase type 1          1.23 
2        GRM2 Metabotropic glutamate receptor 2         -1.23 
3        PRKAR2A Protein kinase type II-alpha  (PKA)         -1.24 
4        PPP1R14D Protein phosphatase 1, regulatory (inhibitor)  14D         -1.61 
    
Toll Like Receptor Signaling   
P= 0.02    
  
Gene ymbol  
    (mouse) 
                 Gene Name 
                   (mouse) 
Gene expression    
         (fold) 
1        MAPK13 Mtogen-activated protein kinase 13           1.48 
2        IRAK3 Interleukin-1 receptor-associated kinase 3          -1.51 
3        TLR2 Toll like receptor 2          -1.29 
    
Solute Carrier Transporter   
p= n/a    
  
Gene ymbol    
    (mouse) 
                  Gene Name  
                     (mouse) 
Gene expression   
      (fold) 
1        SLCO1B3 Solute carrier organic anion transporter 1B3          -1.37 
    
    
Table 5.4. IPA pathway analysis of genes expression data from mouse hippocampus after  
exposure to CM-HBCD. 
 
Proteomics of Hippocampus 
Hippocampal Proteins. There were a number of proteins that were significantly up- or down-
regulated in the hippocampus of mice at PND 14 after exposure to a single oral dose of 
30mg/kg of α-HBCD or γ-HBCD at PND 10.  Analysis of the data shows that the number of 
proteins differentially expressed (fold change 1.2 up- or down-regulated) in developing mice 
exposed to 30 mg/kg HBCD on PND10 was 51 after exposure to  α-HBCD and 159 after  
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exposure to γ-HBCD. An overlap of differentially expressed genes was observed with a mere 
13 proteins being similar between the two treatment groups (Figure 3). 
 
 
 
 
 
 
 
Figure 5.3. Venn diagram of hippocampal protein expression changes observed in mice for 
all HBCD treatment groups four days after a single oral dose of 30mg/kg at PND 10. Genes 
were selected using an analysis of variance (Welch test) criteria of p-value = 0.05 and fold 
change of 1.2. 
 
Hippocampal Protein Pathway Analysis. Due to the limited numbers of proteins on the 
antibody array, IPA was not able to identify any pathways that were significantly altered in 
the hippocampus of mice at PND 14 exposed to a single 30mg/kg oral dose of α-HBCD or γ-
HBCD at PND 10.  The proteomic data was limited in numbers with 1318 proteins as 
compared to 30,000 genes in the whole genome array.   
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Gamma 30 vs control 
159 
Alpha 30 vs control 
51 
38 13 146 
IPA Common Proteins in the Hippocampus 
Comparison between transcriptomics and proteomics. The antibody array is a tool for 
discovery and in light of no pathway analysis, individual proteins will be used here to support 
and validate the transcriptomics data where applicable. There were 51 and 159 proteins found 
to be altered in the hippocampal brain for α-HBCD or γ-HBCD, respectively. Table 5 
demonstrates that there were similarities between transcriptomics gene expression data and 
proteomics analysis when searching for protein counterparts to altered gene transcripts from 
Tables 2 and 3.   
 
α-HBCD     
     
  
Gene Symbol 
  (mouse) 
 Gene expression 
           (fold) 
    Protein Expression             Protein Expression                                           
              (fold)                                     p-value  
1  PIK3R3           1.74     1.29                                      0.038  
2  CAMK4 1.33                 1.21                                      0.049   
3  ADCY1          -1.24                -1.10                                      0.061  
4  PRKCE          -1.42    -1.22                                      0.045  
     
 
γ-HBCD     
     
  
Gene Symbol 
  (mouse) 
 Gene expression 
           (fold) 
    Protein Expression             Protein Expression                                           
              (fold)                                     p-value  
1  PRKAR2A          -1.21              -1.34                                      0.023  
2  VEGFC          -1.33     1.20                                      0.050  
3  FAS           2.34     1.53                                      0.011    
     
     
Table 5.5. Comparison between transcriptomic and proteomics in the hippocampus of 
infantile mice orally exposed to 30mg/kg of either α-HBCD or γ-HBCD. 
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After exposure to α-HBCD,   PIK3R3, CAMK4, ADCY1, and PRKCE protein levels 
were determined to be significantly changed and all were comparable to the transcriptomics 
in intensity and direction (up or down regulated).  Although the protein expression data for 
ADCY1 (p = 0.061) fell below the designated significance criteria (p=0.05), both the gene 
expression and protein levels were found to be unidirectional. Similar patterns were found 
after exposure to γ-HBCD.  PRKAR2A, VEGFC, and FAS, were all significantly changed 
and were comparable to the transcriptomics in intensity and direction.  The only discrepancy 
between gene expression and protein expression was found for VEGFC (gene transcription of 
-1.33 and protein expression of +1.20).  However, it is clear that overall these proteins further 
validate the transcriptomic gene expression data (previous section) and adds further 
confidence in this study with actual translation data.  
 
Transcriptomics of Liver 
 
Liver Gene Expression. There were a number of genes that were significantly up- and down-
regulated in the liver of mice at PND 14 after oral exposure to a single 30mg/kg oral dose of 
α-HBCD, γ-HBCD, or CM-HBCD at PND 10. Analysis of the data demonstrates that the 
number of genes differentially expressed (using the criteria - fold change > 1.2 up- or down-
regulated AND p-value of < 0.05) in developing mice exposed to 30 mg/kg of HBCD  
resulted in 547 regulated genes for α-HBCD, 1812 for γ-HBCD, and 336 for the CM-HBCD, 
respectively (Table 1).  An overlap of 54 genes could be observed between all three treatment 
groups.  
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Principle component analysis. Principle component analysis (PCA) was applied on the entire 
genomic dataset (30,000 genes) and did not reveal specific clustering of treatment groups (α-
HBCD, γ-HBCD or CM-HBCD) in the liver (data not shown). However, very distinctive 
clustering was observed when a subset of genes differentially expressed between groups was 
identified (using a fold change and ANOVA p-value threshold) and then PCA performed. 
Each treatment condition, α-HBCD, γ-HBCD, or CM-HBCD was compared to controls using 
the subset of genes which differentially expressed between the two groups (Figure 4a, b, c).  
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controls Alpha30 
Figure 5.4a. Heat map and PCA analysis of genes of the mouse liver differentially expressed 
between the commercial mixture of HBCD (α-HBCD) and corn oil vehicle (controls) four 
days post oral exposure at PND 10. „Red” signifies an upregulation; “green” signifies a 
downregulation while “black” signifies no change. (P-value < 0.01 AND fold > 1.5) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4b. Heat map and PCA analysis of genes of the mouse liver differentially expressed 
between the commercial mixture of HBCD (γ-HBCD) and corn oil vehicle (controls) four 
days post oral exposure at PND 10. „Red” signifies an upregulation; “green” signifies a 
downregulation while “black” signifies no change. (p-value < 0.01 AND fold > 1.5). 
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controls Gamma30 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4c. Heat map and PCA analysis of genes of the mouse liver differentially expressed 
between the commercial mixture of HBCD (α-HBCD) and corn oil vehicle (controls) four 
days post oral exposure at PND 10. „Red” signifies an upregulation; “green” signifies a 
downregulation while “black” signifies no change. (p-value < 0.01 AND fold > 1.5) 
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controls Mixture 
A heat map also displays the genes altered for each exposed mouse pup (n=6).  The 
first five columns are gene expression profiles for the 6 control treated mice (vehicle; corn 
oil) and the next 6 columns represent the mice orally administered the HBCD solution (α-
HBCD, γ-HBCD, or CM-HBCD) at 30 mg/kg.   Heat map “boxes” displayed in the color red 
signify an “upregulation” in gene expression, black signifies “no gene expression change”, 
and green “denotes a “downregulation” in gene expression. The degree of gene expression 
change translates to the color intensity, with a high level of gene expression being displayed 
with a more intense “red” during upregulation from controls or “green” if the gene was 
downregulated from controls.  The heat maps and PCA analysis were performed for each of 
the three statistical criteria (p-value and fold change; displayed in Figure 1), however, the 
heat maps displayed in Figures 4 a, b, c are results from the highly stringent statistical 
criteria: p-value < 0.01 and fold change > 1.5, as also displayed for the hippocampus. This 
was selected for the ease of visualization as the data generated using the p-value < 0.05 and 
fold > 1.2 resulted in a large amount of hepatic genes which is unsuitable for display.  
However, all of the genes identified on the heat maps in Figures 4 a, b, c are also represented 
(inclusive) using the criteria of p-value < 0.05 and fold change < 1.2.  
 
Liver Gene Pathway analysis.  The subset of diffentially expressed genes represented on the 
heat maps were used to identify common pathways involved in each gene set. Using IPA, 
there were a number of pathways which the genes mapped to in the liver of mice at PND 14.  
Analysis of the data showed that the number of pathways with alteration in developing mice 
exposed to 30 mg/kg of the HBCD resulted in 55 regulated pathways after exposure to α-
HBCD, 25 pathways for γ-HBCD, and 6 for the CM-HBCD (Figure 5).  
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Figure 5.5. Venn diagram of liver pathway analysis using gene expression changes observed 
in mice for all HBCD treatment groups four days after a single oral dose of 30mg/kg at PND 
10. Genes were selected using an analysis of variance (Welch test) criteria of p-value = 0.05 
and fold change of 1.2.  IPA pathways selected had p < 0.05. 
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                     Pathways from gene expression data in the Liver 
There were 2 specific pathways identified between the α-HBCD and γ-HBCD treated 
mice, 6 specific between the α-HBCD and CM-HBCD treated mice, and 1 between the γ-
HBCD and CM-HBCD treated mice. Interestingly, similar to the hippocampal data, there 
was 1 similar canonical pathway that was altered in all three treatment groups (single oral 
dose of 30mg/kg of α-HBCD, γ-HBCD, or CM-HBCD). 
 
 
IPA analyzed our experimental data in the context of networks, maps, and identified 
affected pathways. Therefore, taking a conservative approach, only the most significantly 
affected liver pathways at this HBCD dose level are presented as the outcome of the analysis. 
IPA analysis revealed that there are several pathways affected by HBCD. The top pathways 
based on the gene list are listed beginning with those pathways with the lowest p-values 
(increased confidence of relationship). After exposure to α-HBCD, we observe disruption in 
pathways related to PTEN signaling (p = 0.0019), Type II Diabetes Mellitus Signaling (p = 
0.0038), FAK Signaling (p= 0.01), PI3K/AKT Signaling (p = 0.0135), VEGF Signaling (p = 
0.03), xenobiotic metabolism signaling (p = 0.03), NRF2-mediated oxidative stress response 
(p = 0.04), glycerolipid metabolism (p = 0.046) and tight junction signaling (p = 0.047). 
There were considerably less hepatic specific pathways identified for γ-HBCD than for α-
HBCD: PI3K/AKT Signaling (p = 0.002), p53 signaling (p = 0.008), cysteine metabolism (p 
= 0.016), ERK/MAPK signaling (p = 0.015) and FAK signaling (p = 0.03). After exposure to 
CM-HBCD, the genes mapped to FAK signaling (p = 0.04) only.   
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Proteomics of Liver 
 
Liver Proteins. There were a number of proteins that were significantly up- or down-
regulated in the hippocampus of mice at PND 14 after exposure to a single oral dose of 
30mg/k of α-HBCD or γ-HBCD at PND 10.  Analysis of the data demonstrates that the 
number of proteins differentially expressed (fold change 1.2 up- or down-regulated) in 
developing mice exposed to 30 mg/kg HBCD on PND10 was 10 after exposure to  α-HBCD 
and 14 after exposure to γ-HBCD. An overlap of differentially expressed proteins was 
observed with only 1 protein being similar between the two treatment groups (Figure 6). 
 
 
 
  
 
 
 
 
Figure 5.6. Venn diagram of liver protein expression changes observed in mice for all  
HBCD treatment groups four days after a single oral dose of 30mg/kg at PND 10.  
Genes were selected using an analysis of variance (Welch test) criteria of p-value = 0.05  
and fold change of 1.2. 
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 Common Proteins Changed in the Liver 
Liver Protein Pathway Analysis. Due to the limited numbers of protein on the antibody array, 
IPA was not able to identify any pathways that were significantly altered in the liver of mice 
at PND 14 exposed to a single 30mg/kg oral dose of α-HBCD or γ-HBCD at PND 10.  The 
proteomic data was limited in numbers beginning with 1318 as compared to 30,000 genes in 
the whole genome array. Direct comparison of protein of interest will be conducted against 
transcriptomics results but is currently beyond the scope of this chapter.  As mentioned in the 
introduction, this chapter will focus on the hippocampal effects. 
 
Metabolomics of Serum  
 
Metabolomics analysis was conducted on 60 ul serum aliquots derived from mice 
administered 0, 3, 10, or 30 mg/kg of α-HBCD.  Analysis was conducted on serum from 
mice administered 0, 3, or 30 mg/kg γ-HBCD or administered 0 or 30 mg/kg of CM-HBCD.  
The 950 MHz 
1
H NMR spectrum of serum (example shown in Figure 7) contained signals 
that could be assigned via Chenomx library matching to compounds such as amino acids, 
carboxylic acids, and sugars.  
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Figure 5.7.  950 MHz 
1
H NMR spectrum of metabolites in mouse serum. Signals for the 
higher concentration metabolites are labeled. 
 
Multivariate analysis was conducted using binned data normalized to the total 
intensity. An example analysis is shown in Figure 8 for sample collected from mice 
administered the vehicle control (green), or the high dose of α-HBCD (blue), γ-HBCD 
(orange), or CM-HBCD (red). This analysis indicates that alpha (blue) and gamma (orange) 
groups are more closely clustered and separated from the commercial mixture group (red).  
 
 
 
 
 
 
172 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. Multivariate analysis (PLS-DA score plot) of bin data obtained for serum from 
mice exposed to vehicle (green), α- HBCD (blue), γ-HBCD (orange), or CM-HBCD (red). 
 
In addition to analysis by the binning approach, PCA and PLS-DA were conducted 
using concentration data. Library matching using NMR Suite 5.1 Professional Software 
(Chenomx, Edmonton, Alberta, Canada) was performed to provide a list of metabolites (and 
their respective concentrations) that demonstrated a match within each of the serum spectra. 
The concentration for each metabolite was normalized to that of formate for each serum 
sample. Multivariate analysis was conducted for each chemical investigated (e.g., vehicle vs 
low vs high dose), as well as to enable comparison among chemicals (e.g., alpha vs gamma). 
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The PLS-DA analysis using serum metabolite concentration data differentiated the 
vehicle from the low and high dose groups for mice exposed to α-HBCD (Figure 9a).  PLS-
DA was conducted using data obtained for the vehicle and the high dose groups (Figure 9b), 
and examination of loadings plots, variable importance plots, and contribution plots enabled 
the selection of a subset of metabolites that most contributed to the separation of the two 
groups (Table 6).   
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Figure 5.9a. Score plot of PLS-DA analysis of metabolite concentration data for the serum 
samples obtained from mice administered 0, 3, 10, and 30mg/kg doses of α-HBCD, 
indicating separation between the control (red) and dose groups. 
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 Figure 5.9b. Score plot of PLS-DA analysis of metabolite concentration data for the serum 
samples obtained from mice administered vehicle or 30mg/kg α-HBCD shows a clear 
separation of study groups (Red, Control; Green, high dose α-HBCD).  
 
 
Table 5.6. Serum metabolites that best differentiate the high dose and vehicle control study 
groups for each chemical. 
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HBCD Alpha HBCD Gamma Commercial Mixture 
Increased Decreased Increased Decreased Increased Decreased 
Valine Lactate Glycine  Phenylalanine Taurine  Phenylalanine 
Leucine Pyruvate Glutamine Glutamate Glycerol Methanol 
3-Hydroxybutyrate Glutamate Asparagine  Pyruvate  Lactate Arginine  
Glutamine Choline 3-Hydroxybutyrate Serine O-Phosphocholine  Alanine  
Acetoacetate Methanol Taurine  Lactate 3-Hydroxybutyrate N,N-Dimethylglycine  
2 Hydroxybutyrate Acetate Citrate Threonine  Asparagine  Glucose 
 Citrate Glycerol Choline  Methionine   
 Alanine Glucose Tyrosine Citrate  
 N,N-Dimethylglycine 2-Hydroxybutyrate Lysine Valine   
 Phenylalanine Creatine  Methanol  Creatine   
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-1.4 -1.3 -1.2 -1.1 -1.0 -0.9 -0.8 -0.7 -0.6 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
t[
2
]
t[1]
DSNTP_All_Data_concentrations.M33 (PLS-DA), PLS-DA Control Vs Alpha High Dose
t[Comp. 1]/t[Comp. 2]
Colored according to Obs ID (Condition)
R2X[1] = 0.35714             R2X[2] = 0.188811            
Ellipse: Hotelling T2 (0.95) 
Control
HBCD_Alpha
SIMCA-P+ 12.0.1 - 2010-10-29 15:07:14 (UTC-5)  
Using only this subset of metabolites, the separation of the α-HBCD group from the 
control group in PLS-DA was improved (Figure 9c), confirming these metabolites as being 
significant to the separation of the study groups.  
Figure 5.9c. Score plot of PLS-DA analysis using the subset of metabolites that best define 
the HBCD-Alpha high dose group from the control group. An improvement of the separation 
of the dose group from the control group (Red, Control; Green, high dose α-HBCD) was 
achieved using the subset of metabolites.  
 
This process was repeated using only the γ-HBCD data (control vs each dose group) 
or only the CM-HBCD data (control vs each dose group) to derive a list of metabolites that 
best describe each group (Table 6). PLS-DA analysis of the control and all high dose group 
concentration data provided separation of each high dose group from the control (Figure 10).  
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Figure 5.10.  PLS-DA plot of metabolite concentration data derived for serum samples 
obtained from mice administered vehicle control (green), or a high dose (30mg/kg) of CM-
HBCD (red), α-HBCD  (blue), or γ-HBCD (orange).    
 
The separation ability using the concentration data (Figure 10) was improved beyond 
that provided using bin data (Figure 8).   However, in both analyses, the commercial mixture, 
alpha, and gamma clustered from each other and represent differences in response between 
each treatment. Using this analysis, it is the commercial mixture that may be more distinct 
from either of the two individual stereoisomers and had a trajectory pattern opposite of the 
alpha and gamma group‟s trajectory from control based on the levels of metabolites that were 
differentially measured in the serum (Table 6).  
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DISCUSSION 
 
We propose that CM-HBCD may alter similar molecular mechanism responsible for 
learning and memory as seen for BDEs and PCBs. Our objective was to investigate the 
effects of the CM-HBCD on gene transcription in the hippocampus. The second objective 
was to investigate whether the individual HBCD stereoisomers, α-HBCD and/or γ-HBCD 
may be responsible for driving the neurotoxicity observed after exposure to the CM-HBCD.  
 
The exposure of CM-HBCD took place during a period of rapid brain growth, which 
in mice takes place during the first 1-3 weeks of life, reaching its peak near PND10 (Davison 
and Dobbing 1968). The multitude and complexity of processes during this rapid 
development makes the developing brain particularly vulnerable to the effects of xenobiotics. 
Mice were affected after exposure to the CM-HBCD  during their performance test in the 
Morris water maze (Eriksson et al. 2001), commonly used as a learning task to detect effects 
in the hippocampus.  
 
In the present study, we found that neonatal exposure to the CM-HBCD causes 
developmental effects in gene expression and protein level changes in the mouse 
hippocampus.  Regardless of the treatment group, α-HBCD, γ-HBCD, or CM-HBCD, IPA 
pathway analysis on the hippocampus identified only one canonical pathway which 
happens to be linked directly to learning and memory in the hippocampal target tissue,  
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synaptic long term potentiation (LTP). Furthermore, specific changes of key postsynaptic 
proteins involved in glutamate receptor signaling and calcium homeostasis were revealed. 
The combined results suggest that synaptic changes may directly contribute to the observed 
defect in synaptic plasticity leading to learning and memory deficits after exposure to the 
CM-HBCD previously observed (Eriksson et al., 2006).________________________ 
            
The individual HBCD stereoisomers tested in this study, α-HBCD and γ-HBCD, 
were both found to alter hippocampal gene expression and protein levels where pathway 
differences between the stereoisomers were also identified. The differences between 
treatment groups were overwhelmingly larger than were the similarities at all platforms 
(gene, protein, and pathways). This is evidence that in vivo stereoisomer specific effects 
can occur.  Furthermore, the gene expression and protein data in the liver as well as the 
serum metabolomics data further support that there are clear effect differences between the 
α-HBCD and γ-HBCD stereoisomers and the mixture after exposure to infantile mice. 
Future efforts to map pathways differences are underway. 
 
Our results demonstrated that administration of α-HBCD, γ-HBCD, or the CM-
HBCD alters molecular mechanisms involved in LTP. Calcium-mediated processes are 
important for LTP (Williams and Johnston, 1989), and deletion of the Ca
2+
/calmodulin-
dependent protein kinase (CaMK) genes in mice have resulted in impairment in LTP (Silva et 
al., 1992). That HBCDs are able to affect molecules involved in Ca
2+
 balance in mice brain  
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and change CaMK protein levels may further contribute to the LTP deficit. Similar effects  
have been observed with PBDEs (Kodavanti and Ward, 2005; Viberg et al., 2008). Second, 
the activation of protein kinase C (PKC) plays an important role in the expression and 
persistence of LTP in hippocampal neurons (Klann et al., 1991; Lovinger et al., 1987; 
Malenka et al., 1989; Malinow et al., 1988; Moriguchi et al., 2006). The activation of 
postsynaptic NMDA receptors is critical for the induction of LTP in the hippocampus (Bliss 
and Collingridge, 1993; Burgard et al., 1989; Poncer, 2003; Reymann et al., 1989). From our 
study, HBCD, as previously seen with PBDEs, may decrease the protein levels of NMDA 
receptors by impairing the ratio of their subunits (Dingemans et al., 2007).  
 
It has been proposed that the cholinergic system is altered after exposure to PBDEs 
and HBCD (Eriksson et al., 2001; Eriksson et al., 2006) in both mouse and rat brain (Fischer 
et al., 2008; Viberg et al., 2003, 2007). This impairment may actually be an indirect 
mechanism involving the depression of LTP in the hippocampus (Abe et al., 1994; Blitzer et 
al., 1990; Galey et al., 1994). 
 
As previously mentioned, the data on HBCD‟s effect on the nervous system is 
limited. There is one in vitro study, examining the individual stereoisomer effects on synaptic 
transmission (Dingemans et al., 2009).  Effects of α‐ and β‐HBCD were comparable to that 
of the technical mixture, whereas the inhibitory effect of γ‐HBCD was larger. Using specific 
blockers of voltage‐gated Ca2+ channels (VGCCs), it was shown that the inhibitory effect of  
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HBCD is not VGCC‐specific. Additionally, the number of cells showing 
depolarization‐evoked neurotransmitter release was markedly reduced following HBCD 
exposure. In this system, HBCD inhibits depolarization‐evoked Ca2+ and neurotransmitter 
release and further adds to support the in vivo study presented here.  
 
In general terms, LTP involves strengthening of synapses such that transmission 
between two neurons is enhanced. Following exposure to HBCDs, a number of molecular 
changes support inhibition of this important pathway and, as HBCDs have previously been 
shown to decrease rodent performance in water maze behavioral tests (Eriksson et al., 2006), 
may implicate these chemicals in disruption of learning and memory processes. One way in 
which LTP is thought to be induced at glutamatergic synapses (as can be found in the cortex 
and hippocampus) is through a combination of increased neurotransmitter (i.e., glutamate) 
release from presynaptic neurons and elevated numbers and conduction of glutamate 
receptors at postsynaptic sites.  The top cannonical pathway identified for α-HBCD was 
glutamate signaling (p = 0.002), which was not directly observed for γ-HBCD or CM-HBCD. 
This finding in conjunction with synaptic long term potentiation (p=0.01) supports the high 
likelihood for this system to be altered based on previous published data. Therefore concern 
for effects of the individual α-HBCD stereoisomer should be considered. 
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The proposed molecular mechanisms for HBCD-mediated inhibition of long term 
potentiation (LTP) may include multiple pathways (Figure 11).  
 
 
Figure 5.11. Proposed Molecular Mechanisms for HBCD-Mediated Inhibition of Long Term 
Potentiation (LTP) on Glutamatergic Neurons in Developing Mouse Hippocampus. 
Disrupted LTP is implicated in learning and memory deficits. One way in which LTP is 
thought to be induced at glutamatergic synapses (as can be found in the cortex and 
hippocampus) is through a combination of increased glutamate release from presynaptic  
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neurons and elevated numbers and conduction of glutamate receptors at postsynaptic sites, 
leading to a long-lasting increase in the magnitude and efficiency of synaptic signaling. 
Following exposure to HBCD, a number of molecular changes support inhibition of this 
process, leading to synapse weakening in the hippocampus of developing mice.  Specific 
molecular changes and downstream signaling events of interest are identified as increased 
(red) or decreased (green) from controls.  Lines with a blunt end represent an inhibitory 
process, while activation arrows with “+” symbols indicate a potentiating effect.  Six major 
themes that may be disrupted following HBCD exposure are indicated: (I) Decreases in 
Intracellular Ca
2+ 
and Na
+
; (II) Decreased cyclic AMP (cAMP); (III) Synapse weakening via 
decreases in NO signaling, AMPAR insertion, receptor conductance, and probability of 
depolarization;   (IV) Decreased integrity of the blood brain barrier; (V) Activation of pro-
inflammatory microglia; and (VI) Reduction of T3 to target neurons. Altogether, molecular 
changes by HBCD support inhibition of LTP as a significant adverse effect in the brain.  
 
First, intracellular Ca
2+ 
levels may be altered.  At these synapses, glutamate first 
induces a weak stimulation of AMPA receptors (AMPARs), allowing an influx of Na
+
 and an 
efflux of K
+
 ions. With continued stimulations, activated AMPARs help displace the Mg
2+
 
ion block on NMDA receptors (NMDARs). This results in a strong influx of Ca
2+ 
ions upon 
glutamate binding (again exporting K
+
). The net increase in Na
+
 and Ca
2+
 ions drives 
depolarization and neurotransmission. With HBCD exposure, transcripts for the AMPAR, 
GluR4, NMDAR, and NMDAR2C are decreased. In addition, phospholipase C (B2 isoform),  
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which, through second messenger signaling, increases intracellular Ca
2+
, is also decreased. 
Together, these changes would be expected to dramatically decrease intracellular Ca
2+
 levels 
in the postsynaptic neuron.   
 
Secondly, cellular cyclic AMP (cAMP) signaling is an important second messenger in 
neurons.  cAMP has been implicated as one of the key modulators of LTP. cAMP can be 
synthesized by adenylate cyclase (AC) in an ATP-dependent reaction. With HBCD exposure, 
mRNA for AC (isoform Y1) is decreased, as is mRNA encoding mGluR6, which inhibits the 
activation of AC via G-protein signaling. Phosphodiesterase 4D, which breaks down cAMP, 
is also increased following HBCD exposure. The net result of these changes would be a 
depletion of cAMP in the postsynaptic neuron after HBCD exposure. Although cAMP may 
support LTP through multiple mechanisms, the cAMP-dependent kinase, PKA (2RA), which 
is also decreased by HBCD, is thought to be involved in signaling that results in CREB-
mediated transcription and MAP kinase signaling that increases synthesis of nitric oxide 
(NO). In addition, PKA phosphorylation of postsynaptic ion channels increases the 
likelihood that they will open with stimulation, elevating the potential for depolarization. 
Thus, HBCD would be expected to make activation of these ion channels less likely 
(preventing depolarization) and decrease NO-mediated signaling.  
 
Thirdly, synapse strengthening is a hallmark of LTP:  decreased intracellular Ca2+ by 
HBCD would decrease insertion of AMPARs at the postsynaptic membrane and decrease 
conduction of these same receptors. NO is thought to act as a signaling molecule at these  
 
184 
synapses to stimulate an increased release of neurotransmitter from the presynaptic neuron  
and production may also be decreased following HBCD exposure. Astrocytes help to cycle 
glutamate (Glu) at the synapse by taking up Glu and converting it to glutathione (GSH). This 
GSH is then transferred to the presynaptic neuron where it is once again broken down to 
produce Glu for signaling. A key enzyme family involved in the production of GSH from 
Glu is glutathione synthase (GS, aka GLUL); HBCD decreases expression of this gene. 
These changes would be expected to decrease transmission efficiency at glutamatergic 
synapses.  
 
Fourth, negative impact of pro-inflammatory factors can contribute to alterations in 
LTP.  Both increases in permeability of the blood-brain barrier (BBB) and activation of 
microglia can result in the introduction of pro-inflammatory and cytotoxic molecules to the 
neuronal parenchyma. This can contribute to direct neurotoxicity and disruption of synaptic 
transmission. Two genes associated with permeability of the BBB are decreased by HBCD 
exposure; tight junction protein 2 (TJP2) and the growth factor, vascular endothelial growth 
factor (C, VEGFc). Over-activation of microglia can occur following stimulation of toll-like 
receptors (TLRs) which are inhibited by the protein IRAK3 (interleukin-1 receptor associated 
kinase), transcripts for which are decreased by HBCD.  The pro-inflammatory and cytotoxic 
factors that could be released as a result of BBB breach and excessive microglial activation 
are capable of causing direct neurotoxicity; interestingly, HBCD exposure up regulates 
expression of the pro-apoptotic protein Fas.  
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Lastly, there is the possible contribution of direct thyroid hormone (TH) effects.  It is 
unclear exactly how T4 and T3 regulate brain activity. Of interest is the solute carrier protein, 
SLCO1B3, which is known to transport T3 into cells and which is decreased by HBCD 
exposure in the brain. This along with genes known to be transcriptionally regulated by TH 
and identified by IPA analysis for α-HBCD only; indicates dysregulation of TH homeostasis 
in the hippocampus. Depolarization-induced release of neurotransmitters and other secretions 
from nerve endings is triggered by the rapid entry of Ca
2+ 
through voltage-sensitive channels. 
Thyroid hormones are sequestered by nerve terminals and can result in changes in behavior 
and mood. They may therefore be involved in modulating central synaptic transmission. 
These results suggest a novel mechanism of action for thyroid hormones in the brain.  
 
Altogether, molecular changes by HBCDs suggest inhibition of LTP as a significant 
adverse effect in the brain. Our findings showed that HBCD exposure at a critical window of 
susceptibility during development may impair synaptic plasticity. This study increases our 
understanding of the effects of HBCD during developmental exposure and is the first in vivo 
study demonstrating the 1) potential mechanism involved in the HBCD learning and memory 
deficits and 2) HBCD stereoisomers effect differences in the brain, liver and serum in any 
mammalian system.  Stereoisomer specific contribution within the proposed pathways 
disrupting LTP was reasonably independent from one another but also appeared to overlap to 
a large extent in the  postsynaptic neuron. The similarities observed between α-HBCD and γ-
HBCD may be a function of stereoisomerization. The CM-HBCD, which is 70-90% γ-
HBCD, appeared to have different overall response than after the administration of γ-HBCD  
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in the hippocampus, liver and serum and can be partly attributed to the CM-HBCD having 
higher levels of other stereoisomers (α- and β-HBCD) along with other minor stereoisomers 
not present in the γ-HBCD dosing solution. Further comparisons will include that of CM-
HBCD at the same dose as γ-HBCD (30mg/kg) and with that of α-HBCD at 1/10th of that 
dose (3 mg/kg) as this ratio is closer to that in the commercial mixture. To understand how 
and explain why HBCDs can affect synaptic plasticity, further experimental studies should 
focus on the underlying mechanisms proposed here. Additional studies on the stereoisomer 
specific effect differences observed in this study can also help in identifying specific 
molecular mechanisms for assessing the risk of the individual HBCD stereoisomers.  
 
However, it is clear that we are able to distinguish differences in response between 
stereoisomers of the CM-HBCD in the hippocampus, liver and serum four days after a single 
oral exposure at PND 10 mice. The mechanisms proposed in this chapter have promise to 
explain the disruption of the CNS initiated during development and manifesting in adulthood. 
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Chapter VI 
 
SUMMARY AND IMPACT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY OF THIS DISSERTATION 
 
 
The idea of flame retardant materials dates back to about 450 BC, when the Egyptians 
used alum to reduce the flammability of wood. The Romans (about 200 BC) used a mixture 
of alum and vinegar to reduce combustibility (Hendersinn et al., 1990). Today there are more 
than hundreds of chemicals used as flame retardants. The halogenated organics have caused 
public health concern in the 20
th
 century with their continued consumer use and high levels in 
people combined with the lack of knowledge regarding their effects and fate (Alaee et al., 
2003). 
The use of brominated flame retardants has increased tremendously during the last 
decades mainly for two reasons: 1) the need to meet strict fire safety regulations; and 2) the 
high demand for petroleum-based polymeric materials, which have to meet those same fire 
safety regulations. 
 
Recent public health concern for the brominated flame retardant HBCD has increased 
because of its high environmental persistence and detection in breast milk and human serum. 
Limited toxicology studies suggest that   CM-HBCD is a developmental, reproductive, and 
neurotoxicant, as well as an endocrine disrupter; however, little else is known about the 
overall effects of this chemical. In wildlife and humans, the high prevalence of the γ-HBCD 
diastereomer from the commercial mixture shifts to a dominance of the α-HBCD 
diastereomer. The mechanism of this is unclear. As there are currently no whole animal 
studies investigating the individual stereoisomers, it is difficult to determine whether this is  
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driven by biotransformation and/or bioaccumulation. In order to assess the human health risk  
of HBCD, the individual diastreomers need to be studied for the link between exposure, dose, 
and response to be understood.  
 
The research presented in this dissertation specifically addresses this need for 
toxicokinetic data. The thrust and novelty of this research rest on the examination of two 
different stereoisomers of HBCD. We hypothesized that these isomers differed in 
pharmacokinetic and toxicological properties and moreover could interconvert, thus 
conclusions based on testing the commercially-available mixture might not adequately 
predict the outcome of real-life exposures. To test this hypothesis and provide information 
essential to elucidating the diastereomer shift while adding valuable information for the 
human health risk assessment of HBCD, specific aims included: (1) characterize basic 
toxicokinetics in adult female mice; (3) investigate the impact of repeated dosing on the 
distribution and elimination of α-HBCD and γ-HBCD in adult female mice; (4) investigate 
the distribution and elimination of α-HBCD and γ-HBCD in infantile mice, a developmental 
model; and (5) identify mechanisms leading to the reported developmental neurotoxicity 
after exposure to  CM-HBCD and further determine whether that toxicity is driven by α-
HBCD and/or γ-HBCD.  
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Toxicokinetics of γ-HBCD in Female Mice 
 
Because previous unpublished industry toxicokinetic studies have only been 
performed on the CM-HBCD and are conflicting, the main diastereomer present in the 
commercial mixture, γ-HBCD, was studied in an effort to fully characterize absorption, 
distribution, and elimination parameters following a single dose with respect to dose, time, 
and route of exposure in adult female C57BL/6 mice. Over 85% of the administered dose 
was absorbed following oral administration. Liver was the major depot four-days after 
treatment followed by blood, fat and then brain.  However, γ-HBCD was rapidly metabolized 
and eliminated in the urine and feces.  For the first time, in vivo stereoisomerization was 
observed of the γ-diastereoisomer to the β-diastereoisomer in liver and brain tissues, and to 
the α- and β-diastereoisomer in feces.  Polar metabolites in the blood and urine were a major 
factor in determining the initial whole-body half-life (1 day) after a single oral exposure.  
Elimination, both whole-body and from individual tissues, was biphasic.  Initial half-lives 
were approximately 1 day, whereas terminal half-lives were up to 4 days, suggesting only 
limited potential for γ-diastereoisomer bioaccumulation.  The toxicokinetic behavior reported 
here has important implications for extrapolation of toxicological studies of   CM-HBCD to 
the assessment of HBCD risk.                 
 
Toxicokinetics of α-HBCD in Female Mice 
Since α-HBCD constitutes the minority of the commercial mixture (<10%) but is the 
dominant diastereomer detected in biota (invertebrates, fish, birds, marine mammals, and  
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humans), this study was conducted in an effort to fully characterize absorption, distribution, 
and elimination parameters following a single treatment with respect to dose, time, and route 
of exposure in adult female C57BL/6 mice after administration of α-HBCD. Results indicate 
that approximately 90% of the administered dose was absorbed after an oral exposure.  
Disposition was 1) dictated by lipophilicity as adipose, liver, muscle and skin were major 
depots and 2) was dose-dependent with non-linear accumulation at higher doses.  
Elimination, both whole-body and from individual tissues, was biphasic.  Α-HBCD derived 
radioactivity was excreted in the feces as parent and metabolites whereas urine only 
contained metabolites.  Presence of polar metabolites in the blood and urine were a major 
factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial 
half-lives were ~1-3 days, but much longer terminal half-lives of 17 days were observed, 
suggesting the potential for α-HBCD bioaccumulation.  Stereoisomerization previously 
observed after exposure to γ–HBCD was not seen after exposure of α-HBCD.  The 
toxicokinetic behavior reported here has important implications for extrapolation of 
toxicological studies of   CM-HBCD to assessment of risk of α-HBCD, the major 
stereoisomer found in wildlife and people.  
 
Repeated Dosing on the Disposition of α-HBCD and γ-HBCD 
 
This was the first study to investigate toxic kinetic parameters following repeated 
exposure to α-HBCD and γ-HBCD. The disposition and elimination of α-HBCD and γ- 
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HBCD was monitored in adult female C57BL/6 mice for four days following ten consecutive  
3.0 mg/kg oral doses and then compared with results from our previous studies (Chapter II 
and III, Sabot et al. 2010 and 2011). The results suggest greater retention of α-HBCD in 
developing mice than in adults with non-linear disposition patterns following repeated 
exposure. Repeated exposure to α-HBCD results in higher concentrations remaining in 
adipose tissue which demonstrates its potential for bioaccumulation. Data also suggest that 
elimination of α-HBCD may be decreased following repeated exposure. This was not seen 
after repeated exposure to γ-HBCD where disposition was dose-independent and didn‟t 
significantly change after 10 days of exposure.  These results, in combination with evidence 
of α-HBCD‟s persistence and the toxicity of the commercial mixture, underlie the need to 
further understand α-HBCD and γ-HBCD toxic kinetics across species under steady state 
conditions. 
 
Disposition and Elimination of α-HBCD and γ-HBCD in a Developmental Mouse Model 
 
The majority of public health concern has focused on potential hazardous effects 
resulting from exposure to infants and young children because of studies reporting adverse 
effects in rodent studies following exposure during development in combination with human 
exposure estimates suggesting that nursing infants and young children have the highest 
exposure to HBCD. This study was designed to compare differences in disposition of both α-
HBCD and γ-HBCD in infantile mice reported to be susceptible to the developmental 
neurotoxicity of the HBCD commercial mixture.  
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The results show that the toxic kinetics of both α-HBCD and γ-HBCD  are different 
in developing mice than in adult mice; while tissue distribution patterns are similar, 
concentrations of  both α-HBCD and γ-HBCD  derived radioactivity are higher in pups. 
Developing mice exposed to α-HBCD had an overall higher body burden than γ-HBCD at 
every time point measured 4 days post exposure, however total body burden differences 
between age groups were greater after exposure to γ-HBCD than for α-HBCD. These 
differences lead to higher concentrations of both HBCD diastereomers at target tissues during 
critical windows of development. Because  CM-HBCD, and other organo-halogenated 
compounds (PCBs, PBDEs, etc.), have demonstrated toxicity during development, it is 
essential to understand the kinetic parameters in order to accurately describe the dose 
available to target tissues resulting from exposure, and to more accurately assess risk to 
human health. This study suggests that age may be a risk factor for the harmful effects of 
both HBCD diastereomers when developing animals may have increased susceptibility. 
 
Molecular Mechanisms of Developmental Neurotoxicity in Mice 
 
CM-HBCD has been shown to cause adverse effects on learning and behavior in mice 
(Eriksson et al., 2006). We propose that CM-HBCD may alter similar molecular mechanisms 
responsible for learning and memory as seen for PBDEs and PCBs. Our objective was to 
investigate the molecular mechanistic effects of the CM-HBCD on gene transcription in the 
hippocampus of developing mice. Furthermore as the toxiokinetic differences of α-HBCD  
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and γ-HBCD in adult (Szabo et al., 2010; Szabo et al., 2011) and developing mice (Szabo et  
al., 2011; submitted) were observed, we hypothesize that α-HBCD and γ-HBCD will have 
different biological effects in vivo. The second objective was to investigate whether the 
individual HBCD stereoisomers, α-HBCD and/or γ-HBCD, may be responsible for driving 
the behavioral developmental neurotoxicity observed after exposure to CM-HBCD.  
 
We found that neonatal exposure to CM-HBCD causes effects on gene expression in 
the developing mouse hippocampus. The molecular changes support inhibition of long term 
potentiation (LTP), a process involved in learning and memory, leading to synapse 
weakening in the hippocampus during development. Furthermore, LTP disruption was 
observed for all treatment groups: α-HBCD, γ-HBCD, and CM-HBCD. Our results suggest 
six major cellular pathways may be disrupted following HBCD exposure: (I) decreases in 
intracellular Ca
2+ 
and Na
+
; (II) decreased cyclic AMP (cAMP); (III) synapse weakening via 
decreases in NO signaling, AMPAR insertion, receptor conductance, and probability of 
depolarization; (IV) decreased integrity of the blood brain barrier; (V) activation of pro-
inflammatory microglia; and (VI) reduction of T3 to target neurons. Altogether, molecular 
changes by HBCD, regardless of stereoisomer exposure, support inhibition of LTP as a 
significant adverse effect in the brain.  
 
As stereoisomerization of γ-HBCD to β- and α-HBCD occurs in mice (Szabo et al., 
2010); it is difficult to predict whether α, β, or γ is driving the neurotoxicity since genes  
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involved in long term potentiation were altered with each treatment (α-, γ-, or CM-HBCD).  
However, when we consider that α-HBCD does not stereoisomerize in mice (Szabo et al., 
2011), we suggest that it is α-HBCD which may be driving the behavioral developmental 
neurotoxicity previously observed (Eriksson et al., 2006).   
 
Overall Conclusions 
 
In adult female mice, α-HBCD and γ-HBCD are both well absorbed; distribution is 
dictated by lipophilicity for α-HBCD but not for γ-HBCD.  γ-HBCD was readily metabolized 
and eliminated with a terminal half- life of 4 days while α-HBCD was more biologically 
persistent with a terminal half-life of 17 days.  Repeated exposure resulted in higher body 
burdens than a single exposure alone only after administration of α-HBCD and not γ-HBCD, 
demonstrating the potential for α-HBCD bioaccumulation. In vivo stereoisomerization was 
observed converting the orally administered γ-diastereoisomer to the β-diastereoisomer in 
liver and brain tissues, and to the α- and β-diastereoisomer in feces. The analytical techniques 
used exclude the possibility of thermal isomerism of HBCD. Stereoisomerization was not 
observed after exposure to α-HBCD in any tissue examined. The toxicokinetics of α-HBCD 
and γ-HBCD in young animals, which have been shown to be susceptible to toxicity after 
exposure to CM-HBCD, are different than adults. While tissue distribution is similar to 
adults, actual concentrations are higher in younger animals likely due to a reduced ability to 
metabolize and eliminate HBCD. Efforts were taken to characterize the molecular  
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mechanisms leading to developmental neurotoxicity in these younger mice with a higher 
body burden of α-HBCD and γ-HBCD.  The molecular changes observed in the hippocampus 
support inhibition of long term potentiation (LTP) and were observed after oral exposure to, 
α-HBCD, γ-HBCD, and CM-HBCD.   
 
 
Impact of this dissertation  
 
 
Motivation for research in this dissertation was focused on the α-HBCD stereoisomer 
because it is the major HBCD stereoisomer found in most human and environmental biota 
despite its relatively minor role in commercial production and usage. The dominance of α-
HBCD may be attributed to fate, transport, and exposure from the literature, and from our 
toxicokinetic work – it is biologically persistent and resists stereoisomerization. A wealth of 
data is continually becoming available demonstrating the predominance of α-HBCD in 
higher trophic organism, top of the food chain animals, and in human samples including 
blood, breast milk, and adipose tissue (previously described in the introduction section).  
Developing animals appear to be more susceptible than adults, both as to the window of 
sensitivity and to age-related toxicokinetic differences.  Thus, this research provides support 
to the theory that daily exposure to high levels of α-HBCD from our environment are likely 
responsible for high body burdens observed in humans, although exposure and  
biotransformation  of other stereoisomers may  also  contribute. 
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We observed the kinetics and effects of α-HBCD and γ-HBCD in mice. Although  
informative there are limitations of these studies. Female mice were used as they were 
observed to be more sensitive to thyroid disruption and enzyme induction; however the 
inclusion of male mice could help elucidate possible effect differences between sexes. 
Furthermore, our effects studies in the brain, liver and serum were only after exposure to α-
HBCD and γ-HBCD, but not β-HBCD, which would be an interesting follow-up study since 
we have learned that β-HBCD, can be detected in the brain after exposure to purified γ-
HBCD. In addition, these effect studies could be examined using a repeated dosing paradigm 
as opposed to a single exposure to aid in elucidating possible pathways. Different relevant 
routes of exposure can aid in understanding the behavior of HBCD stereoisomers, such as 
dermal and inhalation, which are currently missing from the literature. 
 
There is an interesting paradox observed between the two stereoisomers, α- and γ-
HBCD investigated in this dissertation. The most water-soluble isomer is α-HBCD, which is 
expected to be more rapidly excreted, but undergoes less metabolism and has a longer 
biological half-life, whereas the least water-soluble isomer γ-HBCD, expected to accumulate 
most in tissues undergoes the most metabolism and has a shorter biological half-life. 
Although, there are slight differences in the log Kow of α- β- and γ-HBCD being 5.65, 6.05 
and 6.34, respectively; they are all within the range of being highly lipophilic which favors 
the likelihood of partitioning into lipid rich tissues, as seen for other POP such as PCBs, 
PBDEs and dioxins. However, the differences in biological behavior observed between the  
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two stereoisomers may be due to the differences in 3-D structure of the stereoisomers which 
appear to make γ-HBCD more readily recognized by XMEs and therefore metabolized and 
eliminated as opposed to α-HBCD whose structure is more resistant to metabolism and 
therefore partitions into fat. The increase in the number of differentially expressed 
hippocampal genes and pathways identified after exposure to α-HBCD (as opposed to γ-
HBCD) further elicits concerns for neurotoxicity from α-HBCD which is the dominant 
stereoisomer found in human food (fish, beef, pork, dairy, etc). 
 
In comparison with the database for other brominated flame retardants such as 
PBDEs, there is limited information on the concentration of HBCD in human tissues (Covaci 
et al., 2006). Several studies have addressed the concentration of HBCD in human breast 
milk, serum and umbilical cord serum, raising concerns about potential lactational and 
prenatal exposure (see   Section 3.2). The isomeric composition of HBCD has been studied in 
commercially available preparations, environmental media, and biological samples. α-HBCD 
is more prevalent in biological samples, but the γ isomer predominates in abiotic 
environmental samples. In vitro studies have explained the different isomeric occurrences 
based upon their metabolism via the cytochrome P450 system (Zegers et al., 2005; Weiss et 
al., 2006).  
 
In combination, our toxicokinetic and toxicity studies raises concerns for humans 
about exposure to CM-HBCD, γ-HBCD, and α-HBCD as they all have elicited, to some  
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degree a response in mice. However, α-HBCD appears to be more resistant to metabolism  
than other stereoisomers in rats and in human in vitro cell culture, more biologically 
persistent, and elicited an increased number of differentially expressed gene changes in the 
hippocampus which are known to be involved in learning and memory deficits. As metabolic 
capabilities have been observed across different species (fish, rats, humans) and similar 
patterns of stereoisomers are observed across biota, with α-HBCD predominating (fish, 
marine mamals, rats, mice, human blood, and breast milk) the likelihood of similar effects 
being observed in humans as found here in mice is increased and suggest a risk from this 
class of chemical. 
 
In combination, our toxicokinetic studies and toxicity studies raises concerns to 
humans for exposure to CM-HBCD, γ-HBCD, and α-HBCD as they all have elicited, to some 
degree, a toxic response in mice. However, α-HBCD appears to be more resistant to 
metabolism than other stereoisomers in rats and human in vitro cell culture, more 
biologically persistent, and elicited an increased number of differentially expressed gene 
changes in the hippocampus involved in learning and memory deficits.  As the metabolic 
capabilities are observed across different species (fish, rats, humans) and similar patterns of 
stereoisomers are also observed across biota with α-HBCD predominating (fish, marine 
mammals, rats, mice, human blood and breast milk), the likelihood of similar effects being 
observed in humans as found here in mice increase validity and should be considered a risk 
of these class of compounds.  
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FUTURE DIRECTIONS 
 
 
Toxicokinetics and Behavior  
 
Considering β-HBCD was detected in the brain of adult mice administered γ-HBCD, 
both toxicokinetic and effects studies of this stereoisomer are warranted. To help explain and 
support the proposed LTP mechanism, it would be important to determine whether 
stereoisomerism also occurs in infantile mice as was seen in adults. Furthermore, Eriksson et 
al (2006) performed behavioral tests after the administration of CM-HBCD in mice. To 
further understand the differences between the stereoisomers and whether one or all isomers 
are driving the developmental neurotoxicity observed with CM-HBCD, future behavioral 
experiments with α-HBCD, β-HBCD and γ-HBCD should be conducted. 
 
Development of a PBPK model for HBCD 
 
Physiologically based pharmacokinetic (PBPK) models are mathematical descriptions 
of the physiological and biochemical processes involved in the absorption, distribution, 
metabolism, and excretion (ADME) of a xenobiotic. The physiological and biochemical 
characteristics of a given model can be altered to reflect species-specific parameters to 
provide a quantitative extrapolation across species. Furthermore, PBPK models can be used 
to describe exposure/dose relationships in developmental scenarios such as the sensitivity of  
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developing rodents to HBCD stereoisomers. By understanding the processes that determine 
tissue dose and chemical interactions with tissues, resulting biological responses can be 
predicted. 
 
Currently, no PBPK models for HBCD or their stereoisomers are available. Studies 
examining windows of sensitivity for HBCD-induced developmental effects have focused on 
both gestational and postnatal exposure. We plan to collaborate with Dr. Claude Emond from 
the University of Montreal) to develop a preliminary PBPK model that can describe 
pharmacokinetic data from acute oral exposures to HBCD stereoisomers in mice. This model 
will be exersized to predict disposition dose, gender, and species as well as aiding in the 
characterization of HBCD disposition during development (i.e. maternal and fetal body 
burdens during critical windows of susceptibility). Such a model can then be used in the 
development of a PBPK model to predict concentrations in human health risk assessments. 
 
 
Validation of Transcriptomics and Proteomics  
 
Individual quantitative RT-PCR analyses are planned to be performed for a subset of 
relevant genes and pathways identified as affected by HBCD in order to further confirm 
microarray and, indirectly, proteomic data.  
 
 
 
 
 
204 
Dose/Response 
 
 
A systems biology approach should be taken to examine the effects of HBCD on the 
liver, brain, and serum in infantile mice. This study used several large data gathering tools to 
evaluate the transcriptomics, proteomics, and metabolomics in a developmentally susceptible 
mouse model. The data presented in this dissertation was limited to data from our high dose 
groups, 30mg/kg dose. This was the maximal concentration used for analysis chosen based 
on previous changes observed in mice (van den Ven, 2008) and toxicokinetic data (Szabo et 
al., 2010, 2011a and 2011b). However, subsequently lower doses were also tested and plans 
to analyze them are in our future (3mg/kg and 10mg/kg). Dose/response relationships are key 
data in the risk assessment process. Determination of a reference dose and the use of 
benchmark dosing software can be generated from such data. Arguably, the future of risk 
assessment is to identify mechanistic data and incorporate such data into the process of 
decision making purposes. One goal is to use this data in the risk assessment process for 
HBCD currently ongoing at the EPA/NCEA. 
 
Long Term Potentiation 
 
 
The impact of HBCD on suppression of long term potentiation, identified in Chapter 
5 of this dissertation, needs additional support. Electrophysiology is a method to record the 
synaptic transmission between two neurons. In vivo extracellular recording on hippocampus 
synapses and could help to confirm the molecular mechanism proposed in this thesis. Our  
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quantitative molecular data reported here in combination with functional neurophysiologic 
effects can provide strong functional support for the previously reported neurobehavioral 
effects (Eriksson et al. 2006) and is essential for characterization of the neurotoxic hazard of 
this brominated flame retardant, particularly for rational risk assessment, which is required in 
response to the general concern about the vulnerability of the developing brain. 
 
 
Metabolomics - biomarkers and systems biology 
 
 
Metabolomics is the most recent systems-biology approach, to complement the 
genomic and proteomic efforts, to characterize an entire biological system. To aid in 
predicting health risks of HBCD, metabolomic analysis of serum was performed to improve 
our ability to draw correlations between early life exposures and developmental outcomes.  
Since metabolites represent end products of the function of the genome and proteome, 
metabolomics holds the promise of providing an integrated physiological phenotype of a 
system. Such metabolic profiling involves a comprehensive and accurate measurement of the 
types and concentrations of metabolites in a system. This current investigation was 
conducted to reveal the impact of HBCD exposure (α-HBCD, γ-HBCD, or CM-HBCD) on 
the biochemical profiles of serum from 14 day old mice, four days following dosing. 
Metabolomics of serum from infantile mice exposed at PND 10 to α-HBCD, γ-HBCD or 
CM-HBCD could be used to reveal endogenous metabolites that distinguish the treatment  
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 groups (α-HBCD, γ-HBCD or CM-HBCD) from one another four days after a single oral 
exposure. Metabolites significant to the separation of dose groups were identified in 
biochemical pathways and significant metabolic perturbations in energy and amino acid 
metabolism were found. 
 
 Efforts to identify the different stereoisomer effects and pathways are underway. Attempts to 
link serum small molecule changes to pathway changes observed in the transcriptomics and 
proteomics from the liver and hippocampus are planned. However, daunting of a task, we 
have begun and will continue in comparing the three data sets.   
 
1) Phenylalanine was observed to decrease in every treatment group tested. 
Phenylalanine is an essential amino acid that is highly concentrated in the brain and 
blood. It is used by the brain to make norepinephrine, a neurotransmitter involved in 
synaptic transduction. Depletion of norepinephrine reduces long-term potentiation in 
the dentate gyrus of rat hippocampus (Stanton et al., 1985). Further research to 
understand the relationship between phenylalanine, norepinephrine, the hippocampus, 
and LTP is currently ongoing.    
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2) 3-hydroxybutyrate is a ketone body used as an energy source by the brain when blood 
glucose is low. It is essential during brain development and increased levels are 
needed to nourish the brain during times of fasting or energy deregulation. Hepatic 
molecular pathways involved in energy deregulation (glycerolipid metabolism and 
type II diabetes) were identified, specifically after exposure to α-HBCD.   
 
    One interesting area is to investigate the mechanism by which HBCD affect hepatic 
glucose/energy metabolism. There is an emerging hypothesis, based on data from several 
chemicals in animal studies, that the obesity epidemic could be due, at least in part, to 
chemical exposures during vulnerable windows of development, mainly in utero and the 
first few years of life (LaMerill and Birnbaum, 2011).  Indeed, in animal models there are 
data showing that developmental exposure to endocrine disrupting chemicals such as 
tributyl tin, bisphenol A, organochlorine pesticides, air pollution, lead, diethylstilbestrol, 
perfluorooctanoic acid, monosodium glutamate, and nicotine can lead to increased weight 
gain later in life. Epidemiology studies report an increased risk of obesity and/or type 2 
diabetes in women who were exposed to persistent organic pollutants (including PCBs, 
DDE, and dioxin) during pregnancy, and there are animal data linking bisphenol A and 
atrazine exposures to altered glucose tolerance and insulin resistance.  
 
Two lines of evidence suggest that BFRs, including HBCD, may promote disruptions in 
metabolism that could lead to obesity. The first is epidemiological: a significant association  
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exists between persistent organic pollutants, including BFRs, and diabetes in sport fishermen 
and people residing near chemical waste sites (Turyk et al., 2009, Kouznetsova et al., 2007). 
The second is molecular: hepatocytes from rats treated with 28 days HBCD treated rats have 
altered hepatic gene expression, many of which are involved in glucose metabolism (Canton 
et al., 2008).  
 
In Chapter 5 of this dissertation, we observed increases in small molecules involved 
in ketosis (elevated levels of the ketone body 3-hydroxybutyrate after exposure to α-HBCD, 
γ-HBCD, and CM-HBCD).  3-hydroxybutyrate is also associated with diabetes mellitus and 
other defects in carbohydrate metabolism. Hepatic genes involved in glycerolipid metabolism 
and Type II diabetes were altered after exposure to α-HBCD as observed in our 
transcriptomics and proteomics data. Whether or not BFRs alter energy metabolism and 
promote obesity is unknown. Previous research has shown that BFRs suppress serum levels 
of thyroid hormone and can cause mild weight gain in animals. Data suggest enhanced 
glucose metabolism occurs compared to controls, which can promote weight gain (Zurlo et 
al., 1990). Fat cells from PBDE treated rats have disrupted glucose and lipid metabolism 
(Hoppe et al., 2007). Future studies would extend our hepatic genomic and proteomic 
findings as well as our serum metabolomics data to investigate the liver and its role in energy 
metabolism and regulating the metabolism of macronutrients. Indeed, aberrations in liver 
glucose and lipid metabolism are a hallmark sign of obesity (Muoio et al., 2006). We 
demonstrate that metabolomics is a promising approach to determine biomarkers for 
examining the mechanistic link between levels of HBCD exposure and disease/dysfunction.  
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CONCLUDING REMARKS 
 
Hexabromocyclododecanes (HBCD) are brominated flame retardants (BFRs) that 
belong to a large group of organohalogen chemicals.  BFRs can be highly persistent, 
bioaccumulative, and cause adverse effects in humans and wildlife.  Although some BFRs 
are banned or voluntarily withdrawn from usage by the manufacturers, emerging and existing 
BFRs continue to be used in industrialized countries.  Because of their widespread use and 
large quantities in consumer products and household items, indoor contamination is proposed 
to be a significant source of human exposure.  It is widely accepted that common exposure 
routes are oral – both via breast milk, animal fat-containing foods, and hand to mouth 
activity.  
 
Recent epidemiological studies clearly indicate that BFRs can affect human health.  
The human health effects include alterations in thyroid hormone homeostasis, reproductive 
effects, and reduced psychomotor development index and IQ performance   in children at 
school age.  .  Studies have also indicated that the daily exposure to PBDEs due to inhalation, 
oral ingestion from food and accidentally from indoor dust, plus dermal absorption was 
significantly higher than that of adults.  Many rodent studies have confirmed that 
developmental exposure to these compounds is problematic.  Studies in rodents indicated that 
both PBDEs and HBCD are developmental neurotoxicants affecting the nervous system.  
Several studies have also confirmed that the PBDEs and HBCDs are endocrine disruptors,  
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with the potential to disrupt male and female reproductive development including altered 
steroidogenic activities.  This has been demonstrated for HBCD in several in vivo studies 
using rodent models and in vitro systems which determine effects on receptor binding and on 
steroidogenesis.  The potential modes of action may be similar between HBCD and PBDEs, 
as well as similar between rodents and humans. This is extremely important to consider as 
there have been several recent reports of adverse health consequences associated with 
increased PBDE exposure in humans (Meeker et al., 2009; Roze et al., 2009; Harley et al., 
2010; Herbstman et al., 2010).   
 
Further research is needed to determine the long-term adverse consequences of 
exposures to all BFRs, especially as current laboratory studies for HBCD are limited, with no 
adequate human studies published to date. In the near future, it can be predicted that after the 
s and withdrawl of PBDEs and HBCD, levels of each will still be detected in the 
environment and humans.  Due to their persistence and toxic effects, new alternatives are 
being investigated. The legacy problem emphasizes the need for proper testing before 
manufacturing replacement chemicals, since these compounds may also bioaccumulate and 
can be transplacentally and lactationally transferred. However, it appears difficult to design 
BFRs which are more environmental friendly but also equally effective as flame retardants 
and cost-effective. 
 
Clearly, it would be better to identify fire resistant materials that are not hazardous, 
but replacement of DecaBDE and HBCD by other flame retardants seems not yet feasible in  
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some applications. For this situation, a temporary solution could be to use only the minimum  
effective amount of BFRs in these consumer goods, e.g. electronics, furniture upholstery, 
thermal insulation. New global guidelines for using the minimum concentration needed of 
these BFRs for fire safety in consumer goods should be implemented. Such guidelines may 
ultimately reduce exposure levels worldwide and reduce the remarkable differences in 
exposures are now observed between different geographical regions. 
 
In their provocative review, “Facing the challenge of data transfer from animal 
models to humans: the case of persistent organohalogens”, Suvorov and Takser (2008) make 
the cogent argument, for scientists whose interest is in improving public health, that 
“studying the mechanisms of toxicity greatly increases the relative value of animal model 
studies” but that “knowledge of toxicity mechanisms impacts only slightly on policy making 
and regulatory action”. Suvorov and Takser (2008) note that after 30 years of intensive 
research, all of the mechanisms by which PCBs are toxic are still not known, but that this 
shouldn‟t, and didn‟t, preclude a ban on PCBs in the 1970‟s. Further, they state that when 
conducting environmental chemicals research, it is critical to (1) employ doses that are 
relevant to human exposure levels, (2) screen compounds at the most sensitive stages of 
development, and (3) verify exposures by internal dose measurements. These basic hallmarks 
were applied to the study ofthe brominated flame retardant, HBCD as reflected in this 
dissertation. 
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